WO1998005635A1 - Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity - Google Patents

Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity Download PDF

Info

Publication number
WO1998005635A1
WO1998005635A1 PCT/GB1997/002129 GB9702129W WO9805635A1 WO 1998005635 A1 WO1998005635 A1 WO 1998005635A1 GB 9702129 W GB9702129 W GB 9702129W WO 9805635 A1 WO9805635 A1 WO 9805635A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
aryl
heteroaryl
tlc
Prior art date
Application number
PCT/GB1997/002129
Other languages
French (fr)
Inventor
David Alan Owen
John Gary Montana
John Fraser Keily
Robert John Watson
Andrew Douglas Baxter
Original Assignee
Darwin Discovery Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9616599.8A external-priority patent/GB9616599D0/en
Priority claimed from GBGB9707427.2A external-priority patent/GB9707427D0/en
Priority to DE69729007T priority Critical patent/DE69729007T2/en
Priority to BR9711027A priority patent/BR9711027A/en
Priority to AU38564/97A priority patent/AU730464B2/en
Priority to PL97331598A priority patent/PL193829B1/en
Application filed by Darwin Discovery Limited filed Critical Darwin Discovery Limited
Priority to EP97935666A priority patent/EP0968182B1/en
Priority to AT97935666T priority patent/ATE266000T1/en
Priority to CA002263154A priority patent/CA2263154A1/en
Priority to JP10507741A priority patent/JP2000517297A/en
Priority to DK97935666T priority patent/DK0968182T3/en
Publication of WO1998005635A1 publication Critical patent/WO1998005635A1/en
Priority to NO19990543A priority patent/NO314452B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

  • This invention relates to hydroxamic and carboxylic acid derivatives, and to their use in medicine.
  • Metalloproteinases including matrix metalloproteinase (MMP), (human fibroblast) collagenase, gelatinase and TNF convertase (TACE), and their modes of action, and also inhibitors thereof and their clinical effects, are described in WO-A- 9611209, WO-A-9712902 and WO-A-9719075, the contents of which are incorporated herein by reference.
  • MMP matrix metalloproteinase
  • TACE TNF convertase
  • MMP inhibitors may also be useful in the inhibition of other mammalian metalloproteinases such as the adamalysin family (or ADAMs) whose members include TNF convertase (TACE) and ADAM- 10, which can cause the release of TNF ⁇ from cells, and others, which have been demonstrated to be expressed by human articular cartilage cells and also involved in the destruction of myelin basic protein, a phenomenon associated with multiple sclerosis.
  • ADAMs adamalysin family
  • TACE TNF convertase
  • ADAM- 10 TNF convertase
  • WO-A-9718188 discloses MMP inhibitors of the formula
  • EP-A-0780386 discloses compounds having MMP and TNF inhibitory activity, of the formula
  • n 0, 1 or 2;
  • Y is OH or NHOH;
  • R 1 is H or lower alkyl;
  • R 2 is H, lower alkyl, heteroalkyl, aryl, aralkyl, arylheteroalkyl, cycloalkyi, heteroaryl, heteroaralkyl, heteroarylheteroalkyl, heterocyclo, heterocyclo-lower alkyl, heterocyclo-lower heteroaryl or NR 6 R 7 ;
  • R 3 is H, lower alkyl, cycloalkyi, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or lower alkoxy;
  • R 4 is H, lower alkyl, cycloalkyi or cycaloalkylalkyl, and
  • R 5 is lower alkyl, cycloalkyi, cycloalkyl
  • R 1 is H
  • R 2 is H, lower alkyl, aralkyl, cycloalkyi, cycloalkylalkyl, heterocyclo or NR 6 R 7
  • R 3 is H, lower alkyl, cycloalkyi, cycloalkylalkyl or aralkyl
  • R 4 is H or lower alkyl
  • R 5 is lower alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl.
  • US-A-4325964 discloses certain benzhydryl sulphinyl hydroxamates, as having utility in neuropsychic ailments.
  • the invention encompasses novel compounds of formula (I) which are useful inhibitors of matrix metalloproteinases and/or TNF ⁇ -mediated diseases, including degenerative diseases and certain cancers.
  • Novel compounds according to the invention are of the general type represented by formula (I):
  • X is O, NR 3 or S(O)o_ 2 ;
  • Y is OR 2 or NHOH
  • R 1 is H or a group (optionally substituted with R 9 ) selected from C w alkyl, C 2 * alkeny aryl, C,_s alkyl-aryl, heteroaryl, C w alkyl-heteroaryl, heterocycloalkyl, C w alkyl- heterocycloalkyl, cycloalkyi and C w alkyl-cycloalkyl;
  • R 2 is H or C, ⁇ alkyl
  • R 3 is H, C, ⁇ alkyl, COR 2 , CON(R 2 ) 2 where each R 2 is the same or different, CO 2 R 4 or SO 2 R ⁇ and R 4 is C.- ⁇ alkyl;
  • B is C, ⁇ alkyl-aryl, C ⁇ alkyl, cycloalkyi, C 1-6 alkyl-cycloalkyl, cycloalkenyl, heterocycloalkenyl, C w alkyl-heteroaryl, heterocycloalkyl, C, ⁇ alkyl-heterocycloalkyl, aryl or heteroaryl, any of which groups is optionally substituted by a substituent selected from R 5 , C w alkyl-R s , C ⁇ alkenyl-R 5 , aryl (optionally substituted with R 5 ), aryl-C, ⁇ alkyl-R 5 , C, ⁇ alkyl-aryl (optionally substituted with R 5 ), C, ⁇ alkyl-heteroaryl (optionally substituted with R 5 ), aryl-C 2 ⁇ alkenyl-R 7 , heteroaryl (optionally substituted with R 5 ), heteroaryl-C, ⁇ alkyl-R 5
  • B is not benzhydryl when X is SO and R 1 is H;
  • R 5 is C ⁇ alkyl, C « alkenyl-R 7 , halogen, CN, NO 2 , N(R 6 ) 2 , OR 6 , COR 6 , CO 2 R 2 , CON(R 6 ) 2 , NR 6 R 7 , S(O), attorneyR g or SO 2 N(R 6 ) 2 ;
  • R 6 is H or a group selected from C, ⁇ alkyl, aryl, C ⁇ alkyl-aryl, heteroaryl, C w alkyl-heteroaryl, cycloalkyi, C M alkyl-cycloalkyl, heterocycloalkyl and C M alkyl- heterocycloalkyl, wherein said group is optionally substituted with R 8 , COR*, CO ⁇ 8 , OR*, CONR 2 R 8 , NR 2 R 8 , halogen, CN, SO 2 NR 2 R 8 or NO 2) and for each case of N(R 6 ) 2 the R 6 groups are the
  • R 7 is COR 6 , CON(R 6 ) 2 , CO 2 R' or SO 2 R 8 ;
  • R 8 is C w alkyl, aryl, C, ⁇ alkyl-aryl, heteroaryl or C, ⁇ alkyl-heteroaryl; and R'is OR 6 , COR 6 , CO ⁇ 2 , CONfll 6 )* NR 6 R 7 , S(O)o. 2 R 8 , SO 2 N(R 6 ) 2 , phthalimido, succinimido or the group
  • Preferred compounds of the invention are those wherein any one or more of the following apply:
  • X is S, SO or SO 2 ;
  • R 1 is H or a group (optionally substituted with R 9 ) selected from C, ⁇ alkyl, C 2 - ⁇ alkenyl, C,_ g alkyl-aryl, C w alkyl-heteroaryl, C, ⁇ alkyl-heterocycloalkyl and C, ⁇ alkyl- cycloalkyl;
  • B is C, ⁇ alkyl-aryl, C, ⁇ alkyl, cycloalkyi, cycloalkenyl, heterocycloalkenyl, C,_ j alkyl-heteroaryl, aryl or heteroaryl, any of which groups is optionally substituted by a substituent selected from R 5 , C, ⁇ alkyl-R 5 , aryl (optionally substituted with R 5 ), aryl-C w alkyl-R 5 , C, ⁇ alkyl-aryl (optionally substituted with R 5 ), C, ⁇ alkyl-heteroaryl (optionally substitute
  • R 5 is halogen, CN, NO 2 , N(R 6 ) 2 , OR 6 , COR 6 , CON(R 6 ) 2 , NR 6 R 7 , or S(O)o. 2 R 8 ;
  • R 7 is COR 6 ;
  • R 9 is OR 6 , CO 2 R 2 , CON(R 6 ) 2 , phthalimido, succini ido or the group
  • the compounds according to the invention can contain one or more asymmetrically substituted carbon atoms.
  • the presence of one or more of these asymmetric centres in a compound of formula (I) can give rise to stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers, including enantiomers and diastereomers, and mixtures including racemic mixtures thereof.
  • C, ⁇ alkyl refers to straight or branched chain alkyl moiety having from one to six carbon atoms, including for example, methyl, ethyl, propyl, isopropyl, butyl, ttvv-butyl, pentyl, hexyl and the like.
  • C 2-6 alkenyl refers to a straight or branched chain alkyl moiety having two to six carbon atoms and having in addition one double bond, of either E or Z stereochemistry where applicable. This term would include for example, vinyl, 1- propenyl, 1- and 2- butenyl, 2- methyl-2-propenyl etc.
  • cycloalkyi refers to a saturated alicyclic moiety having from three to six carbon atoms and includes for example cyclopropyl, cyclobutyl, cyciopentyl, cyclohexyl and the like. "Benzofused cycloalkyi” includes indanyl and tetrahydronaphthyl.
  • heterocycloalkyl refers to a saturated heterocyclic moiety having from three to six carbon atoms and one or more heteroatom from the group N, O, S and includes for example azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl and the like.
  • “Benzofused hetercycloalkyl” includes indolinyl and tetrahydroquinolinyl.
  • cycloalkenyl refers to an alicyclic moiety having from three to six carbon atoms and having in addition one double bond. This term would include for example cyclopentenyl or cyclohexenyl.
  • heterocycloalkenyl refers to an alicyclic moiety having from three to six carbon atoms and one or more heteroatoms from the group N, O, S and having in addition one double bond. This term includes, for example, dihydropyranyl.
  • aryl means an optionally substituted phenyl or naphthyl group with the substituent(s) being selected, for example, from halogen, trifluoromethyl, C, ⁇ alkyl, alkoxy, phenyl and the like.
  • heteroaryl refers to aromatic ring systems of five to ten atoms of which at least one atom is selected from O, N and S, and includes for example furanyl, thiophenyl, pyridyl, indolyl, quinolyl and the like.
  • alkoxy refers to a straight chain or branched chain alkoxy group containing a maximum of six carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tcrt-butoxy and the like.
  • halogen means fluorine, chlorine, bromine or iodine.
  • protected amino and “protected carboxy” mean amino and carboxy groups which can be protected in a manner familiar to those skilled in the art. For example, an amino group can be protected by a benzyloxycarbonyl, t ⁇ r/-butoxycarbonyl, acetyl or like group, or may be in the form of a phthalimido or like group.
  • a carboxyl group can be protected in the form of a readily-cleavable ester such as the methyl, ethyl, benzyl or tort-butyl ester.
  • Salts of compounds of formula (I) include pharmaceutically-acceptable salts, for example acid addition salts derived from inorganic or organic acids, such as hydrochlorides, hydrobromides, p-toiuenesulphonates, phosphates, sulphates, perchlorates, acetates, trifluoroacetates, propionates, citrates, malonates, succinates, lactates, oxalates, tartrates and benzoates.
  • acid addition salts derived from inorganic or organic acids such as hydrochlorides, hydrobromides, p-toiuenesulphonates, phosphates, sulphates, perchlorates, acetates, trifluoroacetates, propionates, citrates, malonates, succinates, lactates, oxalates, tartrates and benzoates.
  • Salts may also be formed with bases.
  • Such salts include salts derived from inorganic or organic bases, for example alkali metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.
  • the "protected carboxy” group in compounds of the invention is an esterified carboxyl group, it may be a metabolically-labile ester of formula CO 2 R 10 where R'° may be an ethyl, benzyl, phenethyl, phenylpropyl, ⁇ - or ⁇ -naphthyl, 2,4- dimethylphenyl, 4-tcvt-butylphenyl, 2,2,2-trifluoroethyl, l-(benzyloxy)benzyl, 1- (benzyloxy)ethyl, 2-methyl- l-propionyloxypropyl, 2,4,6-trimethylbenzyioxymethyl or pivaloylmethyl group.
  • Compounds of the general formula (I) may be prepared by any suitable method known in the art and/or by the following processes.
  • the compounds according to the invention may be prepared by the following process.
  • the groups R ⁇ R 2 , R 3 , R 4 , R 5 , R e , R 7 , R 8 , R 9 , R t0 , B, X and Y are as defined above, except where otherwise indicated.
  • functional groups such as amino, hydroxyl or carboxyl groups, present in the various compounds described below, and which it is desired to retain, may need to be in protected form before any reaction is initiated. In such instances, removal of the protecting group may be the final step in a particular reaction. Suitable protecting groups for such functionality will be apparent to those skilled in the art. For specific details see Greene et al, "Protective Groups in Organic Synthesis", Wiley Interscience.
  • a suitable leaving group e.g. a halogen such as bromine, or an alkylsulphonate ester such as methanesulphonate.
  • Alkylating agents (III) can be obtained in chiral or racemic form. Many of these derivatives can be readily obtained from commercially available starting materials using methods known to those skilled in the art (see WO-A-9005719).
  • hydroxamides NHOR 11
  • R" is a suitable protecting group such as benzyl, fcvr-butyl or tcvf-butyldimethylsilyl (TBDMS).
  • Dicarboxylic acids of formula (V) may be prepared by the alkylation of, for instance, diethyl malonate with an alkylating agent of formula R'-Z (VI), wherein Z is as defined above, followed by hydrolysis under basic conditions.
  • Compounds of formula (II) in which B includes includes an aryl, heteroaryl, functional or other group as a substituent on a core part thereof (B'), may be prepared by palladium-catalysed coupling of an aryl, heteroaryl, functionalising or other compound with a compound of general formula A-B'-XR 12 (VII) wherein R 12 is a suitable protecting group such as a methyl, tert-butyl, benzyl or trityl, and A is a halide such as iodide, bromide or, in some instances, chloride. This is followed by removal of any protecting groups.
  • Compounds of formula (I) may also be prepared by interconversion of other compounds of formula (I).
  • a compound of formula (I) wherein R' is a C,_s alkyl group may be prepared by hydrogenation (using palladium on carbon in suitable solvent, such as an alcohol, e.g. ethanol) of a compound of formula (I) wherein R 1 is a C 2 _s alkenyl group.
  • suitable solvent such as an alcohol, e.g. ethanol
  • a compound of formula (I) wherein X is S(0) ⁇ . 2 may be prepared by oxidation of a compound of formula (I) wherein X is S.
  • Any mixtures of final products or intermediates obtained can be separated on the basis of the physico-chemical differences of the constituents, in known manner, into the pure final products or intermediates, for example by chromatography, distillation, fractional crystallization, or by formation of a salt if appropriate or possible under the circumstances.
  • the compounds according to the invention exhibit in vitro inhibiting activities with respect to the stromelysins, collagenases and gelatinases. Compounds according to the invention also exhibit in vitro inhibition of TNF release, TNF receptor shedding, IL-6 receptor shedding and ⁇ -seiectin shedding.
  • the 80kD TNF receptor (TNFRg o ) is proteolytically cleaved at the cell surface
  • protease cleavage site in pro-TNF(Ala-Val) is also present in the extracellular domain of TNFR g0 (Ala 2l3 -Val 214 ) at a site consistent with the observed molecular weight of the shed receptor fragment.
  • metalloproteinase inhibitors may offer protection from the deleterious systemic effects of TNF ⁇ at two levels simultaneously, firstly by preventing the release of soluble TNF ⁇ , and secondly by blocking the accumulation of shed TNFR J Q.
  • metalloproteinase inhibitors Synergistically with TNF, metalloproteinase inhibitors also inhibit the release of APO- 1 /Fas (CD95) ligand (APO-1L) which induces apoptosis in sensitive target cells.
  • APO- 1 /Fas (CD95) ligand (APO-1L) which induces apoptosis in sensitive target cells.
  • CD95 APO-1/Fas
  • CD95 a type I transmembrane glycoprotein belonging to the nerve growth factor/TNF receptor sub-family is also blocked by known metalloproteinase inhibitors but not by common inhibitors of serine/cysteine proteases; see Mariani et al, Eur. J. Immunol., (1995) 25:2303.
  • sheddases provide new targets for inhibitors of metalloproteinases, including compounds of the present invention.
  • the activity and selectivity of the compounds may be determined by use of the appropriate enzyme inhibition test, for example as described in Examples A-M, below.
  • Certain compounds of this invention have selective inhibitory activity, in particular inhibition of MMP substantially without inhibition of TNF release and related activities as defined above. This may be of particular value where such activities are associated with reduced side-effects.
  • This invention also relates to a method of treatment for patients (including man and/or mammalian animals raised in the dairy, meat or fur industries or as pets) suffering from disorders or diseases which can be attributed to stromelysin as previously described, and more specifically, a method of treatment involving the administration of the matrix metalloproteinase inhibitors of formula (I) as the active constituents.
  • the compounds of formula (I) can be used among other things in the treatment of osteoarthritis and rheumatoid arthritis, and in diseases and indications resulting from the over-expression of these matrix metalloproteinases such as found in certain metastatic tumour cell lines.
  • this invention concerns: a method of management (by which is meant treatment of prophylaxis) of disease or conditions mediated by TNF and/or MMPs in mammals, in particular in humans, which method comprises administering to the mammal an effective, amount of a compound of formula (I) above, or a pharmaceutically acceptable salt thereof; and a compound of formula (I) for use in human or veterinary medicine, particularly in the management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by TNF and/or MMPs; and the use of a compound of formula (I) in the preparation of an agent for the management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by TNF and/or MMPs.
  • the disease or conditions referred to above include inflammatory diseases, autoimmune diseases cancer, cardiovascular diseases, diseases involving tissue breakdown such as rheumatoid arthritis, osteoarthritis, osteoporosis, neurodegeneration, Alzheimer's disease, stroke, vasculitis, Crohn's disease, ulcerative colitis, multiple sclerosis, periodontitis, gingivitis and those involving tissue breakdown such as bone resorption, haemorrhage, coagulation, acute phase response, cachexia and anorexia, acute infections, HIV infections, fever, shock states, graft versus host reactions, dermatological conditions, surgical wound healing, psoriasis, atopic dermatitis, epidermolysis bullosa, tumour growth, angiogenesis and invasion by secondary metastases, ophthalmological disease, retinopathy, corneal ulceration, reperfusion injury, migraine, meningitis, asthma, rhinitis, allergic conjunctivitis, eczema, anaphylaxis, restenos
  • the compounds of formula (I) may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the US Patents 4,256, 108; 4, 166,452; and 4,265,874, to form osmotic therapeutic tablets for control release.
  • Formulations for oral use may also be presented as hard gelatin capsules where in the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy- propylmethylcellulose, sodium alginate polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such a polyoxyethylene with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate.
  • suspending agents for example sodium carboxymethylcellulose, methylcellulose
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n- propyl, p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • preservatives for example ethyl, or n- propyl, p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti- oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent, suspending agent and one or more preservatives Suitable dispersing or wetting agents and suspending agents are exemplified, for example sweetening, flavouring and colouring agents, may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally- occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soya bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavouring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be in a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1 ,3-butane diol.
  • a non-toxic parenterally-acceptable diluent or solvent for example as a solution in 1 ,3-butane diol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the compounds of formula (I) may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • topical use creams, ointments, jellies, solutions or suspensions, etc containing the compounds of Formula (I) are employed.
  • topical application includes mouth washes and gargles.
  • Dosage levels of the order of from about 0.05 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above- indicated conditions (about 2.5 mg to about 7 g per patient per day).
  • inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day (about 0.5 mg to about 3.5 g per patient per day).
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration of humans may vary from about 5 to about 95% of the total composition.
  • Dosage unit forms will generally contain between from about 1 mg to about 500 mg of active ingredient.
  • Diazomethane preparation The reaction vessel of a standard diazomethane kit (fitted with a CO 2 condenser and trap and an addition funnel) was charged with a solution of potassium hydroxide (5.00 g) in water (8 ml) and ethanol (10 ml). The vessel was heated to 65 °C and a solution of ⁇ -methyl- ⁇ -nitroso-4-toIuene sulfonamide (Diazald,® 5.00 g) in diethyl ether (45 ml) was added dropwise over 30 min from an addition funnel.
  • ⁇ -methyl- ⁇ -nitroso-4-toIuene sulfonamide Diazald,® 5.00 g
  • Diazomethane solution was collected by continuous distillation.Ethyl chloroformate was added dropwise to a stirred solution of 4-phenylbutyric acid (1.36 g) and N- methylmo ⁇ holine (1.28 ml) in THF (15 ml) at -12 °C under a nitrogen atmosphere. A white precipitate began to form, which was removed by filtration after 90 min. The filtrate was treated with a pre-formed solution of diazomethane (16.6 mmol) in diethyl ether at 0 °C. The combined solution of diazomethane and anhydride was stirred at 0 °C for 3.5 h and room temperature for 1 h.
  • the mixture was stirred at a temperature not exceeding 0°C for 1 h before being allowed to warm to room temperature and then heated to 40°C for a period of 20 h.
  • a saturated aqueous solution of NH 4 CI (100 ml) was added.
  • the mixture was extracted with ethyl acetate (3 x 100 ml) and the combined extracts were washed with brine and dried (MgSO 4 ).
  • the solvent was removed in vacuo and the residue was eluted from a column of silica with 10 % diethyl ether in hexane to provide the title compound as an equal mixture of £ and Z isomers as a colourless liquid (265 mg. 61 %).
  • the solution was acidified with 6 ⁇ HCl and the mixture was extracted with ethyl acetate (3 x 300 ml). The combined extracts were washed with brine and the solvent was removed / ' // vacuo to give a brown solid (41 g). The solid was dissolved in ethyl acetate (500 ml) and the solution was extracted with ⁇ aOH (5 %, 4 x 200 ml). The combined extracts were acidified to pH 3 with 6 ⁇ HCl and the resulting precipitate was collected by filtration, washed with water and dried in vacuo to give the title compound as a beige solid (21 g, 43%).
  • Benzoyl chloride (1.41 g) was added to a solution of 4-bromopiperidine hydrobromide (2.45 g) in THF (30 ml) at 0°C, followed by triethylamine (2.2 g, 2.2 eq). The solution was stirred at room temperature for 1 h, and evaporated and. The residue was dissolved in dichloromethane ( 100 ml), washed with water, 1M HCl and saturated sodium bicarbonate, dried and evaporated to give the title compound as colourless oil (2.76 g, 100%). TLC R f 0.55 (ether).
  • Chlorine was passed through a suspension of intermediate 57 (0.7 g) in iced water (20 ml) for 30 min. The yellow suspension was then extracted with dichloromethane and the solvent was washed with water, sodium metabisulfite and brine, then dried and evaporated to give a the title compound (0.7g, 100%) as colourless oil.
  • Example 21 2-(4-Met-.oxyphenylsulfonylrnethyI)-5-(3,3,4-trimethyl- hydantoin-l-yI)pentanoic Acid From intermediate 80 (0.8 g) as a white solid (0.6 g, 70%).
  • Example 22 2-(4-MethoxyphenyIsulfonylmethyl)-4-(3,3,4-trimethyl- hydantoin-l-yl)butanoic Acid From intermediate 81 (0.57 g) as a white solid (0.50 g, 79%).
  • Example 33 2-((4-Methoxyphenyl)sulfonyimethyl)-4-(2- pyridyl)butanoic Acid From intermediate 94 (0.25 g), as a white solid (0.26 g, 100 %). TLC R f 0.22 (10% MeOH/dichloromethane). MS 350 (MH + ).
  • Lithium hydroxide (100 mg) was added to a solution of the ester intermediate 143 (0.16 g) in methanol (5 ml) THF (10 ml) and water (5 ml) and the solution was stirred for 6 h, then evaporated in vacuo and the residue dissolved in water. The aqueous solution was washed with ether, then acidified with citric acid and extracted with dichloromethane. The dichloromethane extracts were combined and washed with water, dried and evaporated to give the crude product. This material was purified by flash column chromatography, eluting with 60% ether/hexanes, to give the title compound as colourless oil (60 mg, 40 %).
  • Example 37 2-(4-Benzoylphenylsulfonylmethyl)-5-phthaIimido- pentanoic Acid N-Hydroxyamide
  • a solution of example 2 (0. 1 g) in anhydrous THF (10 ml) was treated at room temperature with O-(/tvY-butyldirnethylsilyI)hydroxylamine (0.032 g) and l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.042 g). The mixture was stirred for 24 hours and the organic solvent removed in vacuo.
  • Example 41 2-(4-N,N-Di ⁇ netl ⁇ yIcarbamoylphenylsulfanylmethyl)-5- phenylpentanoic Acid N-Hydroxy Amide From example 4 (0.232 g) as a white solid (0.046 g, 25%). TLC R f 0.49 (10% methanol-dichloromethane) MS 419 MH *
  • Example 42 2-(4-MethoxyphenylsulfonylmethyI)-5-phthalimido- pentanoic Acid N-Hydroxy Amide From example 5 (0.35 g), as a white solid (0.12 g, 43%). TLC R f 0.52 (5% methanol-dichloromethane) MS 447 MH +
  • Example 43 2-(4-Methoxyphenylsulfonylmethyl)-4-phthalimido- butanoic Acid N-Hydroxy Amide From example 6 (0.3 g), as a white solid (0.1 1 g, 35%). TLC R f 0.48 (5% methanol-dichloromethane) MS 433 MH + Example 44 3-(4-Bromophenylsulfonyl)propanoic Acid N-Hydroxy
  • Example 61 2-(4-Acetylaminophenylsulfonylmethyl)-5- phenylpentanoic Acid ⁇ -Hydroxy Amide From intermediate 129 (0.12 g) as a beige solid (0.04 g, 32%). TLC R f 0.2 (5% methanol-dichloromethane) MS 406 MH+.
  • Example 62 2-(l-Metl ⁇ yIimidazoi-2-ylsulfonylmethyI)-5-phenylpentan- oic Acid N-Hydroxy Amide
  • Example 65 2-(4-Methoxyphenylsulfonylmetl ⁇ yi-5-succinimido- pentanoic Acid N-Hydroxy Amide From example 19 (1.15 g) as a white solid (0.90 g, 74%). TLC R f O.35 (10% methanol-dichloromethane). MS 398 (M+).
  • Example 66 2-(4-Benzoylphenyl)sulfonylmethyi-5-succinimido- pentanoic Acid N-Hydroxy Amide From example 20 (0.26 g) as a white solid (0.22 g, 79%). TLC R f 0.45 (10% methanol-dichloromethane). MS 471 (M+).
  • Example 67 2-(4-MethoxyphenylsulfonylmethyI-5-(3,3,4-trimethyl- hydantoin-l-yl)pentanoic Acid N-Hydroxy Amide From example 21 (0.6 g) as a white solid (0.45 g, 70%). TLC R f 0.55 (10 % methanol-dichloromethane). MS 442 (MH+)
  • Example 68 2-(4-MethoxyphenylsulfonyImethyl-4-(3,3,4-trimethyI- hydantoin-l-yI)butanoic Acid-N-Hydroxy Amide
  • Example 75 2-((4-Trifluoromethoxyphenylsulfonyl)methyI)-5-(l,5,5- trimethylhydantoin-3-yl)pentanoic Acid N-Hydroxy Amide From example 27 (0.46 g), as a white solid (0.36 g, 77%). TLC R f 0.16 (ethyl acetate / hexane (3: 1) with trace acetic acid) MS 496 (MH + ) Example 76 2-((4-TrifIuoromethoxybenzenesulfonylmethyI)pentanoic
  • Example 82 2-((l-Benzoylpiperidine-4-yl)suIfonylmethyI)-5-phenyl- pentanoic Acid N-Hydroxy Amide From intermediate 135 (1.05 g) as white solid (0.85 g, 80%). TLC R f 0.43 (7% MeOH/dichloromethane) MS 458 (M + ).
  • Example 83 2-((l-t ⁇ r «'-B ⁇ tyloxycarbonylpiperidin-4- yI)sulfonylmethyl)-5-phei]ylpentanoic Acid N-Hydroxy Amide From intermediate 142 (3.5 g), as white foam (2.40 g, 66%). TLC R f 0.7 (7% MeOH/dichloromethane). MS 454 (M + ).
  • Example 84 2-(4-Methoxyphenyl)sulfonylmethyI)-4-(pyrid-2-yl)butan- oic Acid N-Hydroxy Amide From example 33 (0.26 g), as white solid (0.20 g, 75 %). TLC R f 0.5 (10% MeOH/dichloromethane). MS 365 (MH + ).
  • Example 85 2-((4-Pyridinoylphenyl)sulfonylmethyI)-5- phenylpentanoic Acid N-Hydroxy Amide From intermediate 136 (1.08 g), as white solid (0.75 g, 67%). TLC R f 0.40 (7% MeOH/dichloromethane). MS 453 (MH + ).
  • Example 86 2-(4-(2-ThienoyI)phcnylsulfonylmethyl)-5- phenylpentanoic Acid N-Hydroxy Amide
  • Example 87 2-((4-(4-Pyridinoyl)phe ⁇ yl)sulfonylmethyI)-5-(3,3,4- trimethyIl ⁇ ydantoin-l-yl)pentanoic Acid N-Hydroxy Amide From intermediate 138 (0.10 g), as white solid (0.025 g, 26%). TLC R f 0.60 (10% MeOH/dichloromethane). MS 517 (MH + ).
  • Example 88 2-((4-(2-Thienoyl)phcnyl)sulfonylmethyl)-5-(3,3,4- trimethyIhydantoin-l-yl)pentanoic Acid N-Hydroxy Amide From intermediate 139 (1.2 g), as white solid (0.66 g, 60%). TLC R f 0.52 (7% MeOH/dichloromethane) MS 521 (M + ).
  • Example 96 5-PhenyI-2-(4-(phenylmethyl)phenylsulfonylmethyI)- pentanoic Acid N-Hydroxy Amide
  • Example 58 (0.203 g) and triethylsilane (0.42 mi) were held at reflux in trifluoroacetic acid (10 ml) for 30 h. The solvent was removed / ' // vacuo, and the residue triturated with hexane (twice) to leave, after vacuum drying, a red solid (0.253 g).
  • the crude red product was then purified by chromatography on silica, with 4% methanol / dichloromethane as eluent collecting fractions at R f 0.27 to give a white solid. Further column purification of the white solid with 2% methanol / dicloromethane eluent collecting at R f 0.14 provided a white solid (0.10 g). In order to remove residual traces of the starting hydroxamic acid, the residue was further purified as follows: 2,4- Dinitrophenylhydrazine (0.15 g) was suspended in methanol and treated with concentrated sulfuric acid (0.3 ml), and the warm mixture filtered.
  • Trifluoroacetic acid (20 ml) was added to a solution of the acid example 83 (2.4 g) in dichloromethane (20 ml) at room temperature and the solution was stirred for 2h, then evaporated in vacuo and the residue azeotroped with toluene (2 x 50 ml). The resulting solid ws then precipitated from methanol by addition of ether to give the title compound (1.54 g, 65 %).
  • Example 98 2-((l-BenzyIpiperidin-4-yl)sulfonylmethyl)-5-phenyl- pentanoic Acid N-Hydroxy Amide Sodium triacetoxyborohydride (0.22 g) was added to a solution of example 97 (0.23 g), triethylamine (60 mg) and benzaldehyde (106 mg) in a mixture of dichloromethane (10 ml) and methanol (2 ml). The mixture was stirred at room temperature for 6 h, then evaporated in vacuo and the residue partitioned between water and dichloromethane.
  • Example 101 2-(4-(l-Methyleth-l-yloxy)pheny.sulfonyimethyl)-5- phenylpentanoic Acid N-Hydroxy Amide From intermediate 147 (0.35 g) as white solid (0.20 g, 48%). TLC R f 0.25 (5% MeOH/dichloromethane). MS 405 (M + ).
  • Example 60 was dissolved in dichloromethane and treated with excess IM HCl in diethyl ether and then evaporated to give the title compound (0.20 g) as a pale yellow solid.
  • Example 107 4-[4-(Methoxycarbonyi)methoxy-3,5-dimethyphenyl]-2- methyl-l(2H)phthalazinone
  • Lithium hydroxide monohydrate (0.22 g) was added to a solution of example 107 (1.52 g) in aqueous tetrahydrofuran (1 : 1 50 ml) and the reaction stirred 18 h. the mixture was the concentrated in vacuo and the residual slurry acidified with 10% hydrochloric acid.
  • example 108 (1. 15 g) in dichloromethane (30 ml) at 0 °C was treated with triethylamine (0.52 g) followed by isopropenyl chloroformate (0.41 g), and the mixture was stirred for 1 h. O-ttrt-butyldimethylsilylhydroxylamine (0.50 g) was then added and the mixture was stirred for a further 18 h. The reaction mixture was washed with 10% citric acid (20 ml), saturated sodium bicarbonate (20 ml) and the concentrated to dryness in vacuo.
  • the potency of compounds of general formula (I) to act as inhibitors of stromelysin was determined using the procedure of Nagase et al (Methods in Enzymology Vol 254, 1994), whereby a 0.1 mM solution of the inhibitor being tested or dilutions thereof was incubated at 37°C for 16 hours with stromelysin and H transferrin (buffered with 50 mM Tris, pH 7.6 containing 10 mM CaCl 2 , 150M NaCl, 0.05% Brij, 35, and 0.02% NaN 3 ). The transferrin was carboxymethylated with 3 H iodoacetic acid.
  • the stromelysin activity in the presence of 1 mM, or a dilution thereof was compared to activity in a control devoid of inhibitor and the results reported as that inhibitor concentration effecting 50% inhibition of the stromelysin (IC 50 )
  • Example C Gelatinase inhibition activity The potency of the compounds of general formula (I) to act as inhibitors of gelatinase was determined using the procedure of Harris & Krane (Biochem Biophys.
  • the potency of compounds of general formula (I) to act as inhibitors of collagenase- 1 (MMP- 1), collagenase-2 (MMP-8), collagenase-3 (MMP- 13), gelatinase- A (MMP-2), gelatinase-B (MMP-9) and stromelysin- 1 (MMP-3) was determined using the following procedure:
  • Inhibitors are dissolved in dimethylsulphoxide containing 0.02% ⁇ - mercaptoethanol and serial dilutions are prepared.
  • Activated enzyme is incubated in assay buffer containing 50mM Tris, pH 7.4, 5mM CaCl 2 , 0.002% NaN 3 and Brij 35 in the presence and absence of inhibitor.
  • Samples are preincubated at 37°C for 15 minutes before the addition of the fluorimetric substrate (Mca-Pro-Leu-GIy-Leu-Dpa-Ala-Arg- NHj) to a final concentration of lO ⁇ M.
  • the assay is incubated for 20-30 min at 37°C and then read in a Fluoroscan II at ⁇ (340nm) and ⁇ ,. m (405nm).
  • the potency of the compounds of general formula (I) to act as inhibitors of the production of TNF ⁇ is determined using the following procedure.
  • a lOO M solution of the inhibitor being tested or dilutions thereof is incubated at 37° C in an atmosphere of 5% CO 2 with THP-1 cells (human monocytes) suspended in RPM1 1640 medium and 20 M ⁇ -mercaptoethanol at a cell density of 1 x lOVml and stimulated with LPS. After 18 hours the supernatant is assayed for the levels of TNF ⁇ using a commercially available ELISA kit (R & D Systems).
  • PBMC peripheral blood mononuclear cells
  • Example G Inhibition of sIl-lRH shedding Compounds of general formula (I) are evaluated in an assay of sIl-lRII shedding by peripheral blood mononuclear cells (PBMC). PBMC are isolated from buffy coats by standard procedures using Ficoll. A 1 OO ⁇ M solution of the inhibitor being tested or dilutions thereof are incubated for 18h at 37° C in an atmosphere of 5% CO 2 with 2 x lOVml PBMC stimulated with 11-13. The cells are centrifuged down and the supernatants tested for sU-l RIl using a commercially available ELISA kit (R & D Systems).
  • PBMC peripheral blood mononuclear cells
  • PBMC peripheral blood mononuclear cells
  • PBMC peripheral blood mononuclear cells
  • a lOO ⁇ M solution of the inhibitor being tested or dilutions thereof is incubated for 24h at 37° C in an atmosphere of 5% CO 2 with 2 x 10 6 /ml HL-60 cells stimulated with PMA.
  • the cells are centrifuged down and the supernatants tested for sIl-6R using a commercially available ELISA kit (R & D Systems).
  • the potency of the compounds of general formula (I) to act as inhibitors of the shedding of TNF RII is determined using the following procedure. A lOO ⁇ M solution of the inhibitor being tested or dilutions thereof are incubated at 37° C in an atmosphere of 5% CO, with THP-1 cells (human monocytes) suspended in RPM1 1640 medium and 20 ⁇ M ⁇ -mercaptoethanol at a cell density of 1 x IOVml and stimulated with LPS. After 18 hours the supernatant is assayed for the levels of sTNF RII using a commercially available ELISA kit (R & D Systems). The activity in the presence of 0.
  • ImM inhibitor or dilutions thereof is compared to activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the shedding of TNF RIL
  • Example J Adjuvant arthritic rat model
  • Compounds of general formula (I) were evaluated in an adjuvant arthritis model in the rat based on the methods employed by B.B. Newbould (1963), Br.J.Pharmacol, 21, 127-136 and CM. Pearson and F.D. Wood (1959), Arthritis Rheum, 2, 440-459. Briefly male Wistar rats ( 180-200g) were injected at the base of the tail with Freund's adjuvant. Twelve days later the responding animals were randomised into experimental groups.
  • the anti-metastatic potential of compounds of general formula (I) is evaluated in a B 16 melanoma model in C57BL/6.
  • Mice are injected intravenously with 2 x 10 5 B 16/F10 murine tumour cells harvested from in vitro cultures.
  • Inhibitors are administered by the oral route as a suspension in 1% methyl cellulose or intraperitoneally as a suspension in phospate buffered saline pH7.2 + 0.01% Tween-20. Mice are killed 14 days after cell inoculation and the lungs removed and weighed prior to fixing in Bouin's solution. The number of colonies present on the surface of each set of lungs is then counted by eye.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention concerns hydroxamic acid and carboxylic acid derivatives of formulae (I): B-X-(CH2)n-CHR1-(CH2)m-CONHOH and (Ia): B-S(O)1-2-(CH2)n-CHR1-(CH2)m-COOR2, in which X is O, NR¿3? or S(O)0-2, and the other variables have the definitions given in the claims, having MMP and TNF inhibitory activity.

Description

HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY Field of the Invention
This invention relates to hydroxamic and carboxylic acid derivatives, and to their use in medicine.
Background to the Invention
Metalloproteinases, including matrix metalloproteinase (MMP), (human fibroblast) collagenase, gelatinase and TNF convertase (TACE), and their modes of action, and also inhibitors thereof and their clinical effects, are described in WO-A- 9611209, WO-A-9712902 and WO-A-9719075, the contents of which are incorporated herein by reference. MMP inhibitors may also be useful in the inhibition of other mammalian metalloproteinases such as the adamalysin family (or ADAMs) whose members include TNF convertase (TACE) and ADAM- 10, which can cause the release of TNFα from cells, and others, which have been demonstrated to be expressed by human articular cartilage cells and also involved in the destruction of myelin basic protein, a phenomenon associated with multiple sclerosis.
Compounds which have the property of inhibiting the action of metalloproteinases involved in connective tissue breakdown, such as collagenase, stromelysin and gelatinase, have been shown to inhibit the release of TNF both in vitro and in vivo. See Gearing et al ( 1994), Nature 370:555-557; McGeehan e/ α/ (1994), Nature 370:558-561; GB-A-2268934; and WO-A-9320047. All of these reported inhibitors contain a hydroxamic acid zinc-binding group, as do the imidazole-substituted compounds disclosed in WO-A-9523790. Other compounds that inhibit MMP and/or TNF are described in WO-A-9513289, WO-A-9611209, WO-A-96035687, WO-A- 9603571 1, WO-A-96035712 and WO-A-96035714.
WO-A-9718188 discloses MMP inhibitors of the formula
Ph1-Ph2-X-(CH2)f 6-(CZ)0.1-(CHR1)0.1-CO-NHOH wherein Ph1 and Pfv* are each optionally-substituted phenyl; X is absent, O, NH or S; Z is -CONR2R3; and R1 is H, alkyl, alkenyl, OH, optionally-substituted phenylalkyl or phenyl-SOo.2-aIkyl, or alkyl-COOR7.
EP-A-0780386 discloses compounds having MMP and TNF inhibitory activity, of the formula
Y-CO-CR'R2-CR3R4-S(O)„R5 wherein n is 0, 1 or 2; Y is OH or NHOH; R1 is H or lower alkyl; R2 is H, lower alkyl, heteroalkyl, aryl, aralkyl, arylheteroalkyl, cycloalkyi, heteroaryl, heteroaralkyl, heteroarylheteroalkyl, heterocyclo, heterocyclo-lower alkyl, heterocyclo-lower heteroaryl or NR6R7; R3 is H, lower alkyl, cycloalkyi, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or lower alkoxy; R4 is H, lower alkyl, cycloalkyi or cycaloalkylalkyl, and R5 is lower alkyl, cycloalkyi, cycloalkylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl.
Compounds of EP-A-0780386 first disclosed in US Application No. 8939, filed 20 December 1995, are of the same formula, wherein R1 is H; R2 is H, lower alkyl, aralkyl, cycloalkyi, cycloalkylalkyl, heterocyclo or NR6R7; R3 is H, lower alkyl, cycloalkyi, cycloalkylalkyl or aralkyl; R4 is H or lower alkyl; and R5 is lower alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl.
US-A-4325964 discloses certain benzhydryl sulphinyl hydroxamates, as having utility in neuropsychic ailments.
Zayed et al, Zeitschrift fur Naturforschung (1966) 180-182, discloses 3- phenylsulphonylpropanoic acid N-hydroxyamide, as a fungicide. Summary of the Invention
The invention encompasses novel compounds of formula (I) which are useful inhibitors of matrix metalloproteinases and/or TNFα-mediated diseases, including degenerative diseases and certain cancers.
Novel compounds according to the invention are of the general type represented by formula (I):
B-X-(CH2)n-CHR'-(CH2)nι-COY (I) wherein m and n are both independently 0 or 1, but are not both 0;
X is O, NR3 or S(O)o_2;
Y is OR2 or NHOH;
R1 is H or a group (optionally substituted with R9) selected from Cw alkyl, C2* alkeny aryl, C,_s alkyl-aryl, heteroaryl, Cw alkyl-heteroaryl, heterocycloalkyl, Cw alkyl- heterocycloalkyl, cycloalkyi and Cw alkyl-cycloalkyl;
R2 is H or C,^ alkyl;
R3 is H, C,^ alkyl, COR2, CON(R2)2 where each R2 is the same or different, CO2R4 or SO2R\ and R4 is C.-β alkyl;
B is C,^ alkyl-aryl, C^ alkyl, cycloalkyi, C1-6 alkyl-cycloalkyl, cycloalkenyl, heterocycloalkenyl, Cw alkyl-heteroaryl, heterocycloalkyl, C,^ alkyl-heterocycloalkyl, aryl or heteroaryl, any of which groups is optionally substituted by a substituent selected from R5, Cw alkyl-Rs, C^ alkenyl-R5, aryl (optionally substituted with R5), aryl-C,^ alkyl-R5, C,^ alkyl-aryl (optionally substituted with R5), C,^ alkyl-heteroaryl (optionally substituted with R5), aryl-C2^ alkenyl-R7, heteroaryl (optionally substituted with R5), heteroaryl-C,^ alkyl-R5, cycloalkyi (optionally substituted with R5), benzofused cycloalkyi (optionally substituted with R5), heterocycloalkyl (optionally substituted with R5), benzofused heterocycloalkyl (optionally substituted with Rs), and the groups:
Figure imgf000005_0001
provided that B is not benzhydryl when X is SO and R1 is H;
R5 is C^ alkyl, C« alkenyl-R7, halogen, CN, NO2, N(R6)2, OR6, COR6, CO2R2, CON(R6)2, NR6R7, S(O),„Rg or SO2N(R6)2; R6 is H or a group selected from C,^ alkyl, aryl, C^ alkyl-aryl, heteroaryl, Cw alkyl-heteroaryl, cycloalkyi, CM alkyl-cycloalkyl, heterocycloalkyl and C M alkyl- heterocycloalkyl, wherein said group is optionally substituted with R8, COR*,
Figure imgf000006_0001
CO^8, OR*, CONR2R8, NR2R8, halogen, CN, SO2NR2R8 or NO2) and for each case of N(R6)2 the R6 groups are the same or different or N(R6)2 is heterocycloalkyl optionally substituted with R8, COR*, SO^R*, CO2R8, OR8, CONR2R8, NR2R8, halogen, CN, SO2NR R8 or NO2;
R7 is COR6, CON(R6)2, CO2R' or SO2R8;
R8 is Cw alkyl, aryl, C,^ alkyl-aryl, heteroaryl or C,^ alkyl-heteroaryl; and R'is OR6, COR6, CO^2, CONfll6)* NR6R7, S(O)o.2R8, SO2N(R6)2, phthalimido, succinimido or the group
Figure imgf000006_0002
and the salts, solvates, hydrates, protected amino and protected carboxy derivatives thereof; provided that the compound is not 3-phenyisulfonylpropanoic acid N-hydroxy amide.
Combinations of substituents and/or variables are only permissible if such combinations result in stable compounds. Description of the Invention
Preferred compounds of the invention are those wherein any one or more of the following apply:
X is S, SO or SO2;
R1 is H or a group (optionally substituted with R9) selected from C,^ alkyl, C2-β alkenyl, C,_g alkyl-aryl, Cw alkyl-heteroaryl, C,^ alkyl-heterocycloalkyl and C,^ alkyl- cycloalkyl; B is C,^ alkyl-aryl, C,^ alkyl, cycloalkyi, cycloalkenyl, heterocycloalkenyl, C,_j alkyl-heteroaryl, aryl or heteroaryl, any of which groups is optionally substituted by a substituent selected from R5, C,^ alkyl-R5, aryl (optionally substituted with R5), aryl-Cw alkyl-R5, C,^ alkyl-aryl (optionally substituted with R5), C,^ alkyl-heteroaryl (optionally substituted with R5), heteroaryl (optionally substituted with Rs), heteroaryl- C alkyl-R5, heteroaryl-Cw alkyl-R5 cycloalkyi (optionally substituted with R5), benzofused cycloalkyi (optionally substituted with R5), heterocycloalkyl (optionally substituted with Rs), benzofused heterocycloalkyl (optionally substituted with R5), and the groups:
Figure imgf000007_0001
R5 is halogen, CN, NO2, N(R6)2, OR6, COR6, CON(R6)2, NR6R7, or S(O)o.2R8;
R7 is COR6; and
R9 is OR6, CO2R2, CON(R6)2, phthalimido, succini ido or the group
Figure imgf000007_0002
The compounds of the Examples are particularly preferred.
It will be appreciated that the compounds according to the invention can contain one or more asymmetrically substituted carbon atoms. The presence of one or more of these asymmetric centres in a compound of formula (I) can give rise to stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers, including enantiomers and diastereomers, and mixtures including racemic mixtures thereof. As used in this specification, alone or in combination, the term "C,^ alkyl" refers to straight or branched chain alkyl moiety having from one to six carbon atoms, including for example, methyl, ethyl, propyl, isopropyl, butyl, ttvv-butyl, pentyl, hexyl and the like.
The term "C2-6 alkenyl" refers to a straight or branched chain alkyl moiety having two to six carbon atoms and having in addition one double bond, of either E or Z stereochemistry where applicable. This term would include for example, vinyl, 1- propenyl, 1- and 2- butenyl, 2- methyl-2-propenyl etc.
The term "cycloalkyi" refers to a saturated alicyclic moiety having from three to six carbon atoms and includes for example cyclopropyl, cyclobutyl, cyciopentyl, cyclohexyl and the like. "Benzofused cycloalkyi" includes indanyl and tetrahydronaphthyl.
The term "heterocycloalkyl" refers to a saturated heterocyclic moiety having from three to six carbon atoms and one or more heteroatom from the group N, O, S and includes for example azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl and the like. "Benzofused hetercycloalkyl" includes indolinyl and tetrahydroquinolinyl.
The term "cycloalkenyl" refers to an alicyclic moiety having from three to six carbon atoms and having in addition one double bond. This term would include for example cyclopentenyl or cyclohexenyl.
The term "heterocycloalkenyl" refers to an alicyclic moiety having from three to six carbon atoms and one or more heteroatoms from the group N, O, S and having in addition one double bond. This term includes, for example, dihydropyranyl.
The term "aryl" means an optionally substituted phenyl or naphthyl group with the substituent(s) being selected, for example, from halogen, trifluoromethyl, C,^ alkyl, alkoxy, phenyl and the like. The term "heteroaryl" refers to aromatic ring systems of five to ten atoms of which at least one atom is selected from O, N and S, and includes for example furanyl, thiophenyl, pyridyl, indolyl, quinolyl and the like.
The term "alkoxy" refers to a straight chain or branched chain alkoxy group containing a maximum of six carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tcrt-butoxy and the like.
The term "halogen" means fluorine, chlorine, bromine or iodine. The terms "protected amino" and "protected carboxy" mean amino and carboxy groups which can be protected in a manner familiar to those skilled in the art. For example, an amino group can be protected by a benzyloxycarbonyl, tør/-butoxycarbonyl, acetyl or like group, or may be in the form of a phthalimido or like group. A carboxyl group can be protected in the form of a readily-cleavable ester such as the methyl, ethyl, benzyl or tort-butyl ester.
Salts of compounds of formula (I) include pharmaceutically-acceptable salts, for example acid addition salts derived from inorganic or organic acids, such as hydrochlorides, hydrobromides, p-toiuenesulphonates, phosphates, sulphates, perchlorates, acetates, trifluoroacetates, propionates, citrates, malonates, succinates, lactates, oxalates, tartrates and benzoates.
Salts may also be formed with bases. Such salts include salts derived from inorganic or organic bases, for example alkali metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.
When the "protected carboxy" group in compounds of the invention is an esterified carboxyl group, it may be a metabolically-labile ester of formula CO2R10 where R'° may be an ethyl, benzyl, phenethyl, phenylpropyl, α- or β-naphthyl, 2,4- dimethylphenyl, 4-tcvt-butylphenyl, 2,2,2-trifluoroethyl, l-(benzyloxy)benzyl, 1- (benzyloxy)ethyl, 2-methyl- l-propionyloxypropyl, 2,4,6-trimethylbenzyioxymethyl or pivaloylmethyl group.
Compounds of the general formula (I) may be prepared by any suitable method known in the art and/or by the following processes.
It will be appreciated that, where a particular stereoisomer of formula (I) is required, the synthetic processes described herein may be used with the appropriate homochiral starting material and/or isomers maybe resolved from mixtures using conventional separation techniques (e.g. HPLC).
The compounds according to the invention may be prepared by the following process. In the description and formulae below the groups R\ R2, R3, R4, R5, Re, R7, R8, R9, Rt0, B, X and Y are as defined above, except where otherwise indicated. It will be appreciated that functional groups, such as amino, hydroxyl or carboxyl groups, present in the various compounds described below, and which it is desired to retain, may need to be in protected form before any reaction is initiated. In such instances, removal of the protecting group may be the final step in a particular reaction. Suitable protecting groups for such functionality will be apparent to those skilled in the art. For specific details see Greene et al, "Protective Groups in Organic Synthesis", Wiley Interscience.
A process for preparing compounds of general formula (I) comprises alkylating a compound of formula B-XH (II) wherein B and X are as previously defined, wit an alkylating agent of formula Z-(CH2)0-CHRl-(CH2)m-COY (III) or (when m=0) an acrylate of formula CH2=CR'-COY (IV) wherein R1 and Y are as defined previously and Z represents a suitable leaving group (e.g. a halogen such as bromine, or an alkylsulphonate ester such as methanesulphonate).
Alkylating agents (III) can be obtained in chiral or racemic form. Many of these derivatives can be readily obtained from commercially available starting materials using methods known to those skilled in the art (see WO-A-9005719). Acrylates of formula (IV) may be prepared by the Mannich reaction (i.e. with paraformaldehyde and piperidine in a suitable organic solvent, such as 1 ,4-dioxane) on a dicarboxylic acid of general formula HO2C-CHR'-CO2H (V). This reaction involves an eliminative decarboxylation step resulting in the formation of an α,β- unsaturated carboxylic acid (i.e. where Y=OH) directly. This carboxylic acid can then be elaborated using standard chemistry, known to those skilled in the art, to provide esters (Y=OR ) or hydroxamides (NHOR11) where R" is a suitable protecting group such as benzyl, fcvr-butyl or tcvf-butyldimethylsilyl (TBDMS).
Dicarboxylic acids of formula (V) may be prepared by the alkylation of, for instance, diethyl malonate with an alkylating agent of formula R'-Z (VI), wherein Z is as defined above, followed by hydrolysis under basic conditions.
Compounds of formula (II) in which B includes includes an aryl, heteroaryl, functional or other group as a substituent on a core part thereof (B'), may be prepared by palladium-catalysed coupling of an aryl, heteroaryl, functionalising or other compound with a compound of general formula A-B'-XR12 (VII) wherein R12 is a suitable protecting group such as a methyl, tert-butyl, benzyl or trityl, and A is a halide such as iodide, bromide or, in some instances, chloride. This is followed by removal of any protecting groups.
Many such palladium-catalysed coupling reactions are known to those skilled in the art and can provide compounds of formula (II) bearing substituents described by R5 such as COR6, CO2R2 or CON(R6)2 as well as aryl, heteroaryl, alkenyl or alkyl groups optionally substituted by R$. See, for example, Syn. Comm. (1981) 11:513; Tet. Lett. (1987) 28:5093; and J. Org. Chem. (1994) 59:6502. Other groups described by B and/or R5 can be introduced by standard chemical transformations known to those skilled in the art. Many compounds of general formulae (II), (VI) and (VII) are commercially available or may be prepared, by standard aromatic, heteroaromatic or other chemistry known to those skilled in the art, from commercially-available materials. If required, intermediates of general formulae (VIII) and (IX)
Figure imgf000011_0001
may be prepared by Friedel-Crafts acylation of a simple aromatic system Ph-XH (X) with phthalic or maleic anhydride, followed by treatment with a hydrazine of general formula H2N-NHR2 (XI).
Compounds of formula (I) may also be prepared by interconversion of other compounds of formula (I). Thus, for example, a compound of formula (I) wherein R' is a C,_s alkyl group may be prepared by hydrogenation (using palladium on carbon in suitable solvent, such as an alcohol, e.g. ethanol) of a compound of formula (I) wherein R1 is a C2_s alkenyl group. Further, a compound of formula (I) wherein X is S(0)ι.2 may be prepared by oxidation of a compound of formula (I) wherein X is S.
Carboxylic acids of general formula (I) (Y=OH) may be converted to other compounds of formula (I) such as esters (Y=OR2) or hydroxamic acids (Y=NHOH) using methods known to those skilled in the art.
Any mixtures of final products or intermediates obtained can be separated on the basis of the physico-chemical differences of the constituents, in known manner, into the pure final products or intermediates, for example by chromatography, distillation, fractional crystallization, or by formation of a salt if appropriate or possible under the circumstances.
The compounds according to the invention exhibit in vitro inhibiting activities with respect to the stromelysins, collagenases and gelatinases. Compounds according to the invention also exhibit in vitro inhibition of TNF release, TNF receptor shedding, IL-6 receptor shedding and Δ-seiectin shedding. The 80kD TNF receptor (TNFRgo) is proteolytically cleaved at the cell surface
(shed), releasing a soluble ligand-binding receptor fragment. Interestingly, the processing of TNFα and shedding of TNFRg0 have been demonstrated to occur concurrently in activated T-cells, arousing speculation that a common protease may be involved. It has been shown by Crowe et al, J. Exp. Med., (1995) 181:1205, that a synthetic inhibitor of TNF processing also blocks the shedding of TNFRg0, suggesting that these processes may be coordinatedly regulated during T-cell activation. Notably, the protease cleavage site in pro-TNF(Ala-Val) is also present in the extracellular domain of TNFRg0 (Ala2l3-Val214) at a site consistent with the observed molecular weight of the shed receptor fragment. Thus, metalloproteinase inhibitors may offer protection from the deleterious systemic effects of TNFα at two levels simultaneously, firstly by preventing the release of soluble TNFα, and secondly by blocking the accumulation of shed TNFRJQ.
Synergistically with TNF, metalloproteinase inhibitors also inhibit the release of APO- 1 /Fas (CD95) ligand (APO-1L) which induces apoptosis in sensitive target cells. The shedding APO-1/Fas (CD95), a type I transmembrane glycoprotein belonging to the nerve growth factor/TNF receptor sub-family is also blocked by known metalloproteinase inhibitors but not by common inhibitors of serine/cysteine proteases; see Mariani et al, Eur. J. Immunol., (1995) 25:2303. Several other important receptors expressed by activated T- and B-cells have also been demonstrated to be shed from the cell surface by the action of metalloproteinases. These enzymes, collectively known as sheddases, provide new targets for inhibitors of metalloproteinases, including compounds of the present invention.
The activity and selectivity of the compounds may be determined by use of the appropriate enzyme inhibition test, for example as described in Examples A-M, below. Certain compounds of this invention have selective inhibitory activity, in particular inhibition of MMP substantially without inhibition of TNF release and related activities as defined above. This may be of particular value where such activities are associated with reduced side-effects.
This invention also relates to a method of treatment for patients (including man and/or mammalian animals raised in the dairy, meat or fur industries or as pets) suffering from disorders or diseases which can be attributed to stromelysin as previously described, and more specifically, a method of treatment involving the administration of the matrix metalloproteinase inhibitors of formula (I) as the active constituents.
Accordingly, the compounds of formula (I) can be used among other things in the treatment of osteoarthritis and rheumatoid arthritis, and in diseases and indications resulting from the over-expression of these matrix metalloproteinases such as found in certain metastatic tumour cell lines.
As mentioned above, compounds of formula (I) are useful in human or veterinary medicine since they are active as inhibitors of TNF and MMPs. Accordingly in another aspect, this invention concerns: a method of management (by which is meant treatment of prophylaxis) of disease or conditions mediated by TNF and/or MMPs in mammals, in particular in humans, which method comprises administering to the mammal an effective, amount of a compound of formula (I) above, or a pharmaceutically acceptable salt thereof; and a compound of formula (I) for use in human or veterinary medicine, particularly in the management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by TNF and/or MMPs; and the use of a compound of formula (I) in the preparation of an agent for the management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by TNF and/or MMPs.
The disease or conditions referred to above include inflammatory diseases, autoimmune diseases cancer, cardiovascular diseases, diseases involving tissue breakdown such as rheumatoid arthritis, osteoarthritis, osteoporosis, neurodegeneration, Alzheimer's disease, stroke, vasculitis, Crohn's disease, ulcerative colitis, multiple sclerosis, periodontitis, gingivitis and those involving tissue breakdown such as bone resorption, haemorrhage, coagulation, acute phase response, cachexia and anorexia, acute infections, HIV infections, fever, shock states, graft versus host reactions, dermatological conditions, surgical wound healing, psoriasis, atopic dermatitis, epidermolysis bullosa, tumour growth, angiogenesis and invasion by secondary metastases, ophthalmological disease, retinopathy, corneal ulceration, reperfusion injury, migraine, meningitis, asthma, rhinitis, allergic conjunctivitis, eczema, anaphylaxis, restenosis, congestive heart failure, endometriosis, atherosclerosis, endosclerosis and aspirin-independent anti-thrombosis. For the treatment of rheumatoid arthritis, osteoarthritis, and in diseases and indications resulting from the over-expression of matrix metalloendoproteinases such as found in certain metastatic tumour cell lines or other diseases mediated by the matrix metalloendoproteinases or increased TNF production, the compounds of formula (I) may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats etc, the compounds of the invention are effective in the treatment of humans. The pharmaceutical composition containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the US Patents 4,256, 108; 4, 166,452; and 4,265,874, to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules where in the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy- propylmethylcellulose, sodium alginate polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such a polyoxyethylene with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n- propyl, p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti- oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified, for example sweetening, flavouring and colouring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally- occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soya bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be in a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1 ,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The compounds of formula (I) may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc containing the compounds of Formula (I) are employed. For the purposes of this specification, topical application includes mouth washes and gargles.
Dosage levels of the order of from about 0.05 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above- indicated conditions (about 2.5 mg to about 7 g per patient per day). For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day (about 0.5 mg to about 3.5 g per patient per day).
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may vary from about 5 to about 95% of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of active ingredient.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy. The following Examples illustrate the invention. In the Examples, the following abbreviations are used: TNFα Tumour Necrosis Factor α
LPS Lipopolysaccharide
ELISA Enzyme linked immunosorbant assay
EDC 1 -Ethyl-2-dimethylaminopropylcarbodiimide
RT Room Temperature Intermediate 1 4-Acetylthiophenol
Was prepared according to EP 302321. TLC Rf 0.3 (5% methanol-dichloromethane) Intermediate 2 i3w(4-Benzenecarboxylate)disulfide
Iodine (1.23 g) was added portionwise to a solution of 4-mercaptobenzoic acid (1.5 g) in methanol (30 ml) at room temperature. Stirring was continued for three hours. Water (1 ml) and sodium sulfite (0.2 g) were added, and the reaction was stirred for 30 minutes. Methanol was removed /// vacuo and the title compound was isolated by filtration as a white solid (1.38 g, 93%). TLC Rf 0.05 (2.5% methanol-dichloromethane) Intermediate 3 -3/s(4-N,N-Dimethylcarboxamidebenzene)disu1fide
A solution of intermediate 2 (0.5g) in a mixture of tetrahydrofuran (15 ml) and DMF (7 ml) was stirred at room temperature. Dimethylamine hydrochloride (0.27 g), triethylamine (1.37 ml) and ED AC (0.63 g) were added and the reaction was stirred overnight. Solvents were removed in vacuo and the residue partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate and the combined organics were dried over MgSO4, filtered, and concentrated in vacuo to give the crude product, which was purified by column chromatography on silica eluting with 5% methanol in dichloromethane. The title compound was isolated as a white solid (0.245 g, 42%).
TLC Rf 0.24 (5% methanol-dichloromethane) Intermediate 4 4-Sulfanyl-NJV-dimethylbenzamide
Sodium borohydride (0.076 g) was added portionwise to a solution of intermediate 3 (0.245 g) in ethanol (10 ml) at room temperature, and the mixture was stirred for 16 h. The solvent was then removed in vacuo and the residue was taken up in water. The resulting solution was acidified to pH 2, then extracted with ethyl acetate. Removal of the solvents gave the title compound as a white solid (0.23 g, 93 %). TLC RfO.41 (5% methanol-dichloromethane) Intermediate 5 l-Bromo-5-phenylpentan-2-one
Diazomethane preparation: The reaction vessel of a standard diazomethane kit (fitted with a CO2 condenser and trap and an addition funnel) was charged with a solution of potassium hydroxide (5.00 g) in water (8 ml) and ethanol (10 ml). The vessel was heated to 65 °C and a solution of Ν-methyl-Ν-nitroso-4-toIuene sulfonamide (Diazald,® 5.00 g) in diethyl ether (45 ml) was added dropwise over 30 min from an addition funnel. Diazomethane solution was collected by continuous distillation.Ethyl chloroformate was added dropwise to a stirred solution of 4-phenylbutyric acid (1.36 g) and N- methylmoφholine (1.28 ml) in THF (15 ml) at -12 °C under a nitrogen atmosphere. A white precipitate began to form, which was removed by filtration after 90 min. The filtrate was treated with a pre-formed solution of diazomethane (16.6 mmol) in diethyl ether at 0 °C. The combined solution of diazomethane and anhydride was stirred at 0 °C for 3.5 h and room temperature for 1 h. A solution of hydrogen bromide in acetic acid (45 %, 10 ml) and water (10 ml) was added slowly. The mixture was stirred for 20 min before a saturated aqueous solution of NaHCO3 (200 ml) was added. The mixture was extracted with ethyl acetate (3 x 200 ml) and the combined extracts were washed with brine and dried (MgSOJ. The solvent was removed /// vacuo and the residue was eluted from a column of silica with 10 % diethyl ether in hexane to provide the title compound as a colourless liquid (765 mg, 38 %). TLC RfO.6 (3:1 hexane-diethyl ether). Intermediate 6 l-(4-Methoxyphenylsulfanyl)-5-phenylpentan-2-one
A solution of intermediate 5 (365 mg) and 4-methoxythiophenol (0.186 ml) in DMF (15 ml) at room temperature under a nitrogen atmosphere was treated with triethylamine (0.210 ml). The mixture was stirred for 4 h before being poured into 0.5 N HCl (100 ml). The mixture was extracted with ethyl acetate (3 x 100 ml) and the combined extracts were washed with brine and dried (MgSO . The solvent was removed in vacuo and the residue was eluted from a column of silica with 10 % diethyl ether in hexane to provide the title compound as a colourless solid (375 mg, 83 %). TLC Rf 0.3 (3: 1 hexane-diethyl ether). Intermediate 7 Methyl 3-(4-Methoxypheny!sulfanyI)methyI-6-phenylhex-2- enoate Methyl diethyl phosphonoacetate (0.246 ml) was added dropwise to a stirred solution of potassium hexamethyldisilazide (0.5 M in toluene, 2.67 ml) in THF (20 ml) at -12 °C under a nitrogen atmosphere. The mixture was stirred for 20 min before a solution of intermediate 6 (365 mg) in THF (20 ml) at -12 °C was added via a double-tipped needle under pressure of nitrogen. The mixture was stirred at a temperature not exceeding 0°C for 1 h before being allowed to warm to room temperature and then heated to 40°C for a period of 20 h. A saturated aqueous solution of NH4CI (100 ml) was added. The mixture was extracted with ethyl acetate (3 x 100 ml) and the combined extracts were washed with brine and dried (MgSO4). The solvent was removed in vacuo and the residue was eluted from a column of silica with 10 % diethyl ether in hexane to provide the title compound as an equal mixture of £ and Z isomers as a colourless liquid (265 mg. 61 %). TLC Rf 0.25 and 0.35 (5: 1 hexane-diethyl ether). Intermediate 8 Methyl-3-(4-Methoxyphenylsulfanyl)methyl-6-phenyl- hexanoate A solution of intermediate 7 (265 mg) in ethyl acetate (20 ml) was added to an evacuated hydrogenation flask containing 10 % palladium on charcoal ( 150 mg). The mixture was degassed before being flushed with hydrogen and agitated overnight. The catalyst was then removed by filtration over Celite® and the solvent was removed in vacuo to give the title compound as a pale yellow liquid (242 mg, 91 %). TLC Rf 0.4 (5: 1 hexane-diethyl ether)
Intermediate 9 _%>(4-Hydroxybeiιzene)d.suIfide
Iodine (5.12 g) was added portionwise to a stirred solution of 4-hydroxythiophenol (5.09 g) in methanol (50 ml) at ambient temperature. After stirring for 2 hours, water (2 ml) and sodium sulfite (0.62 g) were added to decolourise the solution, and after brief stirring the mixture was concentrated to dryness /'// va io. The residual orange solid was partitioned between diethyl ether (50 ml) and water, and the layers were separated. The organic layer washed with water (3 x 20 ml), saturated brine (10 ml), dried (MgSO4) and concentrated to dryness ;'/; vacuo to provide the title compound as a yellow solid (5.06 g, 100%).
TLC Rf 0.29 (5% methanol-dichloromethane)
Intermediate 10 /J s(4-Carbamoylmethyloxybenzene)disulfide
Intermediate 9 (3.00 g), 2-bromoacetamide (3.47 g) and potassium carbonate (3.48 g) were heated in acetone (100 ml) at reflux. After 7 hours the mixture was cooled in ice, and a white solid which precipitated was removed by filtration, washed with acetone, water and acetone and dried to constant weight /; vacuo to provide the title compound (3.659 g, 84%) as a colourless solid. TLC Rf 0.23 (5% methanol-dichloromethane) Intermediate 11 2-(4-Sulfanylphenoxy)acetamide Intermediate 10 (1.46 g) and sodium borohydride (0.45 g) were heated to reflux in absolute ethanol for 90 minutes. Sodium borohydride was added to the refluxing mixture (CAUTION) until the reaction was complete by thin layer chromatography. After cooling, the solution was concentrated to dryness // vacuo, and the residue suspended in water (40 ml). The basic aqueous mixture was acidified with concentrated hydrochloric acid and extracted with diethyl ether (100 ml). The ethereal solution was washed with water (2 x 50 ml), saturated brine (20 ml), dried (MgSO ) and concentrated to dryness in vacuo to provide the title compound (1.22 g, 84%) as an orange solid. TLC Rf 0.54 (5% methanol-dichloromethane) Intermediate 12 Dibenzyl (3-Succinimidopropyl)malonate Sodium hydride (60% dispersion in mineral oil, 4.4g) was added to a solution of dibenzyl malonate (29.5 g) in THF (300 ml) and the mixture was stirred at room temperature for 30 min, then a solution of l-bromo-3-chloropropane (10 ml) in THF (30 ml) was added dropwise. The solution was heated at reflux for 18 h, then cooled and evaporated in vacuo. The oily residue was dissolved in hexane (500 ml) and washed with water and brine, dien dried (MgSOJ and evaporated to give a colourless oil. This oil was dissolved in acetone (300 ml) and sodium iodide (20 g) was added. The solution was stirred at room temperature for 18 h, then evaporated and the residue partitioned between water and hexane. The layers were separated and the organic layer was dried (MgSO4) and evaporated to give a pale yellow oil which was dissolved in dry DMF. Potassium succinimide (15 g) was added and the mixture was heated at 80°C for 18 h. The mixture was cooled, poured into water (500 ml) and extracted with diethyl ether (3 x 200 ml). The ether layers were combined, washed with water, dried and evaporated. The residue was purified by column chromatography, eluting with diethyl ether, to give the title compound (9.65 g, 23%) as a colourless oil. TLC Rf 0.45 (diethyl ether) Intermediate 13 l-(2-Bromoethyl)-3,4,4-trimethylhydantoin
Sodium hydride (60% dispersion in mineral oil, 1.7 g) was added to a solution of 3,4,4- trimethylhydantoin (5.5 g) in DMF (20 ml) at room temperature The mixture was stirred for 30 min, then dibromoethane (3.5 ml) was added dropwise and the solution was stirred overnight. The mixture was added to water (200 ml) and extracted with diethyl ether. The ether layer was washed with water, dried (MgSO4) and evaporated and the residue was purified by column chromatography, eluting with diethyl ether, to give the title compound (4.2 g, 50%) as a colourless solid. TLC Rf 0.5 (diethyl ether). Intermediate 14 l-(3-IodopropyI)-3,4,4-trimethylhydantoin Sodium hydride (2.2 g) was added to a solution of 3,4,4-trimethylhydantoin (7.1 g) in DMF (50 ml) at room temperature and the mixture was stirred for 1 h. 3-Chloro-l- bromopropane (4.9 ml) was then added and the solution was stirred overnight. The ntixture was then poured into water (300 ml) and extracted with diethyl ether; the ether layer was dried (MgSO ) and evaporated and the residue was dissolved in acetone (100 ml) to which was added sodium iodide ( 10 g). The mixture was heated at reflux for 18 h, then evaporated and the residue was dissolved in diethyl ether and washed with water, then dried (MgSO4) and evaporated to give the title compound (1 1 g, 70%) as a brown oil.
TLC Rf 0.85 (diethyl ether) Intermediate 15 4-BenzoylbenzenethioI A stirred solution of sodium hydrosulfide monohydrate (43 g) in N-methylpyrrolidinone (400 ml) under a nitrogen atmosphere was heated at 160 °C under Dean and Stark conditions; 10 ml of water azeotrope was collected over 90 min. The mixture was cooled to 140 °C and 4-chlorobenzophenone (50 g) was added. The mixture was stirred at 160 °C for 3 h before being allowed to cool to room temperature overnight. The N- methylpyrrolidinone was removed // vacuo and the black oily residue was dissolved in water (500 ml). The solution was acidified with 6 Ν HCl and the mixture was extracted with ethyl acetate (3 x 300 ml). The combined extracts were washed with brine and the solvent was removed /'// vacuo to give a brown solid (41 g). The solid was dissolved in ethyl acetate (500 ml) and the solution was extracted with ΝaOH (5 %, 4 x 200 ml). The combined extracts were acidified to pH 3 with 6 Ν HCl and the resulting precipitate was collected by filtration, washed with water and dried in vacuo to give the title compound as a beige solid (21 g, 43%). TLC Rf 0.4 (3: 1 hexane-ethyl acetate) Intermediate 16 Benzo| l,3|dioxole-5-thiol Was prepared according to Hitotsuyangi et al (J. Chem. Soc, Perkin Traits. 1, 1995, 1387-1390) from 5-bromobenzo[l,3]dioxole, as a colourless oil (7.48 g, 61%). TLC Rf 0.5 (10% ethyl acetate/hexane) Intermediate 17 4-AcetyIsulfanyltetrahydropyran
Diethyl azodicarboxylate (7.24 ml) was added to a stirred solution of triphenylphosphine (12.1 g) in THF (80 ml), and stirred at room temperature for 10 min. Thiolacetic acid (3.29 ml) and tetrahydro-4/ -pyran-4-ol (2.3 g) were added (CAUTION: exotherm), and the mixture stirred at room temperature for a further 18 h. After removal of the THF under reduced pressure, stirring with hexane (50 ml) and water (50 ml) gave a precipitate, which was removed by filtration. The biphasic filtrate was separated, and the aqueous phase extracted once with hexane (50 ml). The combined hexane extracts were washed with water (30 ml), brine (10 ml), dried (MgSO4) and evaporated to leave a yellow liquid (2.73 g). Purification by chromatography on silica, eluting with hexane / diethyl ether (10: 1), provided the title compound as a pale yellow liquid (0.98 g, 27%). TLC Rf 0.20 (hexane / diethyl ether (10:1)) Intermediate 18 Tetralιydropyran-4-thiol Sodium borohydride (0.278 g) was added to a stirred solution of intermediate 17 in methanol (15 ml) at 0 °C under nitrogen. After 2 h a further portion of sodium borohydride (0.370 g) was added, and the mixture allowed to warm to room temperature and stirred for a further 18 h. The reaction was then quenched with 1 M hydrochloric acid (50 ml) and extracted with diethyl ether (2 x 30 ml). The combined organic extracts were washed with brine ( 10 ml), dried (MgSO ) and concentrated in vacuo to provide the title compound as a colourless liquid (0.472 g, 60%). TLC Rf 0.70 (hexane / ethyl acetate (3: 1)) Intermediate 19 l-BenzoyI-4-bromopiperidine
Benzoyl chloride (1.41 g) was added to a solution of 4-bromopiperidine hydrobromide (2.45 g) in THF (30 ml) at 0°C, followed by triethylamine (2.2 g, 2.2 eq). The solution was stirred at room temperature for 1 h, and evaporated and. The residue was dissolved in dichloromethane ( 100 ml), washed with water, 1M HCl and saturated sodium bicarbonate, dried and evaporated to give the title compound as colourless oil (2.76 g, 100%). TLC Rf 0.55 (ether).
Intermediate 20 l-Benzoyl-4-(acetyIsuIfanyl)piperidine
Potassium thioacetate (2.3 g) was added to a solution of intermediate 19 in DMF (50 ml) at room temperature. The mixture was stirred at room temperature for 3 days, then added to water and extracted with ether. The solvent was washed with water and sodium bicarbonate solution, dried and evaporated to give the title compound as pale amber oil (2.6 g, 100 %). TLC Rf 0.45 (ether).
Intermediate 21 l-Benzoylpiperidine-4-thiol
A solution of the thioacetate intermediate 20 (2.6 g) in methanol (100 ml) was treated with sodium borohydride (1.2 g) and the mixture was stirred at room temperature for 4 h, then evaporated and the residue dissolved in water. The solution was acidified with solid citric acid and extracted with dichloromethane (2 x 100 ml). The solvent was washed with brine, dried and evaporated to give the title compound as brown oil (2.0 g). TLC Rf 0.30 (ether).
Intermediate 22 l-tør/-Butyloxγcarboιιyl-4-bromopiperidine A solution of di-/tτt-butyldicarbonate (4.4 g) in dichloromethane was added to a suspension of 4-bromopiperidine hydrobromide (5 g) in dichloromethane (100 ml) at 0°C, followed by triethylamine (5.1 g). The solution was stirred for 3 h at room temperature, then washed with water, 0.5 M HCl and saturated sodium bicarbonate, dried and evaporated to give the title compound as colourless oil (5.3 g, 99%). TLC Rf 0.70 (ether).
Intermediate 23 l-f(,rt-Butyloxycarbonyl-4-(acetylsulfanyl)pipeπdine
Potassium thioacetate (4.4 g) was added to a solution of intermediate 22 (5.3 g) in DMF (100 ml) and the mixture was heated to 100 °C for 4 h, then cooled and added to water. The mixture was extracted with ether, and the solvent then washed with water and sodium bicarbonate, dried and evaporated to give the title compound (5.10 g, 96%). TLC Rf 0.60 (ether).
Intermediate 24 4-(4-Sulfanylbenzoyl)pyridine
A suspension of sodium hydrogen sulfide (6 g) in DMF (100 ml) was heated to reflux for 1 h, then cooled and 4-(4-chlorobenzoyl)pyridine (5 g) was added. The mixture was heated at reflux for 2 h, then cooled and added to water. The brown solution was washed with ether, then acidified with citric acid and extracted with dichloromethane (2 x 100 ml). The solvent was dried and evaporated to give the title compound as beige powder (2.4 g, 50 %). TLC Rf 0.45 (ether). Similarly prepared was:
Intermediate 25 2-(4-Sulfanylbenzoyl)thiophene
From 2-(4-fluorobenzoyl)thiophene (10 g) as beige solid (4.50 g, 42%).
TLC Rf 0.65 (ether).
Intermediate 26 4-Methoxy-l-(2-Phenylethylsulfanyl)benzene A solution of 4-methoxybenzene thiol (5.7 g), triethylamine (4.1 g) and 2- bromoethylbenzene (5.6 ml) in DMF (50 ml) at 0 °C was stirred for 2 h, then added to water and extracted with ether. The solvent was washed with water, 1M NaOH and brine, then dried and evaporated to give the title compound as colourless oil (8.9 g, 95%).
TLC Rf 0.80 (ether) Intermediate 27 Dibenzyl-2-(3-plιthaIimidopropyl)malonate
A solution of dibenzyl malonate (20 g) in anhydrous THF (200 ml) was treated at 0 °C with sodium hydride (60% dispersion in mineral oil, 3. lg). The mixture was allowed to warm to room temperature and stirred for 30 minutes under nitrogen. The mixture was then treated with a solution ofN-(3-bromopropyI)phthaIimide (20.5g) in THF (100ml) and heated at reflux for 12 hours. The reaction was then cooled, filtered, and the filtrate evaporated in vacuo. The residue was partitioned between ethyl acetate (200ml) and saturated aqueous ammonium chloride (150ml). The organic layer was washed with water (100ml), brine (100ml), dried (MgSO4), filtered and the filtrate evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with 20% ethyl acetate in hexane to yield the title compound (I7.5g, 50%) as a white solid. TLC Rf 0.16 (20% ethyl acetate-hexaπe) Similarly prepared were:
Intermediate 28 Dibenzyl 2-(2-Phtlιaliιnidoethyi)malonate
From dibenzyl malonate (20 g) and N-(2-bromoethyl)phthaiimide (18.7 g), as a clear gum (32 g, 100%).
TLC Rf 0.15 (20% ethyl acetate-hexane)
Intermediate 29 Dibenzyl (2-(3,4,4-Trimethylhydantoin-l- yl)ethyl)malonate From dibenzyl malonate (4.8 g) and intermediate 13 (4.2 g), as a colourless oil (7.2 g, 100 %).
TLC Rf 0.4 (diethyl ether)
Intermediate 30 Dibenzyl (3-(3,4,4-Trimethylhydantoin-l- yl)propyi)malon-ate From dibenzyl malonate (5.7 g) and intermediate 14 (6.2 g) as a colourless oil (7.1 g, 80 %).
TLC Rf 0.53 (diethyl ether) Intermediate 31 Dibenzyl (3-Phenylpropyl)malonate
From dibenzyl malonate (30 g) and l-bromo-3-phenylpropane (21 g) as a colourless oil
(34 g, 80 %).
TLC Rf 0.48 (20% ethyl acetate-hexane) Intermediate 32 Dibenzyl propylmalonate
From dibenzyl malonate (22 ml) and 1-bromopropane (7.3 g) as a colourless oil (25.9 g, 100 %).
TLC Rf 0.31 (20% ethyl acetate - hexane)
Intermediate 33 Diethyl (3-(Ethoxycarbonyl)propyl)maIonate From diethyl malonate (5.0 g) and ethyl 4-bromobutyrate (6.65 g), as a clear gum (3.79 g, 45%).
TLC Rf 0.29 (20% ethyl acetate in hexane)
Intermediate 34 2-Metliylene-5-phthalimidopentanoic Acid
A solution of intermediate 27 (16.75 g) in dioxane (200 ml) was treated with 10% palladium on charcoal (1.7 g) and hydrogenated at atmospheric pressure until the hydrogen uptake had ceased. The catalyst was removed by filtration through Celite® and the filtrate treated with piperidine (3.2 g) at room temperature. After 30 minutes the reaction was treated with formaldehyde (37% solution in water, 15 ml), stirred for two hours at room temperature and then heated at 80 °C for two hours. The mixture was cooled, the solvent removed /// vacuo and the residue partitioned between ethyl acetate
(200 ml) and 10% aqueous citric acid (100ml). The organic layer was washed with water
(100 ml), brine (100 ml), dried over magnesium sulfate, filtered and the filtrate evaporated //; vacuo. The residue was purified by column chromatography on silica gel eluting with 40% ethyl acetate in hexane to yield the title compound (12.2 g, 70%) as a white solid.
TLC Rf 0.44 (50% ethyl acetate-hexane)
Similarly prepared were:
Intermediate 35 2-Methylene-4-phthalimidobutanoic Acid
From intermediate 28 (10 g) as a white solid (5 g, 93%). TLC Rf 0.12 (50% ethyl acetate-hexane) Intermediate 36 2-Methylene-5-succinimidopentanoic Acid
From intermediate 12 (9.65 g) as colourless oil (2.85 g, 59%).
TLC Rf 0.6 (diethyl ether).
Intermediate 37 2-Metlιylene-4-(3,4,4-trimethylhydantoin-l-yl)butananoic Acid
From intermediate 29 (7.2 g) as a colourless solid (1.5 g, 37 %).
TLC RfO.35 (ethyl acetate)
Intermediate 38 2-Methylene-5-phenylpentanoic Acid
From intermediate 3 1 (17.6 g) as a colourless oil (5.0 g, 60%). TLC Rf0.31 (20% ethyl acetate-hexane)
Intermediate 39 2-Methylene-5-(3,4,4-trimethylhydantoin-l-yl)pentanoιc
Acid
From intermediate 30 (10 g) as a colourless oil (5.40 g, 95%).
TLC Rf 0.4 (ethyl acetate) Intermediate 40 2-Methylene-3-phenylpropanoic Acid
From dibenzyl benzylmalonate ( 10 g) as a colourless oil (4.5 g, 100%).
TLC Rf 0.34 (diethyl ether)
Intermediate 41 2-Methylenepentanoic Acid
From intermediate 32 (25.9 g) as a colourless oil (5.8 g, 64%). TLC Rf 0.33 (ethyl acetate)
Intermediate 42 l-Methylenebutane-l,4-dicarboxylic acid
A solution of intermediate 33 (3.79 g) in ethanol (10 ml) was treated with water (50 ml) and potassium hydroxide (4.65 g). The reaction was heated at 100 °C for two hours and the organic solvent removed in vacuo. The aqueous residue was washed with ethyl acetate (50 ml) separated and the basic layer acidified to pH 1 with 6 M hydrochloric acid. The product was extracted with ethyl acetate (3 x 100ml), the extracts combined, dried over magnesium sulfate and filtered. The filtrate was evaporated in vacuo and the residue treated with piperidine (0.7 g) at room temperature. After 30 minutes the reaction was treated with formaldehyde (37% solution in water, 3.3 ml) , stirred for two hours at room temperature and then heated at 80 °C for two hours. The mixture was cooled, the solvent removed in vacuo and the residue partitioned between ethyl acetate (100 ml) and 10% aqueous citric acid (50ml). The organic layer was washed with water (50 ml), brine (50 ml), dried over magnesium sulfate, filtered and the filtrate evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with 50% ethyl acetate in hexane to yield the title compound as a white solid (1.0 g, 49%). TLC Rf 0.28 (50% ethyl acetate in hexane)
Intermediate 43 2-Methylene-3-methylbutanoic Acid
Piperidine (6 ml) was added to a solution of isopropylmalonic acid (5 g) in dioxan (70 ml) and the reaction was stirred for 0.5 h. Formaldehyde (37% aqueous, 6 ml) was added and the reaction was stirred for 16 hours. The reaction was heated to 80 °C for 2 h, cooled to room temperature, and partitioned between ethyl acetate and water. The aqueous phase was acidified to pH 1 and extracted with dichloromethane. Combined organic phases were dried and the solvents removed /// vacuo to give the title compound as a colourless oil (3.1 g, 79%). TLC Rf 0.5 (5% methanol/dichloromethane) Similarly prepared was:
Intermediate 44 2-Methylene-4-(pyrid-2-yl)butanoic Acid
From 2-(2-pyridyIethyl)malonic acid (2.5 g) as colourless solid (1.80 g, 90 %).
TLC Rf 0.3 (EtOAc).
Intermediate 45 2-Bromomethyl-5-phthnlimidopentanoic Acid Intermediate 34 ( 1.0 g) was treated with 45% hydrogen bromide in acetic acid (30 ml) at room temperature. After three hours the solution was poured into water (300 ml) and the product extracted with ethyl acetate (3 x 100ml). The extracts were combined, washed with water (100 ml), brine (100 ml), dried over magnesium sulfate, filtered and the filtrate evaporated /'/; vacuo. The residue was dried by azeotrope with toluene (2 x 10ml) to yield the title compound as a white solid (1.3 g, 100%). TLC Rf 0.34 (50% ethyl acetate-hexane) Similarly prepared were:
Intermediate 46 2-Bromomethyl-4-phthaIimidobutanoic Acid
From intermediate 35 (4.7 g), as a white solid (5.3 g, 85%). TLC Rf 0.36 (50% ethyl acetate-hexane) Intermediate 47 2-Bromomethyl-5-succinimidopentanoic Acid
From intermediate 36 (2.86g) as colourless solid (2.50 g, 63 %).
TLC RfO.3 (ethyl acetate)
Intermediate 48 2-Bromomethyl-4-(3,4,4-trimethylhydantoin-l- yl)butanoic Acid
From intermediate 37 (1.5 g) as colourless solid (0.80 g, 45 %).
TLC Rf 0.2 (5% methanol-dichloromethane)
Intermediate 49 2-Brornomethyl-5-(3,4,4-trimethylhydantoin-l-yl)- pentanoic Acid From intermediate 39 (5.4 g) as a viscous oil (4.0 g, 56 %).
TLC RfO.35 (ethyl acetate)
Intermediate 50 2-Bromomethyl-3-plιenylproρanoic Acid
From intermediate 40 (26.2 g) as a colourless oil (33.2 g, 86%).
TLC Rf0.45 (1 : 1 ethyl acetate-hexane) Intermediate 51 2-(Bromomethyl)pentanoic Acid
From intermediate 41 (4.8 g) as a colourless oil (7.0 g, 85%).
TLC Rf 0.36 (20% ethyl acetate - hexane)
Intermediate 52 2-Bromomethyl-5-phenylpentanoic Acid
From intermediate 38 (3.4 g) as a colourless oil (4.2 g, 87%). TLC Rf 0.32 (20% ethyl acetate-hexane)
Intermediate 53 l-(BromomethyI)butane-l,4-dicarboxylic Acid
From intermediate 42 (0.6 g), as a white solid (0.8 g, 88%)TLC Rf 0.38 (50% ethyl acetate in hexane)
Intermediate 54 2-Bromomethyl-3-methylbutanoic Acid From intermediate 43 (3.1 g) as a colourless oil (4.6 g, 87%).
MS 196 MH+
Intermediate 55 2-Bromomethyl-4-(2-pyridyl)butanoic Acid
Hydrobromide
Intermediate 44 (1.80 g) was dissolved in 48% HBr/acetic acid (20 ml) and stirred for 2 h, then evaporated /// vacuo and azeotroped with isopropanol (4 x 100 ml) to give the title compound as beige solid (3.3 g, 90 %). TLC Rf 0.40 (1 :4:4 water/EtOAc/MeOH).
Intermediate 56 Methyl 2-(Bromometlιyl)-5-phenylpentanoate
Intermediate 52 (5.0 g) was treated with a solution of diazomethane in diethyl ether.
Removal of the solvent in vacuo gave the title compound as a colourless oil (5.2 g, 100%).
TLC Rf 0.31 (5% ethyl acetate - hexane)
Intermediate 57 Methyl 2-AcetyIsulfanylmethyl-5-phenylpentanoate
A solution of intermediate 56 in DMF was treated with potassium thioacetate (6.0 g) at
60 °C for 18 h. The mixture was added to water and extracted with ether, then the solvent was washed with water and brine, dried and evaporated to give the title compound as a brown oil (8.5 g, 90 %).
TLC Rf 0.80 (ether).
Intermediate 58 Methyl 2-Chlorosulfonylmethyl-5-phenylpentanoate
Chlorine was passed through a suspension of intermediate 57 (0.7 g) in iced water (20 ml) for 30 min. The yellow suspension was then extracted with dichloromethane and the solvent was washed with water, sodium metabisulfite and brine, then dried and evaporated to give a the title compound (0.7g, 100%) as colourless oil.
TLC Rf 0.45 (ether).
Intermediate 59 2-(4-Hydroxy-3,5-din.ethyIbenzoyl)benzoic Acid Was prepared according to Chem. Ber., 1983, 116, 970.
Intermediate 60 4-(4-Hydroxy-3,5-dimethylphenyl)-2-methyl- l(2H)phthalazinone
Was prepared according to Chem. Ber., 1983, 116, 970.
Intermediate 61 l-fcrf-Butoxycarbonylpiperidine-4-thiol Sodium borohydride (5.0 g) was added to a solution of intermediate 23 (5.1 g) in methanol (200 ml). The solution was stirred at room temperature for two hours and then evaporated in vacuo. The residue was carefully dissolved in water and citric acid added
(5.0 g). The product was extracted with dichloromethane (2 x 100 ml), the extracts combined, dried over magnesium sulfate, filtered and the filtrate evaporated in vacuo to give the title compound as a pale yellow oil (4.70 g,98%)
TLC Rf 0.40 (ether). Intermediate 62 2-(4-Benzoylpheιιylsu!fanylmethyl)-5-phthaIimidopentan- oic Acid
A solution of intermediate 45 (1.0 g) in THF (20 ml) was purged with nitrogen for 5 minutes and treated with intermediate 15 (0.7 g) and triethylamine (1.0 ml). The mixture was stirred at room temperature for 24 hours and then the solvent removed in vacuo.
The residue was partitioned between ethyl acetate (100 ml) and water (100 ml). The aqueous layer was extracted with ethyl acetate (50 ml), the extracts combined, washed with brine, dried over magnesium sulfate and filtered. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel eluting with 50% ethyl acetate in hexane to yield the title compound (0.5 g, 35%) as a clear gum.
TLC f 0.33 (50% ethyl acetate-hexane)
Similarly prepared were:
Intermediate 63 3-(4-Bcnzoylphenylsulfanyl)propanoic Acid
From intermediate 15 (1.5 g) and 3-bromopropionic acid (1.07 g), as a white solid (0.32 g, 16%).
TLC f 0.05 (50% ethyl acetate-hexane)
Intermediate 64 2-(4-Acetyiphenylsulfanylmetlιyl)-5-piιenylpentanoic Acid
From intermediate 1 (0.37 g) and intermediate 52 (1.34 g) as an orange oil (0.5 g, 41%).
TLC Rf 0.47 (5% methanol-dichloromethane) Intermediate 65 2-(Thiazol-2-ylsulfanylmethyl)-5-phenylpentanoic Acid
From intermediate 52 (1.16 g) and 2-mercaptothiazole (0.5 g) as a colourless oil
(0.125 g, 9%).
TLC Rf 0.6 (5% methanol-dichloromethane)
Intermediate 66 2-(4-N,N-DimethylcarbamoγlphenylsulfanylmethyI)-5- phenyipentanoic Acid
From intermediate 52 (0.2g) and intermediate 4 (0.344 g) as a colourless oil (0.29 g,
TLC Rf 0.22 (5% methanol-dichloromethane) Intermediate 67 2-(4-MethoxybenzenesuIfanyimethyl)-5-phenylpentanoic
Acid
From 4-methoxybenzenethiol (0.556 g) and intermediate 52 (1.08 g) as a pale yellow oil
(1.021 g, 78%). TLC Rf 0.80 (50% ethyl acetate-hexane)
Intermediate 68 2-(4-MethoxyplιenylsulfanylmethyI)-5- phthalimidopentan-oic Acid
From intermediate 45 (1.0 g) and 4-methoxybenzenethiol (0.45 g), as a clear gum (1.1 g, 94%). TLC Rf 0.62 (4% methanol-dichloromethane)
Intermediate 69 2-(4-MethoxyphenyIsulfanylmethyI)-4-phthaIimidobutan- oic Acid
From intermediate 46 (1.0 g) and 4-methoxybenzenethiol (0.47 g), as a clear gum (0.92 g, 78%). TLC Rf 0.19 (2% methanol-dichloromethane)
TLC Rf 0.41 (50% ethyl acetate-hexane)
Intermediate 70 5-Phcnyl-2-(phenylsulfanylmethyl)pentanoic Acid
From benzenethiol (0.107 g) and intermediate 52 (0.248 g), as a milky white oil (0.223 g, 82%). TLC Rf 0.46 (4: 1 hexane-ethyl acetate)
Intermediate 71 2-(2-MethoxyphenylsuIfanylmethyl)-5-phenylpentanoic
Acid
From 2-methoxybenzenethiol (0.324 g) and intermediate 52 (0.597 g), as a colourless oil (0.539 g, 74%). TLC Rf 0.29 (20% ethyl acetate-hexane)
Intermediate 72 2-(3-Methoxyphenyisulfanyimethyl)-5-phenyipentanoic
Acid
From 3-methoxybenzenethio! (0.318 g) and intermediate 52 (0.585 g), as a colourless oil (0.662 g, 93%). TLC Rf 0.29 (20% ethyl acetate-hexane) Intermediate 73 2-(4-(Carbamoylmethyioxy)phenylsulfanyImethyl)-5- phenylpentanoic Acid
From intermediate 1 1 (0.503 g) and intermediate 52 (0.744 g), as a white solid (0.884 g, 86%). TLC Rf 0. 1 (5% methanol-dichloromethane)
Intermediate 74 2-(4-Benzoylphenylsulfanylmethyl)-5-phenylpentanoic
Acid
From intermediate 52 (5.6 g) and intermediate 15 (4.6 g) as a pale amber oil (7.5 g,
92%). TLC Rf 0.32 (3: 1 hexane-ethyl acetate)
Intermediate 75 2-(Pyrid-4-yIsuIfanylmethyl)-5-phenylpentanoic Acid
From 4-mercaptopyridine (0.33 g) and intermediate 52 (0.84 g) as a white solid (0.53 g,
58%).
TLC Rf 0.45 (ethyl acetate) Intermediate 76 2-(4-MethoxyphenylsulfanyImethyl)-5-succinimido- pentanoic Acid
From intermediate 47 (1.5 g) and 4-methoxybeπzenethiol (0.71 g) as a colourless oil
(1.56 g, 80%).
TLC Rf 0.3 (diethyl ether) Intermediate 77 2-(4-BenzoylphenylsuIfanyImethyI)-5-succinim.do- pentanoic Acid
From intermediate 15 (0.21 g) and intermediate 47 (0.29 g) as a white solid (0.34 g,
80%).
TLC Rf 0.27 (ethyl acetate) Intermediate 78 2-(4-Acetamidophenylsulfanylmethyl)-5-phenylpeπtanoic
Acid
From 4-acetamidobenzenethioI (0.17 g) and intermediate 52 (0.28 g) as a colourless oil
(0.25 g, 45%).
TLC RfO.5 (diethyl ether) Intermediate 79 2-((l-Methylimidazol-2-yl)methylsulfanyl)-5-phenyl- pentanoic Acid
From 2-mercapto-l-methylimidazole (1.14 g) and intermediate 52 (2.8 g) as a white solid (0.5 g, 16%). TLC Rf0.30 (6% methanol-dichloromethane)
Intermediate 80 2-(4-Methoxyphenylsulfanylmethyl)-5-(3,3,4-trimethyl- hydantoin-l-yl)pentanoic Acid From 4-methoxybenzenethiol (0.28 g) and intermediate 49 (0.68 g) as a white solid (0.64 g, 80%). TLC Rf 0.4 (ethyl acetate)
Intermediate 81 2-(4-Metlιoxyphenylsulfanylmethyl-4-(3,3,4-trimethyI- hydantoin-l-yl)butanoic Acid From intermediate 48 (0.48 g) and 4-methoxybenzenethiol (0.21 g) as a white solid (0.49 g, 87%). TLC Rf 0.31 (ethyl acetate)
Intermediate 82 2-(4-Metlιoxyplιenylsulfanylmetlιyl)-3-plιenylpropanoic
Acid From intermediate 50 (2.43 g) and 4-methoxybenzenethiol ( 1.4 g) as a white solid (2.95 g, 98%). TLC Rf 0.55 (ethyl acetate)
Intermediate 83 Ethyl 4-(4-Methoxyphenyl)sulfanylbutanoate
From 4-methoxythiophenol (10.0 g) and ethyl 4-bromobutyrate (10.2 ml) as a colourless liquid (16.7 g, 92 %). TLC Rf 0.5 (3:1 hexane-diethyl ether) Intermediate 84 2-(4-MethoxyphenylsuIfanylmethyl)-pentanoic Acid
From intermediate 51 (2.0 g) and 4-methoxybenzenethiol (1.3 ml) as a yellow oil (2.6 g, 99 %).
TLC Rf 0.40 (50% ethyl acetate - hexane) Intermediate 85 l-(4-MetlιoxyphenylsulfanylmethyI)butane-l,4- dicarboxylic Acid
From intermediate 53 (0.6 g) and 4-methoxybenzenethiol (0.38 g), as a clear gum (0.57
& 76%). TLC Rf 0.36 (50% ethyl acetate in hexane)
Intermediate 86 3-Methyl-2-(4-methoxyphenylsulfanyimethyl)butanoic
Acid
From intermediate 54 (3.5 g) and 4-methoxybenzenethiol (2.5 lg), as a colourless oil
(3.26 g, 71%). TLC Rf 0.25 (5% methanol/dichloromethane)
Intermediate 87 2-[(Benzo(l,3)dioxole-5-yl)sulfanylmethyI)-5- phenylpentanoic Acid
From intermediate 16 (2.0g) and intermediate 52 (3.52g), as a yellow-brown oil (3.78 g, 85%). TLC Rf 0.52 (5% methanol/dichloromethane)
Intermediate 88 2-[(4-Triπuoromethoxyphenylsulfanyl)methyl]-5-(l,5,5- trimethylhydantoin-3-yl)pentanoic Acid
From intermediate 49 (0.51 g) and 4-trifluoromethoxybenzenethiol (0.29 g), as a colourless oil (0.47 g, 70%). TLC Rf 0.32 (50% hexane/ethyl acetate with trace acetic acid)
Intermediate 89 2-|(4-Trifluoromethoxyphenylsulfanyl)methyljpentanoic
Acid
From intermediate 51 (2.00 g) and 4-trifluoromethoxybenzenethiol (1.99 g), as a pale yellow oil (2.78 g, 88%). TLC Rf 0.50 (hexane/ethyl acetate/acetic acid (200:50:3))
Intermediate 90 2-(Quinolin-2-ylsulfanyl)methyl-5-phenylpentanoic Acid
From 2-mercaptoquinoline (256 mg) and intermediate 52 (0.3g) as a colourless solid
(0.3g, 50%)
TLC Rf 0.40 (ethyl acetate) MS 352 [MH+] Intermediate 91 2-(4-Benzoylphenyl)suIfanylmethyl-4-(3,3,4- trimethylhydantoin-l-yl)butanoic Acid From 4-mercaptobenzophenone (0.17 g) and intermediate 48 (0.20 g) as white solid (0.20g, 85%). TLC Rf 0.50 (ether) MS 470 [M+] Intermediate 92 2-(4-Benzoylphenyl)sulfanyImethyI-5-(3,3,4- trimethyIhydantoin-l-yl)pentanoic acid From 4-mercaptobenzophenone (0.34 g) and intermediate 49 (0.40 g) as a pale amber oil (0.52g, 62%)
TLC Rf 0.45 (ethyl acetate)
MS 468 [M+]
Intermediate 93 2-(4-Benzoylphenyl)sulfanyimethyl-3-phenyipropanoic
Acid From 4-mercaptobenzophenone (0.85 g) and intermediate 50 (0.80 g) as a pale yellow gum (1.01g, 59%). TLC Rf 0.60 (ether) MS 372 [MH+]
Intermediate 94 2-(4-MetIιoxyphenyl)sulfanylmethyl-4-(pyrid-2- yI)butanoic Acid
From intermediate 55 (1.0 g) and 4-methoxybenzenethiol (0.42 g) as a colourless oil (0.25 g, 25 %).
TLC Rf 0.25 (10% MeOH/dichloromethane). MS 318 [MH+] Intermediate 95 2-(4-(4-Pyridinoyl)plιenylsulfanyI)methyl-5- phenylpentanoic Acid From intermediate 24 (1.1 g) and intermediate 52 (1.4 g) as white solid (1.62 g, 80%). TLC Rf 0.6 (EtOAc). MS 406 [M+] Intermediate 96 2-(4-(2-Thienoyl)phcnyιsulfanyl)methyI-5- phenylpentanoic Acid
From intermediate 25 (1.3 g) and intermediate 52 (1.4 g) as white solid (1.8 g, 85 %).
TLC Rf 0.60 (ether). MS 410 [MH+]
Intermediate 97 2-(4-(4-Pyridinoy!)plιenyl)sulfanylmethyI-5-(3,3,4- trimethylhydantoin-l-yl)pentanoic Acid
From intermediate 24 (0.21 g) and intermediate 49 (0.34 g) as white solid (0.25g, 65%).
TLC Rf 0.50 (10% MeOH/dichloromethane) MS 469 [MH+]
Intermediate 98 2-(4-(2-Tlιicnoyl)phcnyl)sulfanylmethyI-5-(3,3,4- trimethyllιydantoiιι-I-yl)pentanoic Acid
From intermediate 25 (0.66 g) and intermediate 49 (1.0 g) as white solid (1.3 g, 90 %).
TLC Rf 0.70 (EtOAc) Intermediate 99 2-(4-Hydroxyphenyl)sulfanylmethyl-5-phenylpentanoic
Acid
From 4-mercaptophenol (1.26 g) and intermediate 52 as colourless oil (3.0 g, 95 %).
TLC Rf 0.63 (ether).
Intermediate 100 2-((Quiιιoiin-8-yI)sulfany]methyl)-5-phenylpentanoic Acid From 8-quinoiine thiol (120 mg) and intermediate 52 (170 mg) as colourless solid (105 mg, 50%).
TLC Rf 0.50 (ether).
Intermediate 101 2-(Furan-2-ylmethγlsulfanyI)methyl-5-phenyipentanoic
Acid Potassium tt?r/-butoxide (415 mg) was added to a stirred solution of furfuryl thiol (0.186 ml) in dichloromethane (20 ml) at 0 °C under a nitrogen atmosphere. The mixture was stirred for 3 min before a solution of intermediate 37 (500 mg) in dichloromethane (5 ml) was added. The mixture was allowed to warm to room temperature and stirred for 6 h before being poured into HCl (0.5 M, 100 ml). The mixture was extracted with ethyl acetate (2 x 100 ml). The combined organic phases were washed with brine and dried (MgSO ). The solvent was removed //; vacuo to give the title compound as a yellow oil
(560 mg, 99%).
TLC Rf 0.3 (4:1 hexane-ethyl acetate)
Similarly prepared were: Intermediate 102 2-(CyclopcntyIsulfanyl)nιethyl-5-phenylpentanoic Acid
From intermediate 52 (500 mg), and cyclopentanethiol (0.198 ml) as a pale yellow oil
(540 mg, 99%).
TLC Rf 0.4 (4:1 hexane-ethyl acetate)
Intermediate 103 2-(BenzylsulfanylmethyI)-5-phenylpentanoic Acid From benzylmercaptan (0.059 g) and intermediate 52 (0.128 g) as a colourless oil (0.116 g, 78%).
TLC Rf 0.49 (hexane-ethyl acetate-acetic acid (200:50:3)
Intermediate 104 5-Pheιιyl-2-[(tetrahydropyran-4-ylsuIfanyI)methyl]- pentanoic Acid From intermediate 18 (0.40 g) and intermediate 52 (0.700 g), as a pale yellow oil (0.99 g, 94%).
TLC Rf 0.50 (hexane / diethyl ether (1 : 1))
MS 373 (M+NH4 +)
Intermediate 105 2-(2-Phenyicthy!sulfanyimethyI)-5-pheπylpentanoic Acid Potassium hexamethyldisilazide (0.5 M in toluene, 20 ml) was added to a solution of phenethyl mercaptan (0.7 g) in THF (50 ml) at -78 °C and the solution was stirred for
10 min, then a solution of intermediate 52 (1.4 g) in THF (10 ml) was added dropwise and the mixture was stirred for 3 hours, warming to room temperature. The mixture was added to water and the solution was washed with diethyl ether, acidified with acetic acid and extracted with ether. The ether layer was washed with water and brine, dried and evaporated and the residue purified by column chromatography, eluting with 20% ethyl acetate in hexane to give the title compound (1.30 g, 78%) as a colouriess oil.
TLC Rf 0.3 (20 % ethyl acetate-hexane)
Similarly prepared were: Intermediate 106 2-(3-Phenylpropylsulfanyl)methyI-5-phenylpentanoic
Acid
From phenpropyl mercaptan (1.5 g) and intermediate 52 (2.8 g) as colourless oil (1.6 g, 50%). TLC Rf 0.86 (ether).
Intermediate 107 2-(2-MethylpropyIsulfanyImethyl)-5-phenylpentanoic
Acid From isobutyl mercaptan (0.9 g) and intermediate 52 (2.8 g) as a colourless oil (2.6 g, 93%). TLC Rf 0.83 (diethyl ether).
Intermediate 108 2-(l-Benzoyipiperidiιιe-4-yl)sulfanyImethyl-5- plienyipeiitanoic Acid From intermediate 21 (2.0 g) and intermediate 52 (2.0 g) as colourless oil (1.6 g). TLC Rf 0.34 (ether) Intermediate 109 2-(( I-tt?rt-Butyloxycarbonyl)piperidin-4- yl)suIfanγlιnethyl-5-phenylpentanoic Acid From intermediate 61 (4.2 g) and intermediate 52 (5.2 g) as colourless oil (4.5 g, 53%). TLC Rf 0.3 (1 : 1 ether/hexanes).
Intermediate 110 2-(4-Met.ιoxyplιenyIsulfanylmethyl)-5-(methoxγ- carbonyi)pentanoic Acid
A solution of intermediate 85 (0.5 g) in methanol (10 ml) was treated with 4- toluenesulfonic acid (16 mg) at room temperature. The mixture was heated at 40 °C under nitrogen for 2 h, then allowed to cool and the solvent was removed in vacuo. The residue was partitioned between ethyl acetate ( 100 ml) and water (50 ml). The organic layer was separated, dried over magnesium sulfate, filtered and the filtrate evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with 40% ethyl acetate in hexane to give the title compound as a white solid (0.38 g, 72%). TLC Rf 0.48 (50% ethyl acetate in hexane) Intermediate 111 Methyl 2-(4-Bromoplιenylsulfanylmethyl)-5- phenylpentan-oate
A solution of intermediate 46 (4.70 g) and 4-bromothiophenol (4.79 g) in tetrahydrofuran (50 ml) was treated with 10% sodium hydroxide in water (4.0 ml) and heated at reflux for 3 hours. The reaction mixture was concentrated to an aqueous residue in vacuo and partitioned between diethyl ether (250 ml) and water (150 ml). The organic phase was dried over magnesium sulfate, concentrated onto silica in vacuo and purified by chromatography on silica eluting with 20% ethyl acetate in hexane to give the title compound as a colourless oil (6.46 g, 71 %). TLC Rf 0.2 (3 % ethyl acetate-heptane)
Intermediate 112 Methyl 3-(4-McthoxyphenyIsuifanyi)propanoate
4-Methoxythiophenol (4.80 g) was added to a stirred solution of methyl acrylate (3.08 ml) in dichloromethane (60 ml) at 0 °C. Potassium carbonate (4.72 g) was added and the mixture was allowed to warm to room temperature overnight. The mixture was filtered over a plug of Celite® and the solvent was removed in vacuo to give the title compound as a yellow liquid (7.70 g, 100 %). TLC Rf 0.3 (2: 1 hexane-ethyl acetate) Similarly prepared was: Intermediate 113 Methyl 3-(4-Bromopheπylsulfanyl)propanoate From 4-bromothiophenol (6.26 g) as a yellow oil (8.75 g, 96%). TLC Rf 0.5 (60% ethyl acetate - hexane) Intermediate 114 Methyl 3-|4-(Chiorophenyl)phenylsulfanylmethyl]- propanoate A solution of intermediate 1 13 (2.80 g) and 4-chlorobenzeneboronic acid (1.91 g) in THF (80 ml) at room temperature under a nitrogen atmosphere was treated with dichloro ό/s(triphenylphosphine)palladium(II) (1.43 g). Aqueous sodium carbonate solution (2 M) was added and the mixture was heated at reflux overnight. The mixture was cooled to room temperature and the THF was removed in vacuo. The residue was dissolved in diethyl ether, washed with brine and dried (MgSO4). The solvent was removed in vacuo and the residue was eluted from a column of silica with 10 % diethyl ether in hexane to provide the title compound as a white solid (700 mg, 22 %). TLC Rf 0.2 (5 % diethyl ether-hexane)
MS 323 MNH +
Similarly prepared was:
Intermediate 115 Methyl 2-(4-(4-ClιIorophenyI)phenylsuIfanyl)methylJ-5- p enyipentanoate
From intermediate 1 1 1 (5.20 g) and 4-chlorobenzeneboronic acid (2.48 g), as a colourless oil (4.07 g, 74 %).
TLC Rf 0.3 (10 % diethyl ether-heptane)
MS 425 MH+ Intermediate 116 3-(4-Bromophenylsulfanyl)propanoic Acid
A solution of intermediate 1 13 (1.01 g) in THF (15 ml) and water (5 ml) at 0 °C was treated with lithium hydroxide (154 mg). The mixture was allowed to warm slowly to room temperature and stirred overnight. The mixture was acidified to pH 5 with 10 % aqueous citric acid and diluted with water (75 ml) and ethyl acetate (100 ml). The aqueous phase was extracted with ethyl acetate (100 ml) and the combined organic phases were washed with brine and dried (MgSO4). The solvent was removed in vacuo to give the title compound as a white solid (890 mg, 93 %).
TLC Rf 0.3 (1 :2 hexane-ethyl acetate)
MS 261 MH* Similarly prepared were:
Intermediate 117 3-j4-(Chlorophenyl)phenylsulfanyljpropanoic Acid
From intermediate 114 (450 mg), as a white solid (430 mg, 100 %).
TLC Rf 0.3 (10 % diethyl ether-hexane)
MS 244 Intermediate 118 3-(4-MethoxyphenyI)sulfanylpropanoic Acid
From intermediate 1 12 (5.00 g), as a white solid (4.40 g, 94 %).
TLC Rf 0.4 (1 : 1 hexane-ethyl acetate)
MS 330 MNH +
Intermediate 119 3-(4-Methoxyphenylsulfanylmethyl)-6-phenylhexanoic Acid
From intermediate 8 (240 mg), as a colourless oil (234 mg, 100 %). TLC Rf 0.1 (3: 1 hexane-diethyl ether)
Intermediate 120 4-(4-Methoxyphenylsulfanyl)butanoic Acid
From intermediate 83 (5.00 g), as a white solid (4.10 g, 92 %).
TLC Rf 0.1 (3:1 hexane-diethyl ether) Intermediate 121 2-[4-(4-Clιlorophenyl)phenylsulfanylmethyl]-5-phenγl- pentanoic Acid
From intermediate 115 (1.57 g), as a white solid (1.42 g, 93 %).
TLC Rf 0.3 (10 % diethyl ether-heptane)
MS 428 MNH + Example 1 2-(4-BenzoylplιenylsuIt nylmethyl)-5-phenylpentanoic
Acid
A solution of intermediate 74 (84 mg) in dichloromethane (10 ml) was cooled to 0 °C and treated with 4-chloroperbenzoic acid (73 mg). The reaction was warmed to room temperature and stirred for 3 hours. The reaction mixture was concentrated onto silica in vacuo and purified by chromatography on silica eluting with 1% acetic acid and 1% methanol in dichloromethane to give the title compound as a colourless oil (42 mg,
48%).
TLC Rf 0.10 (30% ethyl acetate - hexane)
MS 421 MH* Similarly prepared was:
Intermediate 122 3-(4-Methoxypιιenyisulfinyl)propanoic Acid
From intermediate 1 18 (1.00 g), as a white solid (688 mg, 63 %).
TLC Rf 0.1 (1 :2 hexane-ethyl acetate)
MS 229 MH+ Example 2 2-(4-Benzoylphenylsulfonylmethyl)-5-phthalimido- pentanoic Acid
A solution of intermediate 62 (0.4 g) in methanol (50 ml) was treated at room temperature with a solution of Oxone® (0.52 g) in water (10 ml). The mixture was stirred for 24 hours and the organic solvent removed in vacuo. The residue was diluted with water (100 ml) and extracted with ethyl acetate (3x100 ml). The organic extracts were combined, washed with brine (40 ml), dried over magnesium sulfate and filtered. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel eluting with 2% methanol in dichloromethane to yield the title compound as a white solid (0.37 g, 87%).
TLC Rf 0.24 (2% methanol-dichloromethane) MS 506 MH+
Similarly prepared were:
Intermediate 123 3-(4-BenzoyipheπyIsulfonyl)propanoic Acid
From intermediate 63 (0.257g) as a white solid (0.20g, 69%)
TLC Rf 0.3 (ethyl acetate) MS 319 MH+
Example 3 2-(4-AcetylphenyIsuIfonylmethyl)-5-phenylpentanoic Acid
From intermediate 64 (0. 12 g) as a cream solid (0.094 g, 72%).
TLC Rf0.43 (10%methanol-dichloromethane)
MS 374 MH+ Intermediate 124 2-(2-ThiazolyIsuIfonylmethyl)-5-phenylpentanoic Acid
From intermediate 65 (0.125 g) as a colourless oil (0.094 g, 67%).
TLC Rf 0.4 (5% methanol-dichloromethane)
MS 341 MH*
Example 4 2-(4-N^V-Dimethylcarbamoylsulfonylmethyl)-5-phenyl pentanoic Acid
From intermediate 66 (0.289 g) as a colourless oil (0.250 g, 83%).
TLC RfO.36 (10% methanol-dichloromethane)
MS 404 MH+
Example 5 2-(4-Methoxypheny!sulfonyimethyI)-5-phthalimido- pentanoic Acid
From intermediate 68 (0.9 g), as a white solid (0.7 g, 72%).
TLC Rf 0.58 (5% methanol-dichloromethane)
MS 432 MH*
Example 6 2-(4-Methoxyphenylsulfonylmethy.)-4-phthaIimido- butanoic Acid
From intermediate 69 (0.9 g), as a white solid (0.8 g, 82%). TLC Rf 0.19 (4% methanol-dichloromethane)
MS 418 MH+
Intermediate 125 3-(4-Bromophenylsulfonyl)propanoic Acid
From intermediate 1 16 (260 mg) as a white solid (241 mg, 83 %). TLC Rf 0.3 (1 :2 hexane-ethyl acetate)
MS 294 MH+
Intermediate 126 3-[4-(ChIorophenyl)plιenylsulfonyl]propanoic Acid
From intermediate 117 (195 mg), as a white solid (196 mg, 90 %).
TLC Rf 0.2 (10 % diethyl ether-hexane) MS 341 MNH4 +
Intermediate 127 3-(4-Methoxyphenylsulfonyl)propanoic Acid
From intermediate 1 18 (1.00 g), as a white solid (1.13 g, 98 %).
TLC Rf 0.2 (1 :2 hexane-ethyl acetate)
MS 262 MNH4 + Example 7 2-(Furan-2-ylmethylsulfonylmethyl)-5-phenylpentanoic
Acid
From intermediate 101 (560 mg), as a colourless oil (401 mg, 64 %).
TLC Rf 0.3 (3:1 hexane-ethyl acetate)
MS 354 MNH4 + Example 8 2-(CycIopentylsulfonylmethyl)-5-phenylpentanoic Acid
From intermediate 102 (540 mg), as a colourless oil (387 mg, 64 %).
TLC Rf 0.3 (3:1 hexane-ethyl acetate)
MS 342 MNH4 +
Example 9 3-(4-MethoxyphenylsuIfonylmethyl)-6-phenylhexanoic Acid
From intermediate 119 (230 mg), as a colourless oil (157 mg, 62 %).
TLC Rf 0.2 (1:2 hexane-ethyl acetate)
MS 394 MNH4 +
Example 10 2-(4-Methoxyphenylsulfonylmethyl)-5-phenylpentanoic Acid
From intermediate 67 (0.50 g) as a white solid (0.52 g, 95%). TLC Rf 0.61 (50% ethyl acetate-hexane)
MS 380 MNH4 +
Example 11 2-(Benzylsulfonylmcthyl)-5-phenylpentanoic Acid
From intermediate 103 (0.569 g), as a white solid (0.613 g, 98%). TLC Rf 0.53 (50% ethyl acetate-hexane)
MS 364 MNH4 +
Example 12 5-Phenyl-2-(phenylsulfonylmethyI)pentanoic Acid
From intermediate 70 (0.494 g), as a white solid (0.543 g, 100%).
TLC Rf 0.52 (50% ethyl acetate-hexane) MS 348 MNH4 +
Example 13 2-(2-Methoxybenzenesulfonylmethyl)-5-phenylpentanoic
Acid
From intermediate 71 (0.539 g), as a colourless oil (0.561 g, 95%).
TLC Rf 0.47 (50% ethyl acetate-hexane) MS 380 MNH
Example 14 2-(3-MethoxyphenylsulfonylmethyI)-5-phenylpentanoic
Acid
From intermediate 72 (0.610 g), as a colourless oil (0.617 g, 92%).
TLC Rf 0.58 (50% ethyl acetate-hexane) MS 380 MNH4 +
Intermediate 128 2-(4-(Carbamoylmellιyloxy)phenylsulfonylmethyl)-5- p enyipentanoic Acid
From intermediate 73 (0.864 g), as a white solid (0.653 g, 70%).
TLC Rf 0.29 (5% methanol-dichloromethane) MS 423 MNH4 +
Example 15 2-(4-Benzoylphenylsulfonylmethyl)-5-phenylpentanoic
Acid
From intermediate 74 (7.5 g) as a colouriess solid (7.4 g, 91%).
TLC Rf0.3 (1: 1 ethyl acetate-hexane). MS 437 MH+ Example 16 2-(Pyrid-4-ylsuIfonylmethyl)-5-pheπylpentanoic Acid
From intermediate 75 (0.52 g) as a white solid (0.55 g, 96%).
TLC Rf 0.25 (5% methanol-dichloromethane).
MS 334 MH+ Intermediate 129 2-((4-Acetylamino)phenylsulfonyimethyl)-5-phenyl- pentanoic Acid
From intermediate 78 (0.20 g) as a colourless solid (0.12 g, 56%).
TLC Rf 0.3 (ethyl acetate).
MS 390 MH+ Intermediate 130 2-((l-MethyiimidazoI-2-yI)suIfonylmethyl)-5-phenyl- pentanoic Acid
From intermediate 79 (0.5 g) as a white solid (0.35 g, 64%).
TLC Rf 0.2 (6% methanol-dichloromethane).
MS 337 MH+ Example 17 2-(2-Phenylethylsulfonylmethyl)-5-phenylpentanoic Acid
From intermediate 105 (1.35 g) as a white solid (1.40 g, 94%).
TLC Rf 0.5 (diethyl ether).
MS 361 MH+
Example 18 2-((2-Methylpropyl)sulfonylmethyl)-5-phenylpentanoic Acid
From intermediate 107 (2.6 g) as a white solid (1.70 g, 59%).
TLC Rf 0.5 (40% diethyl ether-hexane).
MS 312 M*
Example 19 2-(4-Methoxyphenylsulfonylmethyl)-5-succinimido- pentanoic Acid
From intermediate 76 (1.56 g ) as a white solid (1.4 g, 82%).
TLC Rf0.15 (ethyl acetate)
MS 383 M+
Example 20 2-(4~Benzoylphenyl)suIfonylmethyl-5-succinimidopentan- oic Acid
From intermediate 77 (0.34 g) as a white solid (0.28 g, 78%). TLC Rf0.2 (ethyl acetate)
MS 457 M+
Example 21 2-(4-Met-.oxyphenylsulfonylrnethyI)-5-(3,3,4-trimethyl- hydantoin-l-yI)pentanoic Acid From intermediate 80 (0.8 g) as a white solid (0.6 g, 70%).
TLC Rf 0.4 (6% methanol-dichloromethane)
MS 427 MH+
Example 22 2-(4-MethoxyphenyIsulfonylmethyl)-4-(3,3,4-trimethyl- hydantoin-l-yl)butanoic Acid From intermediate 81 (0.57 g) as a white solid (0.50 g, 79%).
TLC RfO.35 (10 % methanol-dichloromethane)
MS 413 MH+
Example 23 2-(4-MethoxyphenylsuIfonyImethyl)-3-phenylpropanoic
Acid From intermediate 82 (2.95 g) as a white solid (3.0 g, 90%).
TLC Rf 0.43 (ethyl acetate)
MS 334 M+
Intermediate 131 4-(4-Methoxyphenylsulfonyl)butanoic acid
From intermediate 120 (1.00 g), as a white solid (1.12 g, 98 %). TLC Rf 0.2 (2: 1 hexane-ethyl acetate)
MS 259 MH+
Example 24 2-[4-(4-Chlorophenyl)phenylsulfonyl)methyl]-5- phenylpentanoic Acid
From intermediate 121 (1.24 g), as a white solid (1.01 g, 75 %). TLC Rf 0.2 ( 10 % diethyl ether-heptane)
MS 443 MH+
Example 25 2-[4-Methoxyphenylsulfonylmethyljpentanoic Acid
From intermediate 84 (2.6 g) as a white solid (2.2 g, 74%).
TLC Rf 0.32 (5% methanol - dichloromethane) MS 287 (M+H). Intermediate 132 2-(4-Methoxyphenylsulfonylmethyl)-5-
(methoxycarbonyl)pentanoic Acid
From intermediate 1 10 (0.3 g), as a white solid (0.2 g, 61%)
TLC Rf 0.19 (50% ethyl acetate in hexane) MS 345 MH+
Example 26 3-Methyl-2-(4-methoxyphenylsulfonylmethyl)butanoic
Acid
From intermediate 86 (3.26 g) as a white solid (2.3 g, 63%)
TLC Rf 0.43 (10% methanol/dichloromethane) Intermediate 133 2-((Benzo| l,3|dioxole-5-yl)sulfonylmethyl)-5- plienylpentanoic Acid
From intermediate 87 as a colourless oil (3.4 g, 81%)
TLC Rf 0.48 (10% methanol/dichloromethane)
Example 27 2-|(4-TrifluoromethoxyphenylsuIfonyl)methyI]-5-(l,5,5- trimethyllιydantoin-3-yl)pentanoic Acid
From intermediate 88 (0.47 g) as a white solid (0.49 g, 96%).
TLC Rf 0.43 (hexane / ethyl acetate (1 :2) with trace acetic acid)
MS 481 (MH+)
Example 28 2-|(4-Trifluoroniethoxyphenylsulfonyl)methyI]pentanoic Acid
From intermediate 89 (2.77 g) as a white solid (2.79 g, 91%).
TLC Rf 0.73 (50% hexane / ethyl acetate with trace acetic acid)
MS 358 (M+NH4 +)
Intermediate 134 5-Phenyl-2-((tetrahydropyran-4-ylsulfonyl)methyl)- pentanoic Acid
From intermediate 104 (0.99 g), as a waxy white solid (0.62 g, 57%).
TLC Rf 0.10 (ethyl acetate / hexane / acetic acid (49:49:2))
Example 29 2-((Quinolin-2-yl)sulfanylmethyl)-5-phenyIpentanoic Acid
From intermediate 90 (0.2g) as a pale yellow gum (0.10 g). TLC Rf 0.53 (60% EtOAc-hexanes).
MS 384 (MH+)- Example 30 2-(4-BenzoylphenyI)suIfonylmethyI-4-(3,3,4- trimethylhydantoin- l-yI)butanoic Acid
From intermediate 91 (0.3g) as white solid (0.20 g, 66 %). TLC Rf 0.54 (10% MeOH/dichloromethane) MS 486 (M+)
Example 31 2-(4-Benzoylphenyl)sulfonylmethyl-5-(3,3,4- trimethylhydantoin-l-yI)pentanoic Acid From intermediate 92 (0.6g) as white solid (0.25 g, 40%) TLC Rf 0.50 (10% MeOH/dichloromethane) MS 500 (M+)
Example 32 2-((4-BetιzoyIphenγlsuIfonyl)methyl)-3-phenylpropanoic
Acid From intermediate 93 (1. lOg) as white solid (0.80 g, 60%). TLC Rf 0.60 (10% MeOH/dichloromethane). MS 408 (M+).
Intermediate 135 2-((l-Benzoylpiperidine-4-yl)sulfonylmethyl)-5- phenylpentanoic Acid From intermediate 108 (1.6 g) as white solid (1.05 g, 26%). TLC Rf 0.57 (EtOAc). MS 443 (M+)
Example 33 2-((4-Methoxyphenyl)sulfonyimethyl)-4-(2- pyridyl)butanoic Acid From intermediate 94 (0.25 g), as a white solid (0.26 g, 100 %). TLC Rf 0.22 (10% MeOH/dichloromethane). MS 350 (MH+).
Intermediate 136 2-(4-(4-Pyridinoyl)phenylsulfonylmethyl)-5- phenylpentanoic acid From intermediate 95 (1.62 g) as white solid (1.20 g, 65 %). TLC Rf 0.65 (10% MeOH/dichloromethane). MS Intermediate 137 2-(4-(2-Thienoyl)phenylsuIfonylmethyl)-5- phenylpentanoic Acid
From intermediate 96 (1.8 g) as white solid (1.60 g, 80%).
TLC Rf 0.60 (10% MeOH/dichloromethane). MS 442 (M+).
Intermediate 138 2-(4-(4-Pyridinoyl)phenylsuIfonylmethyl)-5-(3,3,4- trimethylhydantoin-l-yl)pentanoic Acid
From intermediate 97 (0.25 g), as white solid (0.12 g, 50%).
TLC Rf 0.45 (EtOAc). MS 502 (MTT).
Intermediate 139 2-(4-(2-Thienoyl)phenyisuironylmethyl)-5-(3,3,4- trimethylhydantoin-l-yl)pentanoic Acid
From intermediate 98 (1.3 g), as white solid (1.2 g, 85 %).
TLC Rf 0.45 (EtOAc) MS 506 (M+).
Intermediate 140 2-((4-Hydroxyphenyl)su!fonylmethy!)-5-phenylpentanoic
Acid
From intermediate 99 (3.0 g) as white solid (3.1 g, 95 %).
TLC Rf 0.30 (EtOAc). MS 348 (M+).
Example 34 2-((Quinolin-8-yl)sulfonylmethyl)-5-phenylpentanoic Acid
From intermediate 100 (100 mg) as white solid (60 mg, 55 %).
TLC Rf 0.30 (EtOAc).
MS 391 (M+). Example 35 2-(3-PhenyIpropylsulfonyl)methyl-5-phenylpentanoic
Acid
From intermediate 106 (1.6 g), as colourless solid (1.45 g, 90 %).
TLC Rf 0.75 (ether)
MS 374 (M+). Intermediate 141 4-Methoxy-l-(2-phenylethylsulfonyι)benzene
From intermediate 26 (8.9 g), as white solid (10.0 g, 100 %). TLC Rf 0.75 (ether).
Example 36 3-(4-Methoxybenzenesulfonyl)-4-phenylbutanoic Acid
M-Butyllithium (12.5 mmol) was added to a solution of intermediate 141 (2.75 g) in THF at -78 °C and the solution was stirred for 4 h at that temperature, then a solution of lithium bromoacetate (10 mmol) was added dropwise. The mixture was stirred at -78 °C for 2 h, then warmed to room temperature, quenched with dilute aqueous HCl and evaporated in vacuo. The residue was dissolved in dilute NaOH, washed with ether, acidified with aqueaous HCl and extracted with ethyl acetate. The ethyl acetate extracts were combined, washed with water, dried and evaporated and the residue purified by flash column chromatography, eluting with 40% EtOAc in hexane, to give the title compound as colourless solid (150 mg, 7%). TLC Rf 0.40 (40% EtOAc/hexanes). Intermediate 142 2-((l-/tτ/-Butyloxycarbonylpiperidin-4- yl)sulfonylmethyl)-5-phenylpentanoic Acid Oxone® (1 g) was added to a solution of intermediate 109 (4.5 g) and sodium acetate (5 g) in methanol 200 ml) and water (50 ml) at room temperature and the mixture was stirred for 18 h, then evaporated, diluted with water and the product collected by filtration to give the title compound as white solid (3.50 g, 75 %). TLC Rf 0.35 (EtOAc) MS 439 (M+).
Intermediate 143 Methyl 2-((PyrroIidin-l-yl)sulfonylmethyl)-5-phenyl- pentanoate Pyrrolidine (0.2 ml) was added to a solution of intermediate 58 (0.7 g) and triethylamine (0.5 ml) in dichloromethane (20 ml) at -10 °C and the solution was stirred for 18 h, then washed with water, sodium bicarbonate and 0.5 M HCl. The solvent was dried and evaporated and the residue was purified by flash column chromatography, eluting with 40% ether/hexanes, to give the title compound as colouriess oil (0.16 g, 25 %). TLC Rf 0.28 (40% ether/hexanes). Intermediate 144 2-((Pyrrolidin-l-yl)suIfonyimethyl)-5-pl.enylpentanoic
Acid
Lithium hydroxide (100 mg) was added to a solution of the ester intermediate 143 (0.16 g) in methanol (5 ml) THF (10 ml) and water (5 ml) and the solution was stirred for 6 h, then evaporated in vacuo and the residue dissolved in water. The aqueous solution was washed with ether, then acidified with citric acid and extracted with dichloromethane. The dichloromethane extracts were combined and washed with water, dried and evaporated to give the crude product. This material was purified by flash column chromatography, eluting with 60% ether/hexanes, to give the title compound as colourless oil (60 mg, 40 %). TLC Rf 0.40 (60% ether/hexanes). Example 37 2-(4-Benzoylphenylsulfonylmethyl)-5-phthaIimido- pentanoic Acid N-Hydroxyamide A solution of example 2 (0. 1 g) in anhydrous THF (10 ml) was treated at room temperature with O-(/tvY-butyldirnethylsilyI)hydroxylamine (0.032 g) and l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.042 g). The mixture was stirred for 24 hours and the organic solvent removed in vacuo. The residue was partitioned between water (30 ml) and ethyl acetate (50 ml). The organic extract were was washed with brine (40 ml), dried over magnesium sulfate and filtered. The filtrate was evaporated in vacuo and the residue dissolved in THF (10 ml). The solution was treated at 0°C with a 1.0 M solution of tetrabutylammonium fluoride in THF (1.0 ml) and stirred for 1 hour. The solvent was removed in vacuo and the residue partitioned between ethyl acetate (50 ml) and water (40 ml). The organic layer was washed with brine (20 ml), dried over magnesium sulfate, filtered and the filtrate evaporated in vacuo. The residue was purified by column chromatography on silica gel eluting with 2% methanol in dichloromethane to yield the title compound as a white solid (0.06 g, 58%). TLC Rf 0.74 (ethyl acetate) MS 521 MH+ Similarly prepared were: Example 38 3-(4-Benzoyipiιenylsulfonyl)propanoic Acid N-Hydroxy
Amide
From intermediate 123 (0.158 g) as a white solid (0.032 g, 20%). TLC Rf0.15 (5% methanol-dichloromethane) MS 334 H*
Example 39 2-(4-Acetylphenylsulfonylmethyl)-5-phenyιpentanoic Acid
N-Hydroxy Amide From example 3 (0.080 g) as a white solid (0.022 g, 30%). TLC Rf 0.36 (5% methanol-dichloromethane) MS 389 MH+
Example 40 2-(Thiazol-2-ylsuIfonyimethyl)-5-phenylpentanoic Acid
N-Hydroxy Amide From intermediate 124 (0.125 g) as an oily semi-solid. (0.023 g, 26%). TLC Rf 0.3 (5% methanol-dichloromethane) MS 354 TT
Example 41 2-(4-N,N-DiιnetlιyIcarbamoylphenylsulfanylmethyl)-5- phenylpentanoic Acid N-Hydroxy Amide From example 4 (0.232 g) as a white solid (0.046 g, 25%). TLC Rf0.49 (10% methanol-dichloromethane) MS 419 MH*
Example 42 2-(4-MethoxyphenylsulfonylmethyI)-5-phthalimido- pentanoic Acid N-Hydroxy Amide From example 5 (0.35 g), as a white solid (0.12 g, 43%). TLC Rf 0.52 (5% methanol-dichloromethane) MS 447 MH+
Example 43 2-(4-Methoxyphenylsulfonylmethyl)-4-phthalimido- butanoic Acid N-Hydroxy Amide From example 6 (0.3 g), as a white solid (0.1 1 g, 35%). TLC Rf 0.48 (5% methanol-dichloromethane) MS 433 MH+ Example 44 3-(4-Bromophenylsulfonyl)propanoic Acid N-Hydroxy
Amide
From intermediate 125 (130 mg) as a white solid (87 mg, 64 %). TLC Rf 0.1 (1 :2 hexane-ethyl acetate) MS 310 MH*
Example 45 3-(4-(Chlorophenyl)plιenylsuIfonyI]propanoic Acid N-
Hydroxy Amide From intermediate 126 (123 mg), as a white solid (39 mg, 30 %). TLC Rf 0.1 (10 % diethyl ether-hexane) MS 341 MH+
Example 46 3-(4-Methoxyphenylsulfonyl)propanoic Acid N-Hydroxy
Amide From intermediate 127 (764 mg), as a white solid (100 mg, 12 %). TLC Rf 0.1 (1 :2 hexane-ethyl acetate) MS 277 MNH4 +
Example 47 3-(4-MethoxyphenyIsulfinyI)propanoic Acid N-Hydroxy
Amide From intermediate 122 (200 mg), as a colourless oil (32 mg, 15 %). TLC Rf 0.1 (1 :1 hexane-ethyl acetate) MS 261 MNH4 +
Example 48 2-[(4-Benzoylphenyl)suIfinylmethyl]-5-phenylpentanoic
Acid N-Hydroxy Amide From example 1 (450 mg), as a white solid (42 mg, 9 %). TLC Rf 0.3 (ethyl acetate) MS 436 MH+
Exampie 49 2-(Furan-2-ylmethylsuifonylmethyl)-5-phenylpentanoic Acid
N-Hydroxy Amide From example 7 (350 mg), as a colourless oil (228 mg, 62 %). TLC Rf 0.4 (1 :2 hexane-ethyl acetate) MS 369 MNH4 + Example 50 2-(CyclopentylsuIfonylmethyI)-5-phenylpentanoic Acid N-
Hydroxy Amide
From example 8 (342 mg), as a colourless oil (265 mg, 75 %). TLC Rf 0.2 (1:2 hexane-ethyl acetate) MS 357 MNH4 +
Example 51 3-(4-MethoxyphenylsuIfonylmethyl)-6-phenylhexanoic
Acid N-Hydroxy Amide From example 9 (135 g), as a colouriess oil (86 mg, 61 %). TLC Rf 0.2 (1 :2 hexane-ethyl acetate) MS 392 MH*
Example 52 2-(PhenylmethylsulfonylmetlιyI)-5-phenylpentanoic Acid
N-Hydroxy Amide From example 1 1 (0.559 g) as a white solid (0.500 g, 86%). TLC Rf 0.41 (ethyl acetate-hexane (2: 1)) MS 362 MH+
Example 53 5-Phenyl-2-(pheιιylsulfonyimethyl)pentanoic Acid N-
Hydroxy Amide From example 12 (0.478 g), as a white solid (0.394 g, 79%). TLC Rf 0.51 (ethyl acetate-hexane (2: 1)) MS 348 MH*
Example 54 2-(2-MethoxyphenyisuIfonylmethyl)-5-phenylpentanoic
Acid N-Hydroxy Amide From example 13 (0.547 g), as a white solid (0.392 g, 69%). TLC Rf 0.25 (ethyl acetate-hexane (2: 1)) MS 378 MH+
Example 55 2-(3-Methoxyphenylsulfonylmethyl)-5-phenylpentanoic
Acid N-Hydroxy Amide From example 14 (0.636 g), as a white solid (0.460 g, 70%). TLC Rf 0.48 (ethyl acetate-hexane (2: 1)) MS 378 MH+ Example 56 2-(4-(4-Chlorophenyl)phenylsulfonylmethyl)-5-phenyI- pentanoic Acid N-Hydroxy Amide
From example 24 (0.51 1 g), as a white solid (0.348 g, 66%). TLC Rf 0.61 (ethyl acetate- hexane (2: 1 )) MS 459, 461 (M-O+NH )
Example 57 2-(4-(Carbamoylmethyloxy)benzenesulfonylmethyl)-5- phenyipentanoic Acid, N-Hydroxy Amide From intermediate 128 (0.297 g) as a white solid (0.049 g, 16%). TLC Rf 0.18 (ethyl acetate) MS 422 M-O+ΝH
Example 58 2-(4-BenzoyIphenyIsulfonylmethyl)-5-phenyIpentanoic
Acid Ν-Hydroxy Amide From example 15 (7.4 g) as a colourless solid (3.80 g, 50%). TLC RfO.42 (10 % methanol-dichloromethane) MS 452 MH*
Example 59 2-(4-MethoxyphenylsuIfonylmethyl)-5-phenylpentanoic
Acid Ν-Hydroxy Amide From example 10 (0.425 g) as a white solid (0. 185 g, 40%). TLC Rf 0.31 (ethyl acetate-hexane (2: 1)) MS 378 MH+
Example 60 2-(Pyrid-4-ylsulfonylmethyl)-5-phenylpentanoic Acid Ν-
Hydroxy Amide From example 16 (0.23 g), as a colourless solid (0.2 g, 80%). TLC Rf 0.2 (5% methanol-dichloromethane) MS 337 MH+
Example 61 2-(4-Acetylaminophenylsulfonylmethyl)-5- phenylpentanoic Acid Ν-Hydroxy Amide From intermediate 129 (0.12 g) as a beige solid (0.04 g, 32%). TLC Rf 0.2 (5% methanol-dichloromethane) MS 406 MH+ Example 62 2-(l-MetlιyIimidazoi-2-ylsulfonylmethyI)-5-phenylpentan- oic Acid N-Hydroxy Amide
From intermediate 130 (0.20 g) as a white solid (0.06 g, 1%). TLC RfO.35 (10% methanol-dichloromethane) MS 352 (MH+).
Example 63 2-(2-Phenylethyl)sulfoιιylmethyl)-5-phenylpentanoic Acid
N-Hydroxy Amide From example 17 (0.50 g) as a white powder (0.23 g, 42%). TLC Rf 0.4 (diethyl ether). MS 376 (MH+).
Example 64 2-(2-Methyipropyl)sulfonylmethy!-5-phenyIpentanoic
Acid N-Hydroxy Amide From example 18 (1.7 g) as a white solid (0.85 g, 47%). TLC Rf 0.32 (diethyl ether). MS 328 (MH+).
Example 65 2-(4-Methoxyphenylsulfonylmetlιyi-5-succinimido- pentanoic Acid N-Hydroxy Amide From example 19 (1.15 g) as a white solid (0.90 g, 74%). TLC RfO.35 (10% methanol-dichloromethane). MS 398 (M+).
Example 66 2-(4-Benzoylphenyl)sulfonylmethyi-5-succinimido- pentanoic Acid N-Hydroxy Amide From example 20 (0.26 g) as a white solid (0.22 g, 79%). TLC Rf0.45 (10% methanol-dichloromethane). MS 471 (M+).
Example 67 2-(4-MethoxyphenylsulfonylmethyI-5-(3,3,4-trimethyl- hydantoin-l-yl)pentanoic Acid N-Hydroxy Amide From example 21 (0.6 g) as a white solid (0.45 g, 70%). TLC Rf 0.55 (10 % methanol-dichloromethane). MS 442 (MH+) Example 68 2-(4-MethoxyphenylsulfonyImethyl-4-(3,3,4-trimethyI- hydantoin-l-yI)butanoic Acid-N-Hydroxy Amide
From example 22 (0.42 g) as a white solid (0.22 g, 53%). TLC Rf0.32 (10 % methanol-dichloromethane). MS 428 (MH+).
Example 69 2-(4-Methoxypheπylsulfonylmethyl)-3-plιenylpropanoic
Acid N-Hydroxy Amide From example 23 (1.7 g) as a white solid ( 1.4 g, 78%). TLC RfO.55 (10% methanol-dichloromethane). MS 349 (M+).
Example 70 4-(4-Methoxyphenylsulfonyl)butanoic Acid N-Hydroxy
Amide From intermediate 13 1 (500 mg), as a white solid (210 mg, 40%). TLC Rf 0.1 (1:2 hexane-ethyl acetate) MS 291 MNH
Example 71 2-{4-MethoxyphenylsuIfonylmethyl]pentanoic Acid N-
Hydroxy Amide From example 25 (500 mg), as a white solid (390 mg, 73 %). TLC Rf 0.29 (5% methanol-dichloromethane) MS 302 MH*
Example 72 2-(4-MethoxyphenylsulfonylmethyI)-5-
(methoxycarbonyl)pentanoic Acid N-Hydroxy Amide From intermediate 132 (0.2 g), as a white solid (0.08 g, 38%) TLC Rf 0.45 (10% methanol in dichloromethane) MS 360 MH+
Example 73 2-(4-MethoxyphenylsuIfonylmethy!)-3-methylbutanoic
Acid N-Hydroxy Amide From example 26 (2.2 g), as a white solid (0.46 g, 34%) TLC Rf 0.2 (10% methanol/dichloromethane) MS 302 MH+ Example 74 2-((Benzo( l,3Jdioxole-5-yl)sulfanylmethyl)-5- phenylpentanoic Acid N-Hydroxy Amide
From intermediate 133 as a tan solid (1.636g, 70%) TLC Rf 0.36 (10% methanol/dichloromethane) MS 392MH+
Example 75 2-((4-Trifluoromethoxyphenylsulfonyl)methyI)-5-(l,5,5- trimethylhydantoin-3-yl)pentanoic Acid N-Hydroxy Amide From example 27 (0.46 g), as a white solid (0.36 g, 77%). TLC Rf 0.16 (ethyl acetate / hexane (3: 1) with trace acetic acid) MS 496 (MH+) Example 76 2-((4-TrifIuoromethoxybenzenesulfonylmethyI)pentanoic
Acid N-Hydroxy Amide From example 28 (2.70 g), as a white solid (2.09 g, 74%). TLC Rf 0.53 (10% methanol / dichloromethane) MS 373 (M+NH ) Example 77 5-Plιeιιyl-2-((tetrahydropyran-4-ylsιιIfonyl)methyI)- pentanoic Acid N-Hydroxy Amide From intermediate 134 (0.60 g), as a white solid (0.40 g, 65%). TLC Rf 0.20 (ethyl acetate / hexane (5:1) with trace acetic acid) MS 373 (M+NH ) Example 78 2-((Quinoline-2-yl)sulfonylmethyl)-5-phenylpentanoic
Acid N-Hydroxy Amide From example 29 (100 mg), as pale yellow solid (0.046 g, 42%) TLC Rf 0.5 (6% MeOH/dichloromethane). MS 396 (MH+) Example 79 2-(4-benzoylphenyl)sulfonylmethyI-4-(3,3,4-trimethyI- hydantoin-l-yl)butanoic Acid N-Hydroxy Amide From example 30 (0.25 g) as white solid (0.20 g, 80%). TLC Rf 0.55 (6% MeOH dichloromethane) MS 501 (M+). Example 80 2-((4-Benzoylphenyl)sulfonylmethyl)-5-(3,3,4-trimethyI- hydantoin-l-yI)pentanoic Acid N-Hydroxy Amide
From example 31 (0.25 g) as white solid (0.20 g). TLC Rf 0.50 (6% MeOH/dichloromethane). MS 515 (M+).
Example 81 2-((4-Benzoylphenyl)sulfonylmethyl)-3-phenylpropanoic
Acid N-Hydroxy Amide From example 32 (0.80 g), as white solid (0.43 g, 50%). TLC RfO.43 (10% MeOH/dichloromethane). MS 423 (M+)
Example 82 2-((l-Benzoylpiperidine-4-yl)suIfonylmethyI)-5-phenyl- pentanoic Acid N-Hydroxy Amide From intermediate 135 (1.05 g) as white solid (0.85 g, 80%). TLC Rf 0.43 (7% MeOH/dichloromethane) MS 458 (M+).
Example 83 2-((l-tør«'-Bιιtyloxycarbonylpiperidin-4- yI)sulfonylmethyl)-5-phei]ylpentanoic Acid N-Hydroxy Amide From intermediate 142 (3.5 g), as white foam (2.40 g, 66%). TLC Rf 0.7 (7% MeOH/dichloromethane). MS 454 (M+). Example 84 2-(4-Methoxyphenyl)sulfonylmethyI)-4-(pyrid-2-yl)butan- oic Acid N-Hydroxy Amide From example 33 (0.26 g), as white solid (0.20 g, 75 %). TLC Rf 0.5 (10% MeOH/dichloromethane). MS 365 (MH+).
Example 85 2-((4-Pyridinoylphenyl)sulfonylmethyI)-5- phenylpentanoic Acid N-Hydroxy Amide From intermediate 136 (1.08 g), as white solid (0.75 g, 67%). TLC Rf 0.40 (7% MeOH/dichloromethane). MS 453 (MH+). Example 86 2-(4-(2-ThienoyI)phcnylsulfonylmethyl)-5- phenylpentanoic Acid N-Hydroxy Amide
From intermediate 137 (1.4 g) as white solid (0.85 g, 57%). TLC Rf 0.63 (10% MeOH/dichloromethane). MS 457 (M+).
Example 87 2-((4-(4-Pyridinoyl)pheπyl)sulfonylmethyI)-5-(3,3,4- trimethyIlιydantoin-l-yl)pentanoic Acid N-Hydroxy Amide From intermediate 138 (0.10 g), as white solid (0.025 g, 26%). TLC Rf 0.60 (10% MeOH/dichloromethane). MS 517 (MH+).
Example 88 2-((4-(2-Thienoyl)phcnyl)sulfonylmethyl)-5-(3,3,4- trimethyIhydantoin-l-yl)pentanoic Acid N-Hydroxy Amide From intermediate 139 (1.2 g), as white solid (0.66 g, 60%). TLC Rf 0.52 (7% MeOH/dichloromethane) MS 521 (M+).
Example 89 2-((4-Hydroxypheιιyl)sulfonyimethyl)-5-pheny!pentanoic
Acid N-Hydroxy Amide From intermediate 140 (0.35 g), as white solid (0.20 g, 60%). TLC Rf 0.40 (7% MeOH/dichloromethane). MS 363 (M+).
Example 90 2-((PyrroIidin-l-yl)suIfonylmethyl)-5-phenylpentanoic
Acid N-Hydroxy Amide From intermediate 144 (60 mg) as colourless solid (30 mg, 50%). TLC Rf 0.40 (7% MeOH/dichloromethane). MS 340 (M+).
Example 91 2-((Quinolin-8-yl)sulfonylmethyl)-5-phenylpentanoic Acid
N-Hydroxy Amide From example 34 (60 mg) as white solid (20 mg, 30%). TLC Rf 0.30 (5% MeOH/dichloromethane). MS 396 (MH+).
Example 92 3-(4-MethoxyphenylsulfonyI)-4-phenylbutanoic Acid N-
Hydroxy Amide
From example 36 (100 mg), as white solid (60 mg, 60 %). TLC Rf 0.30 (6% MeOH/dichloromethane).
MS 348 (M+)
Example 93 2-(3-Phenyipropylsulfonyimethyl)-5-phenylpentanoic
Acid N-Hydroxy Amide
From example 35 (1.45 g), as white solid (1.35 g, 90 %). TLC Rf 0.42 (5% MeOH/dichloromethane).
MS 389 (M+).
Example 94 3-(4-Clιlorophenylsulfonyl)butanoic Acid N-Hydroxy
Amide
From 3-(4-chlorophenylsulfonyl)butanoic acid (2.63 g), as a colourless solid (1.00 g, 37%).
TLC Rf 0.37 (5% MeOH/dichloromethane).
MS 277 (M+).
Example 95 2-(4-Metlιoxyphenylsulfanyl)-5-phenylpentanoic Acid N-
Hydroxy Amide From intermediate 67 (0.53 g) as a colourless solid (0.17 g, 31%)
TLC Rf 0.25 (5% MeOH/dichloromethane)
MS 345 (M+)
Example 96 5-PhenyI-2-(4-(phenylmethyl)phenylsulfonylmethyI)- pentanoic Acid N-Hydroxy Amide Example 58 (0.203 g) and triethylsilane (0.42 mi) were held at reflux in trifluoroacetic acid (10 ml) for 30 h. The solvent was removed /'// vacuo, and the residue triturated with hexane (twice) to leave, after vacuum drying, a red solid (0.253 g). The crude red product was then purified by chromatography on silica, with 4% methanol / dichloromethane as eluent collecting fractions at Rf 0.27 to give a white solid. Further column purification of the white solid with 2% methanol / dicloromethane eluent collecting at Rf 0.14 provided a white solid (0.10 g). In order to remove residual traces of the starting hydroxamic acid, the residue was further purified as follows: 2,4- Dinitrophenylhydrazine (0.15 g) was suspended in methanol and treated with concentrated sulfuric acid (0.3 ml), and the warm mixture filtered. To this was added a solution of the column purified product in methanol (3 ml), and the mixture briefly warmed. Acetone (1 ml) was added and the mixture left to crystallise. The solids were then removed by filtration, and the residue obtained by concentration of the filtrate was diluted with water (20 ml) and extracted with ethyl acetate (2 x 30 ml). The combined organic extracts were then washed with water (2 x 10 ml), brine (10 ml), dried (MgSOJ and evapourated in vacuo. Purification of the red oil by chromatography on silica, with 4% methanol / dichloromethane as eluent, provided the title compound as a pale orange solid (0.061 g, 3 1%).
TLC Rf 0.29 (4% methanol / dichloromethane) MS 439 (M-O+NH ) Example 97 2-((Piperidin-4-yl)sulfonyImethyl)-5-phenylpentanoic Acid N-Hydroxy Amide Trifluoroacetate
Trifluoroacetic acid (20 ml) was added to a solution of the acid example 83 (2.4 g) in dichloromethane (20 ml) at room temperature and the solution was stirred for 2h, then evaporated in vacuo and the residue azeotroped with toluene (2 x 50 ml). The resulting solid ws then precipitated from methanol by addition of ether to give the title compound (1.54 g, 65 %).
TLC Rf 0.25 (10% MeOH/dichloromethane 2% NH4OH). MS 323 (MH+).
Example 98 2-((l-BenzyIpiperidin-4-yl)sulfonylmethyl)-5-phenyl- pentanoic Acid N-Hydroxy Amide Sodium triacetoxyborohydride (0.22 g) was added to a solution of example 97 (0.23 g), triethylamine (60 mg) and benzaldehyde (106 mg) in a mixture of dichloromethane (10 ml) and methanol (2 ml). The mixture was stirred at room temperature for 6 h, then evaporated in vacuo and the residue partitioned between water and dichloromethane. The organic solvent was washed with water, dried and evaporated and the residue purified by chromatography, eluting with 6% MeOH in dichloromethane and 1% NH4OH, to give the title compound as white solid (60 mg, 25 %). TLC Rf 0.35 (6% MeOH/dichloromethane 1% NH4OH). MS 445 (MH+). Similarly prepared was:
Example 99 2-(( l-(4-CyanobenzyI)piperidin-4-yl)suIfonylmethyl)-5- phenylpentanoic Acid N-Hydroxy Amide
From example 97 (0.23 g) and 4-cyanobenzaldehyde (65 mg) as white solid (35 mg, 14
%)-
TLC Rf 0.40 (6% MeOH/dichloromethane).
MS 470 (MH+). Intermediate 145 2-((4-Hydroxyphenyl)sulfonylmethyI)-5-phenylpentanoic
Acid N-ferf-Butyloxy Amide
EDC (2.0 g) was added to a solution of intermediate 140 (3.5 g), triethylamine (1.0 g) and O-fcrt-butythydroxylamine hydrochloride ( 1.3 g) in dichloromethane (100 ml) at room temperature and the mixture was stirred for 18 h. The mixture was then washed with water, IM HCl and saturated sodium bicarbonate, dried and evaporated to give the title compound as colourless solid (4.0 g, 95 %). TLC Rf 0.46 (ether) Intermediate 146 2-((4-Benzyloxypiιenyl)sulfonylmethyl)-5- phcnylpentanoic Acid N-tert-Butyloxy Amide Benzyl bromide (0.16 g) was added to a suspension of intermediate 145 (0.42 g) and caesium carbonate (0.33 g) in DMF (10 ml) and the mixture was stirred for 18 h at room temperature, then added to water and extracted with ether. The solvent was washed with water and brine, dried and evaporated. The residue was purified by flash column chromatography, eluting with ether, to give the title compound as colourless oil (0.25 g, 50 %).
TLC Rf 0.70 (ether). Similarly prepared were
Intermediate 147 2-(4-(l-Methyleth-l-yIoxy)phenylsulfonylmethyl)-5- phenyipentanoic Acid N-rerf-Butyloxy Amide From intermediate 145 (0.42 g), as colourless oil (0.35 g, 80%). TLC Rf 0.65 (ether). Intermediate 148 2-((4-Butyloxy)plιenylsulfonylmethyl)-5-phenylpentanoic
Acid N-tørf-Butyloxy Amide
From intermediate 145 (0.42 g), as colouriess oil (0.40 g, 90%). TLC Rf 0.75 (ether). Intermediate 149 2-((4-CyclopentyIoxy)phenylsuIfonylmethyl)-5-phenyI- pentanoic Acid N-/tτ/-Butyloxy Amide From intermediate 145 (0.42 g), as colourless oil (0.40 g, 90%). TLC Rf 0.68 (ether).
Intermediate 150 2-(4-(4-Cyanobenzyloxy)phenyisulfonylmethyl)-5-phenyl- pentanoic Acid N-terf-Butyloxy Amide
From intermediate 145 (0.42 g) as colourless oil (0.35 g, 75%). TLC Rf 0.63 (ether).
Example 100 2-((4-BenzyIoxyphenyi)sulfonyImethyl)-5- phenyipentanoic Acid N-Hydroxy Amide A solution of intermediate 146 (0.17 g) in TFA ( 10 ml) and dichloromethane ( 1 OmI) was stirred overnight and then evaporated /'// vacuo. The residue was azeotroped with toluene, then purified by flash column chromatography, eluting with 7% MeOH/dichloromethane, to give the title compound as colourless solid (0.06 g, 40 %). TLC Rf 0.45 (5%MeOH/dichloromethane). MS 453 (M+).
Example 101 2-(4-(l-Methyleth-l-yloxy)pheny.sulfonyimethyl)-5- phenylpentanoic Acid N-Hydroxy Amide From intermediate 147 (0.35 g) as white solid (0.20 g, 48%). TLC Rf 0.25 (5% MeOH/dichloromethane). MS 405 (M+).
Example 102 2-((4-Butyloxy)phenyIsulfonylmethyI)-5-phenylpentanoic
Acid N-Hydroxy Amide From intermediate 148 (0.40 g) as white solid (0.20 g, 45%). TLC Rf 0.30 (5% MeOH dichloromethane). MS 419 (M+). Example 103 2-((4-Cyclopentyloxyphenyl)sulfonyimethyl)-5-phenyl- pentanoic Acid N-Hydroxy Amide
From intermediate 149 (0.40 g), as white solid (0.15 g, 33%).
TLC Rf 0.30 (5% MeOH/dichloromethane). MS 431 (M+).
Example 104 2-(4-(4-Cyanobenzyloxy)phenylsulfonyImethyl)-5-phenyl- pentanoic Acid N-Hydroxy Amide
From intermediate 150 ( 0.25g) as white solid ( 0.265g, 100%).
TLC Rf 0.25 (6% MeOH/dichloromethane). MS 469 (M+).
Example 105 2-((4-(l-Hydroxy-l-plιenylmethyl)phenyl)sulfonyl- methyl)-5-phenyipentanoic Acid N-Hydroxy Amide
Sodium borohydride (0.38 g) was added to a solution of example 58 (0.45 g) in MeOH
(100 ml) and the solution was stirred for 2 h, then evaporated and the residue dissolved in water, acidified with citric acid and extracted with ethyl acetate. The organic layer was washed with brine, dried and evaporated to give the crude product, which was purified by column chromatography, eluting with 7% MeOH in dichloromethane to give the title compound (0.43 g, 95%) as white solid.
TLC Rf 0.53 (7% MeOH dichloromethane). MS 454 (M+).
Example 106 2-(Pyrid-4-ylsulfonylmethyl)-5-phenylpentananoic Acid
N-Hydroxy Amide Hydrochloride
Example 60 was dissolved in dichloromethane and treated with excess IM HCl in diethyl ether and then evaporated to give the title compound (0.20 g) as a pale yellow solid. Example 107 4-[4-(Methoxycarbonyi)methoxy-3,5-dimethyphenyl]-2- methyl-l(2H)phthalazinone
Intermediate 60 (1.40 g) was added to a suspension of sodium hydride (0.24 g) in DMF
(30 ml) at 0 βC. After stirring for 30 min, methyl bromoacetate (1.15 g) was added and the mixture stirred for 18 h. Water (90 ml) was added and the resultatnt precipitate was collected by filtration and dried in vacuo to provide the title compound as a white solid
(1.54 g) MS 353 MH+
Example 108 4-[4-(Carboxy)methoxy-3,5-dimethyphenyIJ-2-methyI- l(2H)phtha!azinone
Lithium hydroxide monohydrate (0.22 g) was added to a solution of example 107 (1.52 g) in aqueous tetrahydrofuran (1 : 1 50 ml) and the reaction stirred 18 h. the mixture was the concentrated in vacuo and the residual slurry acidified with 10% hydrochloric acid.
The resulting precipitate was collected to give the title compound as a white solid (1.36 g).
MS 338 MH+ Example 109 4-(4-(Hydroxyaminocarbonyi)methoxy-3,5- dimethyphenyI]-2-methyl-l(2H)phthaIazinone
A solution of example 108 (1. 15 g) in dichloromethane (30 ml) at 0 °C was treated with triethylamine (0.52 g) followed by isopropenyl chloroformate (0.41 g), and the mixture was stirred for 1 h. O-ttrt-butyldimethylsilylhydroxylamine (0.50 g) was then added and the mixture was stirred for a further 18 h. The reaction mixture was washed with 10% citric acid (20 ml), saturated sodium bicarbonate (20 ml) and the concentrated to dryness in vacuo. A solution of the residual solid in tetrahydrofuran (30 ml) and water (5 ml) was then treated with a 1.0 M solution of tetrabutylammonium fluoride in tetrahydrofuran (1 ml) and stirred 1 h. the resultant crude mixture was concentrated on to silica and purified by chromatography, eluting with 5% methanol in dichloromethane, to provide the title compound as a white solid (0. 10 g). Rf 0.18 (5% methanol in dichloromethane) Example A Collagenase inhibition activity The potency of compounds of general formula (I) to act as inhibitors of collagenase was determined by the procedure of Cawston and Barrett, (Anal. Biochem., 99:340-345, 1979) whereby a lmM solution of the inhibitor being tested or dilutions thereof was incubated at 37°C for 16 hours with collagen and collagenase (buffered with 50 mM Tris, pH 7.6 containing 5 mM CaCl2, 0.05% Brij 35, 60 mM NaCl and 0.02% NaN3). The collagen was acetylated 3H or l4C-collagen prepared by the method of Cawston and Muφhy (Methods in Enzymolgy, 80:711, 1981). The choice of radiolabel did not alter the ability of collagenase to degrade the collagen substrate. The samples were centrifuged to sediment undigested collagen and an aliquot of the radioactive supernatant removed for assay on a scintillation counter as a measure of hydrolysis. The collagenase activity in the presence of ImM inhibitor, or a dilution thereof, was compared to activity in a control devoid of inhibitor and the results reported as that inhibitor concentration effecting 50% inhibition of the collagenase (IC50). Example B Stromelysin inhibition activity
The potency of compounds of general formula (I) to act as inhibitors of stromelysin was determined using the procedure of Nagase et al (Methods in Enzymology Vol 254, 1994), whereby a 0.1 mM solution of the inhibitor being tested or dilutions thereof was incubated at 37°C for 16 hours with stromelysin and H transferrin (buffered with 50 mM Tris, pH 7.6 containing 10 mM CaCl2, 150M NaCl, 0.05% Brij, 35, and 0.02% NaN3). The transferrin was carboxymethylated with 3H iodoacetic acid. The stromelysin activity in the presence of 1 mM, or a dilution thereof was compared to activity in a control devoid of inhibitor and the results reported as that inhibitor concentration effecting 50% inhibition of the stromelysin (IC50) Example C Gelatinase inhibition activity The potency of the compounds of general formula (I) to act as inhibitors of gelatinase was determined using the procedure of Harris & Krane (Biochem Biophys. Acta, 258:566 - 576, 1972), whereby a 1 mM solution of the inhibitor being tested or dilutions thereof was incubated at 37°C for 16 hours with gelatinase and heat denatured 3H or 14C-acetylated collagen (buffered with 50 mM Tris, pH 7.6 containing 5 mM CaCl2, 0.05% Brij 35 and 0.02% NaN3). The 3H or 14C gelatin was prepared by denaturing 3H or 14C-collagen produced according to the method of Cawston and Muφhy (Methods in Enzymology, 80:71 1, 1981) by incubation at 60°C for 30 minutes. Undigested gelatin was precipitated by addition of trichloroacetic acid and centrifugation. The gelatinase activity in the presence of 1 mM, or dilution thereof, was compared to the activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the gelatinase (IC50). Example D
MMP Inhibition Activity-Fluorimetric Assay
The potency of compounds of general formula (I) to act as inhibitors of collagenase- 1 (MMP- 1), collagenase-2 (MMP-8), collagenase-3 (MMP- 13), gelatinase- A (MMP-2), gelatinase-B (MMP-9) and stromelysin- 1 (MMP-3) was determined using the following procedure:
Inhibitors are dissolved in dimethylsulphoxide containing 0.02% β- mercaptoethanol and serial dilutions are prepared. Activated enzyme is incubated in assay buffer containing 50mM Tris, pH 7.4, 5mM CaCl2, 0.002% NaN3 and Brij 35 in the presence and absence of inhibitor. Samples are preincubated at 37°C for 15 minutes before the addition of the fluorimetric substrate (Mca-Pro-Leu-GIy-Leu-Dpa-Ala-Arg- NHj) to a final concentration of lOμM. The assay is incubated for 20-30 min at 37°C and then read in a Fluoroscan II at λ^ (340nm) and λ,.m (405nm).
The enzyme activity was compared to activity in a control devoid of inhibitor and the results reported as that inhibitor concentration effecting 50% inhibition of the stromelysin (ICS0). Example E Inhibition of TNF α production
The potency of the compounds of general formula (I) to act as inhibitors of the production of TNFα is determined using the following procedure. A lOO M solution of the inhibitor being tested or dilutions thereof is incubated at 37° C in an atmosphere of 5% CO2 with THP-1 cells (human monocytes) suspended in RPM1 1640 medium and 20 M β-mercaptoethanol at a cell density of 1 x lOVml and stimulated with LPS. After 18 hours the supernatant is assayed for the levels of TNF α using a commercially available ELISA kit (R & D Systems).
The activity in the presence of 0. ImM inhibitor or dilutions thereof is compared to activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the production of TNFα, Example F
Inhibition of L-selectin shedding
Compounds of general formula (I) are evaluated in an assay of L-selectin shedding by peripheral blood mononuclear cells (PBMC). PBMC are isolated from buffy coats by standard procedures using Ficoll. A lOOμM solution of the inhibitor being tested or dilutions thereof is incubated for 20min at 37° C in an atmosphere of 5% CO2 with 4 x 106/ml PBMC stimulated with PMA. The cells are centrifuged down and the supernatants tested for sL-selectin using a commercially available ELISA kit (R & D Systems). The activity in the presence of lOOμM inhibitor or dilutions thereof was compared to activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the shedding of L-selectin. Example G Inhibition of sIl-lRH shedding Compounds of general formula (I) are evaluated in an assay of sIl-lRII shedding by peripheral blood mononuclear cells (PBMC). PBMC are isolated from buffy coats by standard procedures using Ficoll. A 1 OOμM solution of the inhibitor being tested or dilutions thereof are incubated for 18h at 37° C in an atmosphere of 5% CO2 with 2 x lOVml PBMC stimulated with 11-13. The cells are centrifuged down and the supernatants tested for sU-l RIl using a commercially available ELISA kit (R & D Systems).
The activity in the presence of lOOμM inhibitor or dilutions thereof is compared to activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the shedding of sIl-lRII. Example H
Inhibition of D-6R shedding
Compounds of general formula (I) are evaluated in an assay of sIl-6R shedding by HL-60 cells. PBMC are isolated from buffy coats by standard procedures using Ficoll. A lOOμM solution of the inhibitor being tested or dilutions thereof is incubated for 24h at 37° C in an atmosphere of 5% CO2 with 2 x 106/ml HL-60 cells stimulated with PMA. The cells are centrifuged down and the supernatants tested for sIl-6R using a commercially available ELISA kit (R & D Systems).
The activity in the presence of lOOμM inhibitor or dilutions thereof is compared to activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the shedding of I1-6R. Example I Inhibition of TNF RII shedding
The potency of the compounds of general formula (I) to act as inhibitors of the shedding of TNF RII is determined using the following procedure. A lOOμM solution of the inhibitor being tested or dilutions thereof are incubated at 37° C in an atmosphere of 5% CO, with THP-1 cells (human monocytes) suspended in RPM1 1640 medium and 20μM β-mercaptoethanol at a cell density of 1 x IOVml and stimulated with LPS. After 18 hours the supernatant is assayed for the levels of sTNF RII using a commercially available ELISA kit (R & D Systems). The activity in the presence of 0. ImM inhibitor or dilutions thereof is compared to activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the shedding of TNF RIL Example J Adjuvant arthritic rat model Compounds of general formula (I) were evaluated in an adjuvant arthritis model in the rat based on the methods employed by B.B. Newbould (1963), Br.J.Pharmacol, 21, 127-136 and CM. Pearson and F.D. Wood (1959), Arthritis Rheum, 2, 440-459. Briefly male Wistar rats ( 180-200g) were injected at the base of the tail with Freund's adjuvant. Twelve days later the responding animals were randomised into experimental groups. Compounds of general formula (I) were dosed either orally as a suspension in 1% methyl cellulose or intraperitoneally in 0.2% carboxymethylcellulose from day 12 to the end of the experiment on day 22. Hind paw volumes were measured every two days from day 12 onwards and X-rays were taken of the hind feet on completion of the experiment. Results were expressed as the percent increase of foot volume over day 12 values. Example K
Mouse ovarian carcinoma xenograft model
Compounds of general formula (I) were evaluated in an ovarian carcinoma xenograft model of cancer, based on that described by B. Davies et al (1993), Cancer Research, 53, 2087-2091 This model, in brief, consists of inoculating female nu/nu mice with 1 x 109 OVCAR3-icr cells into the peritoneal cavity. Compounds of general formula (I) are administered by the oral route as a suspension in 1% methyl cellulose or intraperitoneally as a suspension in phosphate buffered saline in 0.01% Tween-20. At the conclusion of the experiment (4-5 weeks) the number of peritoneal cells are counted and any solid tumour deposits weighed. In some experiments tumour development is monitored by measurement of tumour specific antigens. Example L Rat mammary carcinoma model
Compounds of general formula (I) were evaluated in a HOSP.1 rat mammary carcinoma model of cancer (S.EccIes et al ( 1995), Cancer Research, in press). This model consists of the intravenous inoculation of female CBH/cbi rats with 2 x 104 tumour cells into the jugular vein. Compounds of general formula (I) are administered by the oral route as a suspension in 1% methyl cellulose or intraperitoneally as a suspension in phosphate buffered saline + 0.01% Tween-20. At the conclusion of the experiment (4-5 weeks) the animals are killed, the lungs are removed and individual tumours counted after 20 hours fixation in Methacarn. Example M Mouse B16 melanoma model
The anti-metastatic potential of compounds of general formula (I) is evaluated in a B 16 melanoma model in C57BL/6. Mice are injected intravenously with 2 x 105 B 16/F10 murine tumour cells harvested from in vitro cultures. Inhibitors are administered by the oral route as a suspension in 1% methyl cellulose or intraperitoneally as a suspension in phospate buffered saline pH7.2 + 0.01% Tween-20. Mice are killed 14 days after cell inoculation and the lungs removed and weighed prior to fixing in Bouin's solution. The number of colonies present on the surface of each set of lungs is then counted by eye.

Claims

1. A compound of formula (I)
B-X-(CH2)„-CHR,-(CH2)_.-CONHOH (I)
wherein m and n are each independently 0 or 1 , but are not both 0; X is O, NR3 or S(O)„.2;
R1 is H or a group selected from C,^ alkyl, C^ alkenyl, aryl, Cw alkyl-aryl, heteroaryl, CM alkyl-heteroaryl, heterocycloalkyl, C,^ alkyl-heterocycloalkyl, cycloalkyi and Cw alkyl-cycloalkyl, and said group is optionally substituted with R9; R2 is H or Cι.6 alkyl;
R3 is H, C,_5 alkyl, COR2, CON(R2)2 where each R2 is the same or different, CO2R4 or SO2R4, and R4 is C1-6 alkyl;
B is Cl-6 alkyl-aryl, Cw alkyl, cycloalkyi, C,^ alkyl-cycloalkyl, cycloalkenyl, heterocycloalkenyl, CI-6 alkyl-heteroaryl, heterocycloalkyl, C1-6 alkyl-heterocycloalkyl, aryl or heteroaryl, any of which groups is optionally substituted by a substituent selected from R5, CM alkyl-R5, Cw alkenyl-R5, aryl (optionally substituted with R5), aryl-C,^ alkyl-R5, C,^ alkyl-aryl (optionally substituted with R5), C,^ alkyl-heteroaryl (optionally substituted with R5), aryl-C^ alkenyl-R7, heteroaryl (optionally substituted with R5), heteroaryl-Ci-g alkyl-R5, cycloalkyi (optionally substituted with R5), benzofused cycloalkyi (optionally substituted with R5), heterocycloalkyl (optionally substituted with R5), benzofused heterocycloalkyl (optionally substituted with R5), and the groups:
Figure imgf000074_0001
provided that B is not benzhydryl when X is SO and R1 is H;
R5 is Cw alkyl, C^ alkenyl-R7, halogen, CN, NO2, N(R6)2, OR6, COR6, CO2R2, CON(R6)2, NR6R7, S(O)MR8 or SO2N(R°)2;
R6 is H or a group selected from Cl-6 alkyl, aryl, C,^ alkyl-aryl, heteroaryl, C,_s alkyl-heteroaryl, cycloalkyi, C,^ alkyl-cycloalkyl, heterocycloalkyl and C,^ alkyl- heterocycloalkyl, wherein said group is optionally substituted with R8, COR8, SO^R*, CO2R8, OR8, CONR2R8, NR2R8, halogen, CN, SO2NR2R8 or NO2, and for each case of N(R6)2 the R6 groups are the same or different or N(R6)2 is heterocycloalkyl optionally substituted with R8, COR8, SO^R8, CO2R\ OR8, CONR2R8, NR R8, halogen, CN, SO2NR2R8 or NO2;
R7 is COR6, CON(R6)2, CO2R8 or SO2R8;
R8 is C,.6 alkyl, aryl, C,^ alkyl-aryl, heteroaryl or C,^ alkyl-heteroaryl; and
R9 is OR6, COR6, CO2R2, CON(R6)2, NR6R7, S(O)fJ_2R8, SO2N(R6)2, phthalimido, succinimido or the group
Figure imgf000075_0001
or a salt, solvate, hydrate or protected amino or protected carboxy derivative thereof; provided that the compound is not 3-phenylsulfonylpropanoic acid N-hydroxy amide.
2. A compound of formula (la)
B-S(O)1.2-(CH2)n-CHR1-(CH2)m-COOR2 (la)
wherein and n are each independently 0 or 1 , but are not both 0; R1 is Cj-6 alkyl (optionally substituted with R9), Cw alkyl-aryl (optionally substituted with R9) or C,_6 alkyl-heteroaryl (optionally substituted with R9);
R2 is H or C,^ alkyl;
B is C alkyl-aryl, Cw alkyl, cycloalkyi, C,_β alkyl-heteroaryl, C6 aryl or heteroaryl, any of which groups is optionally substituted by a substituent selected from Rs, aryl (optionally substituted with R5), heteroaryl (optionally substituted with Rs), and the groups:
Figure imgf000076_0001
R5 is halo, N(R6)2, OR6, OC,^ alkyl-R7, COR6, CO2R2, CON(R6)2 or NR6R7; R6 is C,.,, alkyl optionally substituted by one or more F atoms or aryl, and for each case of N(R6)2 the R6 groups are the same or different; R7 is CON(R6)2; and R9 is OR6, phthalimido, succini ido or the group
Figure imgf000076_0002
or a salt, solvate or hydrate thereof.
3. A compound of claim 1, wherein
R1 is H or optionally-substituted alkyl, alkenyl, aryl, alkyl-aryl, heteroaryl or alkyl-heteroaryl;
B is C,^ alkyl-aryl, C,^ alkyl, cycloalkyi, C,^ alkyl-heteroaryl, heterocycloalkyl, C6 aryl or Cw heteroaryl, any of which groups is optionally substituted by a substituent selected from Rs, Cw alkyl-R5, CM alkenyl-R5, aryl (optionally substituted with R5), aryl-C1-6 alkyl-R5, aryl-C2.6 alkenyl-R7, heteroaryl (optionally substituted with R5), cycloalkyi (optionally substituted with Rs), benzofused C$^ cycloalkyi (optionally substituted with R5), heterocycloalkyl (optionally substituted with R5), benzofused CM heterocycloalkyl (optionally substituted with R5), and the groups:
Figure imgf000077_0001
R5 is C,-5 alkyl, C„ alkenyl-R5, halogen, CN, NO2, N(R6)2, OR6, OC alkyl- R7, COR6, CO2R2, CON(R6)2, NR6R7, S(O)o.2R8 or SO2N(R6)2; and R6 is H, alkyl, aryl, alkyl-aryl, heteroaryl or alkyl-heteroaryl.
4. A compound of claim 2, wherein
B is C|_s alkyl-aryl, C,_j alkyl, cycloalkyi, C,^ alkyl-heteroaryl, C6 aryl or C5-6 heteroaryl, any of which groups is optionally substituted by a substituent selected from R5, aryl (optionally substituted with R5), heteroaryl (optionally substituted with R5), and the groups:
Figure imgf000077_0002
and R5 is halo, NfR6)* OR6, OCM alkyl-R7, COR6, CO2R2, CON(R6)2 or NR6R7;
5. A compound of claim 1 or claim 3, wherein X is S(O)o.2 .
6. A compound of any preceding claim, wherein R1 is H or a group (optionally substituted with R9) selected from CM alkyl, C^ alkenyl, Cw alkyl-aryl, Cw alkyl- heteroaryl, C,_j alkyl-heterocycloalkyl and C,_s alkyl-cycloalkyl.
7. A compound of any preceding claim, wherein B is C alkyl-aryl, CM alkyl, cycloalkyi, cycloalkenyl, heterocycloalkenyl, C,^ alkyl-heteroaryl, aryl or heteroaryl, any of which groups is optionally substituted by a substituent selected from Rs, C,^ alkyl-R5, aryl (optionally substituted with R5), aryl-Cw alkyl-R5, Cw alkyl-aryl (optionally substituted with R5), Cw alkyl-heteroaryl (optionally substituted with R5), heteroaryl (optionally substituted with Rs), heteroaryl-C,^ alkyl-R5, heteroaryl-C,^ alkyl-R5 cycloalkyi (optionally substituted with R5), benzofused cycloalkyi (optionally substituted with Rs), heterocycloalkyl (optionally substituted with Rs), benzofused heterocycloalkyl (optionally substituted with R5), and the groups:
Figure imgf000078_0001
8. A compound of any preceding claim, wherein R is halogen, CN, NO2, N(R6)2, OR6, COR6, CON(R°)2, NR6R7, or S(O)„.2R8.
9. A compound of any preceding claim, wherein R7 is COR6.
10. A compound of any preceding claim, wherein R9 is OR6, CO2R2, CONfR6)^ phthalimido, succinimido or said group.
11. A compound of any preceding claim, wherein m is O; B is C6 aryl or CM heteroaryl substituted with said substituent;
R5 is C,.« alkyl, CM alkenyl, halo, CN, NO2, N(R6)2, OR6, COR6, CO2R2, CON(R°)2, NR R7, S(O)o.2R8 or
Figure imgf000078_0002
and
R9 is OR6, COR6, CO2R2, CON(R6)2, NR6R7, S(O)o.2R8, SO2N(R6)2, phthalimido or succinimido.
12. A compound of any of claims 1 , 3 and 5 to 11, which is a hydroxamic acid wherein X is SO2;
B is aryl or heteroaryl, either of which groups is optionally substituted by R5; and
R5 is COR6.
13. A compound of any of claims 1, 3 and 5 to 11, which is a hydroxamic acid wherein
X is SO2; and
B is cycloalkyi, cycloalkenyl, heterocycloalkenyl, heterocycloalkyl or C,^ alkyl-heterocycloalkyl, any of which groups is optionally substituted by a substituent selected from R5, C,^ alkyl-R5, Cw alkenyl-R5, aryl (optionally substituted with R5), aryl-C,^ alkyl-R5, C,^ alkyl-aryl (optionally substituted with R5), C,^ alkyl-heteroaryl (optionally substituted with R5), aryl-CM alkenyl-R7, heteroaryl (optionally substituted with R5), heteroaryl-C,.6 alkyl-R5, cycloalkyi (optionally substituted with R5), benzofused cycloalkyi (optionally substituted with R5), heterocycloalkyl (optionally substituted with R5), and benzofused heterocycloalkyl (optionally substituted with R5), provided that B is not unsubstituted cycloalkyi.
14. A compound of claim 1 or claim 2, selected from 4-[4-(methoxycarbonyl)methoxy-3,5-dimethylphenyl]-2-methyl-l(2H)- phthalazinone 4-[4-(carboxy)methoxy-3,5-dimethylphenyl]-2-methyl-l(2H)-phthalazinone and
4-[4-(hydroxyaminocarbonyl)methoxy-3,5-dimethylphenyl]-2-methyl-l(2H)- phthalazinone.
15. A compound of claim 1 or claim 2, selected from those of the Examples first disclosed in Application No. 9707427.2.
16. A compound according to claim 12 or claim 13, which is exemplified herein.
17. A compound of any preceding claim, in the form of a single enantiomer or diastereomer.
18. A pharmaceutical composition for use in therapy, comprising a compound of any preceding claim, and a pharmaceutical ly-acceptable diluent or carrier.
19. Use of a compound of any of claims 1 to 16, for the manufacture of a medicament for the treatment or prevention of a condition associated with matrix metalloproteinases or that is mediated by TNF α or enzymes involved in the shedding of L-selectin, the TNF receptors or IL-6 receptors.
20. Use according to claim 19, wherein the condition is selected from cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia, anorexia, acute infection, HIV infection, shock states, graft versus host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-independent anti- thrombosis..
21. Use according to claim 19, wherein the condition is selected from tumour growth, angiogenesis, tumour invasion and spread, metastases, malignant ascites and malignant pleural effusion.
22. Use according to claim 19, wherein the condition is selected from cerebral ischaemia, ischaemic heart disease, rheumatoid arthritis, osteoarthritis, osteoporosis, asthma, multiple sclerosis, neurodegeneration, Alzheimer's, atherosclerosis, stroke, vasculitis, Crohn's disease and ulcerative colitis.
23. Use according to claim 19, wherein the condition is selected from corneal ulceration, retinopathy and surgical wound healing.
24. Use according to claim 19, wherein the condition is selected from psoriasis, atopic dermatitis, chronic ulcers and epidermolysis bullosa.
25. Use according to claim 19, wherein the condition is selected from periodontitis and gingivitis.
26. Use according to claim 19, wherein the condition is selected from rhinitis, allergic conjunctivitis, eczema and anaphylaxis.
27. Use according to claim 19, wherein the condition is selected from restenosis, congestive heart failure, endometriosis, atherosclerosis and endosclerosis.
PCT/GB1997/002129 1996-08-07 1997-08-07 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity WO1998005635A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK97935666T DK0968182T3 (en) 1996-08-07 1997-08-07 Hydroxamic and carboxylic acid derivatives with MMP and TNF inhibitory activity
JP10507741A JP2000517297A (en) 1996-08-07 1997-08-07 Hydroxamic acid derivatives and carboxylic acid derivatives having MMP and TNF inhibitory activities
BR9711027A BR9711027A (en) 1996-08-07 1997-08-07 Hydroxic and carboxylic acid derivatives having mmp and tnf inhibitory activity
AU38564/97A AU730464B2 (en) 1996-08-07 1997-08-07 Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
PL97331598A PL193829B1 (en) 1996-08-07 1997-08-07 Derivatives of hydroxamic and carboxylic acids of mmp activity and tnf inhibiting action
DE69729007T DE69729007T2 (en) 1996-08-07 1997-08-07 HYDROXAMIC ACID AND CARBOXYLIC DERIVATIVES WITH MMP AND TNF HEMMENDER EFFECT
EP97935666A EP0968182B1 (en) 1996-08-07 1997-08-07 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
AT97935666T ATE266000T1 (en) 1996-08-07 1997-08-07 HYDROXAMIC ACID AND CARBOXIC ACID DERIVATIVES WITH MMP AND TNF INHIBITING EFFECTS
CA002263154A CA2263154A1 (en) 1996-08-07 1997-08-07 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
NO19990543A NO314452B1 (en) 1996-08-07 1999-02-05 Hydroxamic and Carboxylic Acid Derivatives with MMP and TNF Inhibition Activity, Their Use and Pharmaceutical Preparations Containing Dissert Derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9616599.8 1996-08-07
GBGB9616599.8A GB9616599D0 (en) 1996-08-07 1996-08-07 Compounds
GB9707427.2 1997-04-11
GBGB9707427.2A GB9707427D0 (en) 1997-04-11 1997-04-11 Compounds having mmp and tnf inhibitory activity

Publications (1)

Publication Number Publication Date
WO1998005635A1 true WO1998005635A1 (en) 1998-02-12

Family

ID=26309836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002129 WO1998005635A1 (en) 1996-08-07 1997-08-07 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Country Status (17)

Country Link
US (1) US6118001A (en)
EP (1) EP0968182B1 (en)
JP (1) JP2000517297A (en)
KR (1) KR20000029858A (en)
CN (1) CN1227540A (en)
AT (1) ATE266000T1 (en)
AU (1) AU730464B2 (en)
BR (1) BR9711027A (en)
CA (1) CA2263154A1 (en)
CZ (1) CZ297278B6 (en)
DE (1) DE69729007T2 (en)
DK (1) DK0968182T3 (en)
ES (1) ES2217425T3 (en)
NO (1) NO314452B1 (en)
PL (1) PL193829B1 (en)
PT (1) PT968182E (en)
WO (1) WO1998005635A1 (en)

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032734A1 (en) * 1997-01-22 1998-07-30 Rhone-Poulenc Rorer Pharmaceuticals Inc. SUBSTITUTED β-THIOCARBOXYLIC ACIDS
WO1998055449A1 (en) * 1997-06-06 1998-12-10 The University Of Queensland Hydroxamic acid compounds having anticancer and anti-parasitic properties
WO2000000473A1 (en) * 1998-06-30 2000-01-06 Adir Et Compagnie Carboxylic and hydroxamic acid compounds inhibiting metalloproteases, method for preparing same and pharmaceutical compositions containing them
EP0983258A1 (en) * 1997-03-04 2000-03-08 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
WO2000012477A1 (en) * 1998-08-29 2000-03-09 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as proteinase inhibitors
WO2000069822A1 (en) * 1999-05-12 2000-11-23 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
WO2000069839A1 (en) * 1999-05-12 2000-11-23 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
WO2001005756A1 (en) * 1999-07-14 2001-01-25 Pharmacia & Upjohn Spa 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors
WO2001062751A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
WO2001087844A1 (en) * 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO2001087883A1 (en) * 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6342639B1 (en) 1998-06-18 2002-01-29 Syntex (U.S.A.) Llc Processes for preparing 3-Arylsulfur hydroxamic acids
JP2002523493A (en) * 1998-08-31 2002-07-30 アストラゼネカ・アクチエボラーグ Arylpiperazines and their use as metalloproteinase inhibitors (MMPs)
US6437177B1 (en) 1997-11-21 2002-08-20 Martha A. Warpehoski α-hydroxy, -amino, and halo derivatives of β-sulfonyl hydroxamic acids as matrix metallopropteinases inhibitors
WO2001022952A3 (en) * 1999-09-25 2003-02-20 Smithkline Beecham Plc Use of tace inhibitors
JP2004500346A (en) * 1999-11-12 2004-01-08 セルジーン　コーポレイション Pharmaceutically active isoindoline derivatives
US6787536B2 (en) 2000-05-15 2004-09-07 Darwin Discovery Limited Hydroxamic acid derivatives
US6969598B2 (en) 2001-04-30 2005-11-29 Oxford Biomedica (Uk) Limited Methods for producing high titre vectors and compositions used in such methods
WO2005115996A1 (en) 2004-05-24 2005-12-08 Sterix Limited Sulfamic acid ester compounds useful in the inhibition of seroid sulphatase activity and aromatase activity
US7102008B2 (en) 2002-08-01 2006-09-05 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
US7153857B2 (en) 2001-08-09 2006-12-26 Astrazeneca Ab Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
WO2007072056A2 (en) 2005-12-22 2007-06-28 Oxford Biomedica (Uk) Limited Vectors
WO2008014430A1 (en) 2006-07-27 2008-01-31 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
WO2010055413A1 (en) 2008-11-12 2010-05-20 Fondazione Centro San Raffaele Del Monte Tabor Gene vector for inducing transgene-specific immune tolerance
EP2194137A2 (en) 2000-04-19 2010-06-09 Oxford BioMedica (UK) Limited Cells comprising codon optimized retroviral particles
EP2202240A1 (en) 2000-08-18 2010-06-30 Sterix Limited Compound
WO2011023989A1 (en) 2009-08-24 2011-03-03 Sterix Limited Aromatase inhibitor
US7968561B2 (en) 2006-03-01 2011-06-28 Sterix Limited Steroidal compounds as steroid sulphatase inhibitors
US8119627B2 (en) 2005-07-04 2012-02-21 Sterix Limited Heterocyclic compounds as inhibitors of 17beta-HSD3
WO2012156839A2 (en) 2011-05-19 2012-11-22 Ospedale San Raffaele S.R.L. New generation of splice-less lentiviral vectors for safer gene therapy applications
US8394825B2 (en) 2007-03-28 2013-03-12 Sterix Limited Compound
US8470860B2 (en) 2004-06-04 2013-06-25 Sterix Limited Phenyl-sulfamates as aromatase inhibitors
US8558028B2 (en) 2007-11-20 2013-10-15 University Of Bath Of Claverton Down Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase
WO2014121884A1 (en) 2013-02-06 2014-08-14 Merck Patent Gmbh Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
WO2016009326A1 (en) 2014-07-14 2016-01-21 Ospedale San Raffaele S.R.L Vector production
EP3002330A1 (en) 2005-05-27 2016-04-06 Ospedale San Raffaele S.r.l. Gene vector
WO2016063264A1 (en) 2014-10-24 2016-04-28 Ospedale San Raffaele S.R.L. Permanent epigenetic gene silencing
EP3192874A1 (en) 2008-06-18 2017-07-19 Oxford BioMedica (UK) Limited Virus purification
WO2018193118A1 (en) 2017-04-21 2018-10-25 Ospedale San Raffaele S.R.L Gene therapy
US10391201B2 (en) 2014-04-25 2019-08-27 Ospedale San Raffaele Srl Gene therapy
WO2019219836A1 (en) 2018-05-16 2019-11-21 Ospedale San Raffaele S.R.L. Virus vector production
WO2019219838A1 (en) 2018-05-16 2019-11-21 Ospedale San Raffaele S.R.L. Compositions and methods for haematopoietic stem cell transplantation
WO2020002380A1 (en) 2018-06-25 2020-01-02 Ospedale San Raffaele S.R.L Gene therapy
EP3613859A1 (en) 2013-10-24 2020-02-26 Ospedale San Raffaele S.r.l. Method
WO2020074729A1 (en) 2018-10-11 2020-04-16 Ospedale San Raffaele S.R.L Selection by means of artificial transactivators
EP3650548A1 (en) 2013-12-20 2020-05-13 Oxford BioMedica (UK) Limited Viral vector production system
WO2020148445A1 (en) 2019-01-18 2020-07-23 Société des Produits Nestlé S.A. Agents and methods for increasing stem cell function
EP3733214A1 (en) 2009-04-30 2020-11-04 Ospedale San Raffaele S.r.l. Gene vector
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
WO2021160993A1 (en) 2020-02-13 2021-08-19 Oxford Biomedica (Uk) Limited Production of lentiviral vectors
WO2021181108A1 (en) 2020-03-13 2021-09-16 Oxford Biomedica (Uk) Limited Lentiviral vectors
WO2021229237A1 (en) 2020-05-14 2021-11-18 Ucl Business Ltd Cyclosporine analogues
WO2021229242A1 (en) 2020-05-15 2021-11-18 Oxford Biomedica (Uk) Limited Viral vector production
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
WO2022064061A1 (en) 2020-09-28 2022-03-31 Société des Produits Nestlé S.A. Compositions and methods for increasing stem cell function
WO2022064063A1 (en) 2020-09-28 2022-03-31 Société des Produits Nestlé S.A. Compositions and methods for increasing stem cell function
WO2022101617A1 (en) 2020-11-10 2022-05-19 Oxford Biomedica (Uk) Limited Preparation of a solution of polymer/nucleic acid complexes
WO2022162247A1 (en) 2021-02-01 2022-08-04 Epsilen Bio S.R.L. Gene silencing
WO2022229227A1 (en) 2021-04-28 2022-11-03 Ospedale San Raffaele S.R.L. Compositions for improving the transduction of cells by viral vectors
WO2022233767A1 (en) 2021-05-05 2022-11-10 Société des Produits Nestlé S.A. Urolithin for increasing stem cell function
WO2023062359A2 (en) 2021-10-12 2023-04-20 Oxford Biomedica (Uk) Limited Novel viral regulatory elements
WO2023062363A1 (en) 2021-10-12 2023-04-20 Oxford Biomedica (Uk) Limited Lentiviral vectors
WO2023066735A1 (en) 2021-10-19 2023-04-27 Ospedale San Raffaele S.R.L. Gene therapy
WO2023105235A1 (en) 2021-12-09 2023-06-15 Oxford Biomedica (Uk) Limited Purification method of viral vectors
WO2023209225A1 (en) 2022-04-29 2023-11-02 Ospedale San Raffaele S.R.L. Gene therapy
WO2023209223A1 (en) 2022-04-28 2023-11-02 Ospedale San Raffaele S.R.L. Methods for haematopoietic stem cell transplantation
WO2023247937A1 (en) 2022-06-21 2023-12-28 Ucl Business Ltd Cyclosporine analogues
WO2024038266A1 (en) 2022-08-16 2024-02-22 Oxford Biomedica (Uk) Limited Envelope proteins
WO2024079644A1 (en) 2022-10-11 2024-04-18 Fondazione Telethon Ets 3d cell culture methods
US12059478B2 (en) 2016-05-20 2024-08-13 Ospedale San Raffaele S.R.L. Gene therapy

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794511B2 (en) * 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
CA2486402C (en) * 2002-05-22 2013-04-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds
CA2486303C (en) 2002-05-22 2013-04-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
DE10226370B4 (en) 2002-06-13 2008-12-11 Polyic Gmbh & Co. Kg Substrate for an electronic component, use of the substrate, methods for increasing the charge carrier mobility and organic field effect transistor (OFET)
DE10233085B4 (en) 2002-07-19 2014-02-20 Dendron Gmbh Stent with guide wire
US8425549B2 (en) 2002-07-23 2013-04-23 Reverse Medical Corporation Systems and methods for removing obstructive matter from body lumens and treating vascular defects
ATE457716T1 (en) 2002-12-30 2010-03-15 Angiotech Int Ag RELEASE OF ACTIVE INGREDIENTS FROM QUICK-GELLING POLYMER COMPOSITION
US20050277897A1 (en) * 2004-06-14 2005-12-15 Ghannoum Ziad R Handpiece tip
DE102005019181A1 (en) * 2005-04-25 2006-10-26 Novartis Ag New indene compound are peptide-deformylase inhibitors useful e.g. to treat or prevent diseases mediated by metalloproteinase activity and peptide-deformylase activity
CA2606251A1 (en) * 2005-04-25 2006-11-02 Novartis Ag Imidazo(1,2-a)pyridine derivatives useful as peptide deformylase (pdf) inhibitors
ATE509956T1 (en) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY
US11337714B2 (en) 2007-10-17 2022-05-24 Covidien Lp Restoring blood flow and clot removal during acute ischemic stroke
US8088140B2 (en) 2008-05-19 2012-01-03 Mindframe, Inc. Blood flow restorative and embolus removal methods
CN103549986B (en) 2008-02-22 2015-12-09 泰科保健集团有限合伙公司 The thrombosis device agglomerate of removable combination
US9039749B2 (en) 2010-10-01 2015-05-26 Covidien Lp Methods and apparatuses for flow restoration and implanting members in the human body
US10076399B2 (en) 2013-09-13 2018-09-18 Covidien Lp Endovascular device engagement
DE102017211110A1 (en) 2017-06-30 2019-01-03 Continental Reifen Deutschland Gmbh A method of producing a silane, a method of modifying a silicic acid with the silane and modified silicic acid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098824A (en) * 1975-10-02 1978-07-04 Laboratoire L. Lafon Benzhydrylsulphinyl derivatives
US4325964A (en) * 1977-02-15 1982-04-20 Laboratoire L. Lafon Phenylamidine derivatives
WO1993020047A1 (en) * 1992-04-07 1993-10-14 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
WO1995023790A1 (en) * 1994-03-03 1995-09-08 Smithkline Beecham Corporation Cytokine inhibiting imidazole substituted hydroxamic acid derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698706A (en) * 1995-05-10 1997-12-16 Chiroscience Limited Heterocyclic amides and methods of use
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
PT780386E (en) * 1995-12-20 2003-02-28 Hoffmann La Roche MATRIX METALOPROTEASE INHIBITORS
PT871439E (en) * 1996-01-02 2004-08-31 Aventis Pharma Inc SUBSTITUTED HYDROXYLIC ACID COMPOUNDS (ARYLETHYLETHYLRENE ARYLMETHYL OR HETEROYARMETHYL)
ES2236829T3 (en) * 1996-09-27 2005-07-16 PHARMACIA & UPJOHN COMPANY LLC BETA-SULFONIL HYDROXAMIC ACIDS AS INHIBITORS OF THE METALOPROTEINS OF THE MATRIX.
WO1998039316A1 (en) * 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098824A (en) * 1975-10-02 1978-07-04 Laboratoire L. Lafon Benzhydrylsulphinyl derivatives
US4325964A (en) * 1977-02-15 1982-04-20 Laboratoire L. Lafon Phenylamidine derivatives
WO1993020047A1 (en) * 1992-04-07 1993-10-14 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
WO1995023790A1 (en) * 1994-03-03 1995-09-08 Smithkline Beecham Corporation Cytokine inhibiting imidazole substituted hydroxamic acid derivatives

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
C. BÖDEKER, ET AL.: "A saturated asymmetric isoprene synthon. Synthesis, resolution and absolute configuration", TETRAHEDRON, vol. 37, no. 6, 1981, OXFORD, GB, pages 1233 - 1235, XP002031786 *
CHEMICAL ABSTRACTS, vol. 116, no. 17, 27 April 1992, Columbus, Ohio, US; abstract no. 173677t, J. POLANSKI, ET AL.: "Synthesis of 2-arylsulphonylisovaleric acids" page 815; XP002031741 *
CHEMICAL ABSTRACTS, vol. 51, no. 2, 25 January 1957, Columbus, Ohio, US; abstract no. 1064b, O. ACHMATOWICZ, ET AL.: "Sulphinic acids. I. Addition of sulphinic acid salts to alpha,beta-unsaturated compounds. Synthesis of sulphones" column 1064; XP002031740 *
CHEMICAL ABSTRACTS, vol. 52, no. 14, 25 July 1958, Columbus, Ohio, US; abstract no. 11786h, Z. ECKSTEIN, ET AL.: "Hydroxamic acids. VI. Chemical properties and fungicidal activity of some derivaitves of aryloxyacetohydroxamic acids" column 11786; XP002031818 *
CHEMICAL ABSTRACTS, vol. 82, no. 7, 17 February 1975, Columbus, Ohio, US; abstract no. 43119f, I.M. NASYROV, ET AL.: "Synthesis and oxidation of 3-oxo-1-thiaindans" page 413; XP002031739 *
D.F. BIGGS, ET AL.: "Potential hypotensive compounds: substituted 3-aminopopionates and 3-aminopropionohydroxamic acids", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 61, no. 10, October 1972 (1972-10-01), WASHINGTON US, pages 1739 - 1745, XP002031817 *
DOKL. AKAD. NAUK TADZH. SSR, vol. 17, no. 7, 1974, pages 37 - 39 *
G.G. LEVKOVSKAYA, ET AL.: "Alkylation of arylsulphonic esters", JOURNAL OF ORGANIC CHEMISTRY OF THE USSR, vol. 20, no. 7, pt. 1, July 1984 (1984-07-01), NEW YORK, US, pages 1310 - 1314, XP002031789 *
H. FUKUDA, ET AL.: "Synthesis of beta-disulphones from sulphonyl fluorides and organometallic compounds", JOURNAL OF ORGANIC CHEMISTRY, vol. 28, no. 5, May 1963 (1963-05-01), WASHINGTON, DC, US, pages 1420, XP002031733 *
H. SU, ET AL.: "Diastereoselectivity in the preparation of 4-phenylthio-4-butanolide derivatives by the use of the Pummerer rearrangement", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 66, no. 9, September 1993 (1993-09-01), TOKYO, JP, pages 2603 - 2611, XP002031735 *
J. DURMAN, ET AL.: "Synthesis of alpha-phenylthio enones and esters of alpha-phenylthio alkenoic acids", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, no. 11, November 1986 (1986-11-01), LETCHWORTH, GB, pages 1939 - 1945, XP002031788 *
K. NANJO, ET AL.: "Formic acid reduction. XXVII. Selective reduction of carbon-carbon double bonds conjugated with nitro and sulphonyl groups", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 27, no. 1, January 1979 (1979-01-01), TOKYO, JP, pages 198 - 203, XP002031738 *
L.N. OWEN, ET AL.: "Olefinic acids. Part V. gamma-Methoxycrotonic acid", JOURNAL OF THE CHEMICAL SOCIETY, 1949, LETCHWORTH, GB, pages 3098 - 3105, XP002031732 *
M. JULIA, ET AL.: "Synthèses ä l'aide de sulfones. XI. - Synthèse d'acides carboxyliques", BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, no. 3-4, March 1976 (1976-03-01), PARIS, FR, pages 525 - 529, XP002031734 *
POL. J. CHEM., vol. 65, no. 11, 1991, pages 1973 - 1977 *
PRZEMSYL CHEM., vol. 12, no. 35, 1956, pages 640 - 642 *
R. BREITSCHUH, ET AL.: "Herstellung von stereoismeren 3-Sulfinylbuttersäuren aus (R)- und (S)-4-Methyl-2-oxetanon", SYNTHESIS, no. 1/2, January 1992 (1992-01-01), STUTTGART, DE, pages 83 - 89, XP002031736 *
R.T. COUTTS, ET AL.: "Synthesis and properties of some hypotensive N-alkylaminopropionic esters and N,N-dialkylaminopropionic esters and their hydroxamic acids", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 60, no. 1, January 1971 (1971-01-01), WASHINGTON US, pages 28 - 33, XP002031816 *
ROCZNIKI CHEM., vol. 30, 1956, pages 243 - 251 *
S. CHODROFF, ET AL.: "The preparation of unsaturated sulphones by condensation reactions", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 72, no. 3, March 1950 (1950-03-01), WASHINGTON, DC, US, pages 1073 - 1076, XP002031787 *
S. DE LOMBAERT, ET AL.: "Synthesis and phase-transfer mediated alkylations of 2-diethylamino-4- and phenylsulphonyl-2- butenenitrile. An efficient homoenolate equivalent", TETRAHEDRON LETTERS, vol. 25, no. 32, 1984, OXFORD, GB, pages 3475 - 3478, XP002031790 *
S.M.A.D. ZAYED, ET AL.: "Preparation and fungicidal properties of some arylthioalkanoyl- and (arylsulphonyl)-aceto-hydroxamic acids", ZEITSCHRIFT FUER NATURFORSCHUNG, TEIL B: ANORGANISCHE CHEMIE, ORGANISCHE CHEMIE, vol. 21b, no. 2, 1966, TÜBINGEN, DE, pages 180 - 182, XP000674908 *
Y.-C. KUO, ET AL.: "New methods and reagents in organic synthesis. 26. Reductive desulphonylation of alpha-sulphonylacetates", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 30, no. 8, August 1982 (1982-08-01), TOKYO, JP, pages 2787 - 2792, XP002031737 *
Z. ECKSTEIN, ET AL.: "On the properties and fungicidal activity of aryloxyalkanehydroxamic acids. VI. Influence of iodine as substituent", BULLETIN DE L'ACADEMIE POLONAISE DES SCIENCES, SERIE DES SCIENCES CHIMIQUES, vol. 11, no. 12, 1963, WARSAW, PL, pages 671 - 675, XP000675071 *

Cited By (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1486486A2 (en) * 1997-01-22 2004-12-15 Aventis Pharmaceuticals Inc. Substituted B-thiocarboxylic acids
WO1998032734A1 (en) * 1997-01-22 1998-07-30 Rhone-Poulenc Rorer Pharmaceuticals Inc. SUBSTITUTED β-THIOCARBOXYLIC ACIDS
US6306873B1 (en) 1997-01-22 2001-10-23 Aventis Pharmaceuticals Products Inc. Substituted β-thiocarboxylic acids
EP1486486A3 (en) * 1997-01-22 2009-06-10 Aventis Pharmaceuticals Inc. Substituted B-thiocarboxylic acids
EP0983258A1 (en) * 1997-03-04 2000-03-08 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
EP0983258A4 (en) * 1997-03-04 2001-01-17 Monsanto Co N-hydroxy 4-sulfonyl butanamide compounds
WO1998055449A1 (en) * 1997-06-06 1998-12-10 The University Of Queensland Hydroxamic acid compounds having anticancer and anti-parasitic properties
US6437177B1 (en) 1997-11-21 2002-08-20 Martha A. Warpehoski α-hydroxy, -amino, and halo derivatives of β-sulfonyl hydroxamic acids as matrix metallopropteinases inhibitors
US6518460B2 (en) 1998-06-18 2003-02-11 Syntex (U.S.A.) Llc Processes for preparing 3-arylsulfur hydroxamic acids
US6342639B1 (en) 1998-06-18 2002-01-29 Syntex (U.S.A.) Llc Processes for preparing 3-Arylsulfur hydroxamic acids
US6420573B1 (en) 1998-06-18 2002-07-16 Syntex (U.S.A.) Llp Processes for preparing 3-arylsulfur hydroxamic acids
US6605604B1 (en) 1998-06-30 2003-08-12 Les Laboratoires Servier Carboxylic and hydroxamic acid compounds inhibiting metalloproteases, method for preparing same and pharmaceutical compositions containing them
WO2000000473A1 (en) * 1998-06-30 2000-01-06 Adir Et Compagnie Carboxylic and hydroxamic acid compounds inhibiting metalloproteases, method for preparing same and pharmaceutical compositions containing them
WO2000012477A1 (en) * 1998-08-29 2000-03-09 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as proteinase inhibitors
US6479502B1 (en) 1998-08-29 2002-11-12 British Biotech Pharmaceuticals Hydroxamic acid derivatives as proteinase inhibitors
JP4776778B2 (en) * 1998-08-31 2011-09-21 アストラゼネカ・アクチエボラーグ Aryl piperazines and their use as metalloproteinase inhibitors (MMPs)
JP2002523493A (en) * 1998-08-31 2002-07-30 アストラゼネカ・アクチエボラーグ Arylpiperazines and their use as metalloproteinase inhibitors (MMPs)
US6503910B1 (en) * 1999-05-12 2003-01-07 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives
US6506764B1 (en) 1999-05-12 2003-01-14 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives
WO2000069839A1 (en) * 1999-05-12 2000-11-23 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
WO2000069822A1 (en) * 1999-05-12 2000-11-23 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
US6765003B1 (en) 1999-07-14 2004-07-20 Pharmacia Italia, Spa 3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors
WO2001005756A1 (en) * 1999-07-14 2001-01-25 Pharmacia & Upjohn Spa 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors
WO2001022952A3 (en) * 1999-09-25 2003-02-20 Smithkline Beecham Plc Use of tace inhibitors
JP2004500346A (en) * 1999-11-12 2004-01-08 セルジーン　コーポレイション Pharmaceutically active isoindoline derivatives
WO2001062751A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
EP2194137A2 (en) 2000-04-19 2010-06-09 Oxford BioMedica (UK) Limited Cells comprising codon optimized retroviral particles
US6809100B2 (en) 2000-05-15 2004-10-26 Darwin Discovery Ltd. Hydroxamic acid derivatives
US6787536B2 (en) 2000-05-15 2004-09-07 Darwin Discovery Limited Hydroxamic acid derivatives
WO2001087844A1 (en) * 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6734189B2 (en) 2000-05-15 2004-05-11 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives
US6933306B2 (en) 2000-05-15 2005-08-23 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives
WO2001087883A1 (en) * 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6469020B2 (en) 2000-05-15 2002-10-22 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives
US6506773B2 (en) 2000-05-15 2003-01-14 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives
EP2202240A1 (en) 2000-08-18 2010-06-30 Sterix Limited Compound
US6969598B2 (en) 2001-04-30 2005-11-29 Oxford Biomedica (Uk) Limited Methods for producing high titre vectors and compositions used in such methods
US7153857B2 (en) 2001-08-09 2006-12-26 Astrazeneca Ab Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
US7102008B2 (en) 2002-08-01 2006-09-05 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
WO2005115996A1 (en) 2004-05-24 2005-12-08 Sterix Limited Sulfamic acid ester compounds useful in the inhibition of seroid sulphatase activity and aromatase activity
US8470860B2 (en) 2004-06-04 2013-06-25 Sterix Limited Phenyl-sulfamates as aromatase inhibitors
US10000757B2 (en) 2005-05-27 2018-06-19 Ospedale San Raffaele S.R.L. Gene vector
EP3002330A1 (en) 2005-05-27 2016-04-06 Ospedale San Raffaele S.r.l. Gene vector
US11753643B2 (en) 2005-05-27 2023-09-12 Ospedale San Raffaele S.R.L. Gene vector
US9556438B2 (en) 2005-05-27 2017-01-31 Fondazione Centro San Raffaele Del Monte Tabor Gene vector
US8119627B2 (en) 2005-07-04 2012-02-21 Sterix Limited Heterocyclic compounds as inhibitors of 17beta-HSD3
WO2007072056A2 (en) 2005-12-22 2007-06-28 Oxford Biomedica (Uk) Limited Vectors
US7968561B2 (en) 2006-03-01 2011-06-28 Sterix Limited Steroidal compounds as steroid sulphatase inhibitors
EP2046736A1 (en) * 2006-07-27 2009-04-15 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
EP2046736A4 (en) * 2006-07-27 2011-07-13 Emisphere Tech Inc Arylsulfanyl compounds and compositions for delivering active agents
WO2008014430A1 (en) 2006-07-27 2008-01-31 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
US9873667B2 (en) 2006-07-27 2018-01-23 Emisphere Technologies Inc. Arylsulfanyl compounds and compositions for delivering active agents
US8394825B2 (en) 2007-03-28 2013-03-12 Sterix Limited Compound
US8558028B2 (en) 2007-11-20 2013-10-15 University Of Bath Of Claverton Down Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase
EP3192874A1 (en) 2008-06-18 2017-07-19 Oxford BioMedica (UK) Limited Virus purification
WO2010055413A1 (en) 2008-11-12 2010-05-20 Fondazione Centro San Raffaele Del Monte Tabor Gene vector for inducing transgene-specific immune tolerance
EP3733214A1 (en) 2009-04-30 2020-11-04 Ospedale San Raffaele S.r.l. Gene vector
WO2011023989A1 (en) 2009-08-24 2011-03-03 Sterix Limited Aromatase inhibitor
US8846737B2 (en) 2009-08-24 2014-09-30 Sterix Limited Compound
WO2012156839A2 (en) 2011-05-19 2012-11-22 Ospedale San Raffaele S.R.L. New generation of splice-less lentiviral vectors for safer gene therapy applications
WO2014121884A1 (en) 2013-02-06 2014-08-14 Merck Patent Gmbh Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
US10617721B2 (en) 2013-10-24 2020-04-14 Ospedale San Raffaele S.R.L. Methods for genetic modification of stem cells
EP3613859A1 (en) 2013-10-24 2020-02-26 Ospedale San Raffaele S.r.l. Method
EP3650548A1 (en) 2013-12-20 2020-05-13 Oxford BioMedica (UK) Limited Viral vector production system
US10391201B2 (en) 2014-04-25 2019-08-27 Ospedale San Raffaele Srl Gene therapy
US11957747B2 (en) 2014-07-14 2024-04-16 Ospedale San Raffaele S.R.L. Vector production
WO2016009326A1 (en) 2014-07-14 2016-01-21 Ospedale San Raffaele S.R.L Vector production
US10912824B2 (en) 2014-07-14 2021-02-09 Ospedale San Raffaele S.R.L. Vector production
WO2016063264A1 (en) 2014-10-24 2016-04-28 Ospedale San Raffaele S.R.L. Permanent epigenetic gene silencing
EP3995584A1 (en) 2014-10-24 2022-05-11 Ospedale San Raffaele S.r.l. Gene silencing
US12059478B2 (en) 2016-05-20 2024-08-13 Ospedale San Raffaele S.R.L. Gene therapy
WO2018193118A1 (en) 2017-04-21 2018-10-25 Ospedale San Raffaele S.R.L Gene therapy
EP3973996A1 (en) 2017-04-21 2022-03-30 Ospedale San Raffaele S.r.l. Gene therapy
WO2019219838A1 (en) 2018-05-16 2019-11-21 Ospedale San Raffaele S.R.L. Compositions and methods for haematopoietic stem cell transplantation
WO2019219836A1 (en) 2018-05-16 2019-11-21 Ospedale San Raffaele S.R.L. Virus vector production
WO2020002380A1 (en) 2018-06-25 2020-01-02 Ospedale San Raffaele S.R.L Gene therapy
WO2020074729A1 (en) 2018-10-11 2020-04-16 Ospedale San Raffaele S.R.L Selection by means of artificial transactivators
WO2020148445A1 (en) 2019-01-18 2020-07-23 Société des Produits Nestlé S.A. Agents and methods for increasing stem cell function
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
WO2021160993A1 (en) 2020-02-13 2021-08-19 Oxford Biomedica (Uk) Limited Production of lentiviral vectors
WO2021181108A1 (en) 2020-03-13 2021-09-16 Oxford Biomedica (Uk) Limited Lentiviral vectors
WO2021229237A1 (en) 2020-05-14 2021-11-18 Ucl Business Ltd Cyclosporine analogues
WO2021229242A1 (en) 2020-05-15 2021-11-18 Oxford Biomedica (Uk) Limited Viral vector production
WO2022064061A1 (en) 2020-09-28 2022-03-31 Société des Produits Nestlé S.A. Compositions and methods for increasing stem cell function
WO2022064063A1 (en) 2020-09-28 2022-03-31 Société des Produits Nestlé S.A. Compositions and methods for increasing stem cell function
WO2022101617A1 (en) 2020-11-10 2022-05-19 Oxford Biomedica (Uk) Limited Preparation of a solution of polymer/nucleic acid complexes
EP4335458A2 (en) 2020-11-10 2024-03-13 Oxford BioMedica (UK) Limited Preparation of a solution of polymer/nucleic acid complexes
EP4335457A2 (en) 2020-11-10 2024-03-13 Oxford BioMedica (UK) Limited Preparation of a solution of polymer/nucleic acid complexes
WO2022162247A1 (en) 2021-02-01 2022-08-04 Epsilen Bio S.R.L. Gene silencing
WO2022229227A1 (en) 2021-04-28 2022-11-03 Ospedale San Raffaele S.R.L. Compositions for improving the transduction of cells by viral vectors
WO2022233767A1 (en) 2021-05-05 2022-11-10 Société des Produits Nestlé S.A. Urolithin for increasing stem cell function
WO2023062366A1 (en) 2021-10-12 2023-04-20 Oxford Biomedica (Uk) Limited Retroviral vectors
WO2023062363A1 (en) 2021-10-12 2023-04-20 Oxford Biomedica (Uk) Limited Lentiviral vectors
WO2023062365A2 (en) 2021-10-12 2023-04-20 Oxford Biomedica (Uk) Limited Lentiviral vectors
WO2023062367A1 (en) 2021-10-12 2023-04-20 Oxford Biomedica (Uk) Limited Lentiviral vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
WO2023062359A2 (en) 2021-10-12 2023-04-20 Oxford Biomedica (Uk) Limited Novel viral regulatory elements
WO2023066735A1 (en) 2021-10-19 2023-04-27 Ospedale San Raffaele S.R.L. Gene therapy
WO2023105235A1 (en) 2021-12-09 2023-06-15 Oxford Biomedica (Uk) Limited Purification method of viral vectors
WO2023209223A1 (en) 2022-04-28 2023-11-02 Ospedale San Raffaele S.R.L. Methods for haematopoietic stem cell transplantation
WO2023209225A1 (en) 2022-04-29 2023-11-02 Ospedale San Raffaele S.R.L. Gene therapy
WO2023247937A1 (en) 2022-06-21 2023-12-28 Ucl Business Ltd Cyclosporine analogues
WO2024038266A1 (en) 2022-08-16 2024-02-22 Oxford Biomedica (Uk) Limited Envelope proteins
WO2024079644A1 (en) 2022-10-11 2024-04-18 Fondazione Telethon Ets 3d cell culture methods

Also Published As

Publication number Publication date
ATE266000T1 (en) 2004-05-15
AU3856497A (en) 1998-02-25
PL331598A1 (en) 1999-08-02
PL193829B1 (en) 2007-03-30
JP2000517297A (en) 2000-12-26
CZ36899A3 (en) 1999-07-14
EP0968182A1 (en) 2000-01-05
EP0968182B1 (en) 2004-05-06
CZ297278B6 (en) 2006-10-11
US6118001A (en) 2000-09-12
KR20000029858A (en) 2000-05-25
DE69729007D1 (en) 2004-06-09
CA2263154A1 (en) 1998-02-12
NO314452B1 (en) 2003-03-24
NO990543L (en) 1999-04-06
DE69729007T2 (en) 2005-04-07
PT968182E (en) 2004-08-31
NO990543D0 (en) 1999-02-05
ES2217425T3 (en) 2004-11-01
CN1227540A (en) 1999-09-01
BR9711027A (en) 1999-08-17
AU730464B2 (en) 2001-03-08
DK0968182T3 (en) 2004-08-16

Similar Documents

Publication Publication Date Title
US6118001A (en) Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
US6465468B1 (en) Hydroxamic and carboxylic acid derivatives
EP1030836B1 (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6566384B1 (en) Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
AU735929B2 (en) Hydroxamic and carboxylic acid derivatives
US5955435A (en) Peptidyl compounds having MMP and TNF inhibitory activity
US6455531B1 (en) Hydroxamic acid derivatives
EP0891328B1 (en) Peptidyl compounds having mmp and tnf inhibitory activity
AU746158B2 (en) Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
EP1053233B1 (en) Hydroxamic and carboxylic acid derivatives
US6506764B1 (en) Hydroxamic and carboxylic acid derivatives
US6680338B2 (en) Hydroxamic and carboxylic acid derivatives
MXPA99001298A (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO2000069827A1 (en) Hydroxamic and carboxylic acid derivatives
WO1999007679A1 (en) Peptidyl compounds having mmp and tnf inhibitory activity
KR100665761B1 (en) Hydroxamic and carboxylic acid derivatives
MXPA00004747A (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97197048.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997935666

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV1999-368

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/001298

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1019997001020

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2263154

Country of ref document: CA

Ref document number: 2263154

Country of ref document: CA

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: PV1999-368

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1997935666

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997001020

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997935666

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997001020

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV1999-368

Country of ref document: CZ